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Endocrine disrupting compounds (EDCs), including pesticides, plasticizers, and personal 
care products that accumulate in wastewater, are exogenous chemicals that can alter hormonal 
regulation and gene transcription, in part by mimicking natural hormones and binding to 
receptors. Environmental EDC exposures can cause profound effects for humans, ranging from 
breast, prostate, and lung cancer to obesity and infertility. Some epidemiological studies indicate 
disinfection by-products (DBPs), formed during drinking water treatment, could cause similar 
adverse health effects.  A more complete assessment of endocrine active DBP structural classes 
and the remediation of known EDCs from wastewater are required. This dissertation identifies 
EDCs of concern in drinking water and evaluates the removal of estrogenic activity from 
wastewater using a combination of chemical and biochemical techniques.  
Using receptor-binding assays and in silico molecular docking, the binding affinity of 21 
DBPs were tested individually and in binary mixtures at concentrations ranging from 0.1 nM to 2 
mM for their affinity to the human estrogen alpha and chimp androgen receptor. 14 DBPs were 
found to bind to the androgen receptor, at IC50 values in the range of 1.86 mM for 2,3-
dichloropropionamide to 13.5 µM for 3,4,5,6-tetrachloro-benzoquinone, and were predicted to 
adopt the antagonist conformation. For the estrogen receptor, 9 of the 21 DBPs were able to bind 
weakly, with affinities ranging from IC50 values of 1.44 mM for dibromoacetonitrile to 148 µM 
	 iv	
for bromopicrin, which was contrary to in silico predictions that showed a low probability of 
binding. In binary mixtures, the DBPs followed concentration addition for both receptors.  
The yeast estrogen screen (YES) was then used to evaluate remediation of estrogenic 
activity in a simulated vertical flow filtration on-site wastewater treatment system. A laboratory-
scale column study of dose loading intervals of 8, 12, 24, 36, and 48h free flowing and 8h 
saturated conditions showed higher removal of target anthropogenic chemicals and estrogenic 
activity with decreasing dose intervals. Moreover, higher levels of activity in the treated 
wastewater were measured by the YES assay than explained by the chemical concentrations. 
These results highlight the utility of complementary chemical and biological analyses for 


















 I would like to express my gratitude to my advisor, Dr. Howard Weinberg, and my 
committee, Dr. Fry, Dr. Aitken, Dr. Singleton and Dr. House, for their guidance and suggestions 
throughout this process. The input they each gave from their respective fields helped me to grow 
as a scientist and made this dissertation a truly interdisciplinary degree. In particular, I would 
like to thank Dr. House for being so patient when discussing engineering principles with a 
chemist that is used to thinking on a much smaller scale. I would also like to thank Dr. Fry for 
her useful suggestions with the manuscripts for Aims 1 and 2 and for providing access to 
instrumentation in her laboratory, and to thank Dr. Singleton for his assistance and training in the 
microbial work associated with Aim 3.  
A number of other people at UNC have made this work possible. Lisa Smeester provided 
useful insight with the receptor work in Aims 1 and 2, and I would like to thank her for always 
being available to discuss the assays and that field of science. I would also like to express my 
appreciation to Leonard, Wanda, and Pete of the Biomarker Mass Spectrometry Center for their 
help with questions for the chemical analyses. In addition, I would like to thank my funding 
sources: the Water Research Foundation, the National Science Foundation, the Universität 
Tübingen Teach at Tübingen Fellowship program, and the UNC Graduate School Doctoral 
Dissertation Completion Fellowship. I am especially grateful to Dr. Christian Zwiener for giving 
me the opportunity to teach and work in Tübingen, Germany; it was a truly memorable 
experience.  
	 vi	
 My labmates have been supportive throughout my time here, so I would like to thank the 
past and present members of the Weinberg group for always being willing to provide feedback 
on conference presentations, insight into research questions, and listening ears for the usual 
graduate school stressors. In particular, I would like to thank Kathleen McDermott for being so 
helpful and always willing to lend a hand when necessary, and for sitting through countless hours 
of discussion about the endocrine activity of mixtures.  
 This degree would not have been possible without the support of my family and friends. 
First and foremost, I would like to thank my parents for their endless encouragement, 
understanding, and patience throughout my education and for continually taking an interest in the 
somewhat esoteric research avenues I have pursued.  They have always been there to listen, 
provide perspective, and offer help and I cannot thank them enough for the impact they have had 
on me. I would also like to give a big thank you to Di, AC, Tricia, Kasia, Carlin and Sam for 
being my constant champions during this process, my consummate travel partners, and my 
outlets from graduate school. To Wan and the rest of the climbing crew, I would like to say thank 
you for all of the fun hours away from the lab working on different types of problems. Finally, I 
would like to thank my grandfather for setting the bar so incredibly high and for having been 
















TABLE OF CONTENTS 
LIST OF TABLES ......................................................................................................................... xi	
LIST OF FIGURES ...................................................................................................................... xiv	
LIST OF ABBREVIATIONS ...................................................................................................... xix	
CHAPTER 1: INTRODUCTION TO ENDOCRINE ACTIVITY IN WATER ............................. 1	
1.1. Research Motivations ........................................................................................................... 1	
1.2. Knowledge Gap .................................................................................................................... 5	
1.3. Specific Aims ..................................................................................................................... 13	
REFERENCES .............................................................................................................................. 15	
CHAPTER 2: IDENTIFICATION OF ENDOCRINE ACTIVE DISINFECTION                      
BY-PRODUCTS (DBPS) THAT BIND TO THE ANDROGEN RECEPTOR ........................... 23	
2.1. Introduction ........................................................................................................................ 23	
2.2. Materials and Methods ....................................................................................................... 26	
2.2.1. Chemicals .................................................................................................................... 26	
2.2.2. Androgen receptor binding assay (ARBA): Single chemical analysis ........................ 27	
2.2.3. In silico binding prediction .......................................................................................... 28	
2.2.4. ARBA binary assay ..................................................................................................... 29	
2.2.5. Data Analysis ............................................................................................................... 29	
2.3. Results ................................................................................................................................ 30	
2.3.1. Individual chemical binding ........................................................................................ 30	
2.3.2. In silico binding predictions ........................................................................................ 36	
2.3.3. Binding as mixtures ..................................................................................................... 37	
2.4. Discussion........................................................................................................................... 39	
	 viii	
2.5. Conclusions ........................................................................................................................ 43	
REFERENCES .............................................................................................................................. 44	
CHAPTER 3: DISINFECTION BY-PRODUCTS (DBPS) AS ESTROGEN ACTIVE 
SUBSTANCES .............................................................................................................................. 50	
3.1. Introduction ........................................................................................................................ 50	
3.2. Materials and Methods ....................................................................................................... 55	
3.2.1. Chemicals .................................................................................................................... 55	
3.2.2. Estrogen receptor binding assay (ERBA): Single chemical analysis .......................... 56	
3.2.3. In silico binding predictions ........................................................................................ 58	
3.2.4. ERBA binary assay ...................................................................................................... 58	
3.2.5. Data Analysis ............................................................................................................... 58	
3.3. Results ................................................................................................................................ 60	
3.3.1. Individual chemical binding ........................................................................................ 60	
3.3.2. In silico binding predictions ........................................................................................ 62	
3.3.3. Binding as binary mixtures .......................................................................................... 63	
3.4. Discussion........................................................................................................................... 64	
REFERENCES .............................................................................................................................. 69	
CHAPTER 4: OPTIMIZATION STUDIES FOR ENDOCRINE ACTIVITY                 
REMOVAL IN A VERTICAL FLOW STALITE FILTER ......................................................... 73	
4.1. Introduction ........................................................................................................................ 73	
4.2. Materials and Methods ....................................................................................................... 78	
4.2.1. Chemicals .................................................................................................................... 78	
4.2.2. Solid Phase Extraction (SPE) ...................................................................................... 79	
4.2.3. Chemical Analysis ....................................................................................................... 80	
4.2.4. Yeast Estrogen Screen ................................................................................................. 81	
4.2.5. Other Analyses ............................................................................................................ 83	
	 ix	
4.2.6. Column Study .............................................................................................................. 84	
4.2.7. Batch Study .................................................................................................................. 92	
4.3. Results and Discussion ....................................................................................................... 93	
4.3.1. Column Study .............................................................................................................. 93	
4.3.2. Batch Study ................................................................................................................ 112	
4.4. Conclusions ...................................................................................................................... 114	
REFERENCES ............................................................................................................................ 118	
CHAPTER 5: CONCLUSIONS .................................................................................................. 126	
5.1. Summary of Motivation ................................................................................................... 126	
5.2. Major Findings ................................................................................................................. 128	
5.3. Future Work ...................................................................................................................... 131	
REFERENCES ............................................................................................................................ 133	
APPENDIX A: DETAILED METHODS FOR CHAPTER 2 .................................................... 135	
APPENDIX B: DETAILED METHODS FOR CHAPTER 3 .................................................... 143	
APPENDIX C: OPTIMIZATION STUDIES OF A VERTICAL FLOW                            
STALITE FILTER STUDY 1 DATA ......................................................................................... 151	
APPENDIX C.1. Study Design ............................................................................................... 151	
APPENDIX C.2. Preliminary Study 1 Results ........................................................................ 152	
REFERENCES ............................................................................................................................ 170	
APPENDIX D: FULL DATA SETS FOR CHAPTER 4 STUDY 2 AND                     
SUPPORTING YES DATA ........................................................................................................ 171	
APPENDIX D.1. Dose interval clarification. .......................................................................... 171	
APPENDIX D.2. Additional data for the YES assay work. .................................................... 172	
REFERENCES ............................................................................................................................ 186	
APPENDIX E: CHAPTER 4 DETAILED METHODS ............................................................. 187	
APPENDIX E.1. Yeast Estrogen Screen (YES) Protocol ....................................................... 187	
	 x	
APPENDIX E.2. MO Bio FastDNA Spin Kit Protocol .......................................................... 201	
	
	 xi	
LIST OF TABLES 
	
Table 2.1. Androgen receptor-binding assay results for 21 potential  
 DBPs, the positive control 4-n-nonylphenol (4-NP), and the androgen  
 standard, R1881, n=3. ............................................................................................................ 33 
	
Table 2.2. Binding predictions for the 21 DBPs as antagonists or  
 agonists to the Androgen Receptor using Endocrine Disruptome.  
 (*) indicates favorable binding. ............................................................................................. 37 
	
Table 2.3. Equipotent binding assays presented as mean values of  
 log(IC50) and standard deviation (SD), individual concentrations at  
 mixture IC50, potency ratio, and result of the concentration addition  
 test, n =3. ............................................................................................................................... 39 
	
Table 3.1. Estrogen receptor-binding assay results for 21 test compounds,  
 the positive control 4-n-nonylphenol (4-NP), and the estrogen standard,  
 E2. NB = nonbinder, SB = slight binder. .............................................................................. 61 
	
Table 3.2. The results of the molecular docking predictions for the 21  
 DBPs and weak positive control with the ERα and ERβ as agonists  
 and antagonists, with all indicating low probability and the free  
 binding energy indicated in kcal/mol. ................................................................................... 63 
	
Table 3.3. Equipotent binding assays presented as log(IC50), IC50, RBA,  
 potency ratio, and result of the concentration addition test. .................................................. 64 
	
Table 4.1. Test chemicals used in the column and batch studies. ................................................. 89 
	
Table 4.2. The batch loading intervals and volumes used for each  
 of the column studies. ............................................................................................................ 90 
	
Table 4.3. Cumulative removal of target chemicals after each column in  
 study 2 measured for each dose interval from columns 1 (n=2) and 2  
 (n=2), and column 3 (n as indicated) presented as mean ±  
 standard deviation. ................................................................................................................. 96 
	
Table 4.4. Summary of analysis of dose response curves for the most  
 estrogenically active among the target chemicals. .............................................................. 101 
	
Table 4.5. Experimental, predicted and percent accounted for of  
 EEQs (ng/L) calculated for samples from the column study, 
 *denotes a statistically significant difference between predicted  




Table 4.6. Wastewater carbon and nitrogen concentrations before and after  
 adding the target chemical spikes. (n=2). ............................................................................ 107 
	
Table 4.7. The total percent removal results for the TOC, DOC, TN and  
 DN measurements of effluent after each of the columns, relative to  
 the spiked wastewater, at the final time point and as the average ±  
 standard deviation of all of the samples from that column  
 during each study. ................................................................................................................ 107 
	
Table 4.8. Analysis of inorganic nitrogen and pH for each of the final  
 time points and the average for all time points from each column  
 compared to column 1 influent levels. N/A = not applicable as the  
 effluent samples are the final readings. ............................................................................... 109 
	
Table 4.9. Log removal values of total coliform from the dose intervals  
 compared to the source water. ............................................................................................. 110 
	
Table 4.10. Estrogenic activity of extracted core samples from  
 column 1, 2, and 3. .............................................................................................................. 111 
	
Table 4.11. Batch study results for percent removal of target compounds  
 with two substrate:solute ratios and four conditions, including  
 1) LGW with autoclaved Stalite, 2)Autoclaved JLBC wastewater  
 with autoclaved Stalite, 3) Aerobic wastewater with an active biofilm,  
 and 4) Hypoxic wastewater with an active biofilm. NM = not measured. .......................... 114 
	
Table A.1. Diagram of the competitive binding 96-well plate. ................................................... 141 
	
Table B.1. Diagram of the competitive binding 96-well plate. ................................................... 149 
	
Table C.1. Target chemical percent removal for trail 1 experiments  
 of 8, 24, 36, and 48 h dose intervals at the final time points for  
 columns 1, 2, and 3 and the average daily removal for column 3.  
 (LOQ= limit of quantitation, not detected). ......................................................................... 153 
	
Table D.1. Dose interval time points compared to hours and  
 days for clarification. ........................................................................................................... 171 
	
Table D.2. Average EEQs Mix of the Seven Targets Spiked in  
 Solvent at 12.5mg/L. ........................................................................................................... 172 
	
Table D.3. Comparison of EEQs for SPE Extracts for the Batch Study  
 from LCMS and YES Data. ................................................................................................. 173 
	
Table D.4. Comparison of EEQs Calculated from LCMS and YES  
 Assay Derived Data. ............................................................................................................ 173 
	 xiii	
Table D.5. The results for the TOC, DOC, TN and DN measurements  
 of effluent from each column presented for the final time points  
 and as the average and standard deviation for that column for  
 the duration of each study. ................................................................................................... 174 
	
Table D.6. Batch study chemical concentrations. ....................................................................... 185 
	




















LIST OF FIGURES 
	
Figure 1.1. A) Agonist binding of the EDC (blue and red) is shown with  
 a conformational change allowing for the recruitment and association  
 with the coactivator. B) Antagonist binding is shown with the EDC  
 (blue and red) preventing the conformational change necessary for the  
 coactivator to interact. ............................................................................................................. 7 
	
Figure 1.2. Examples of A) a surface flow-constructed wetland, B) a  
 vertical flow sand filter, C) a subsurface flow-constructed wetland,  
 and D) a vertical subsurface flow-constructed wetland. ........................................................ 11 
	
Figure. 2.1. Chemical structures of the twenty-one DBPs tested with the  
 androgen receptor binding assay (ARBA). ............................................................................ 31 
	
Figure 2.2. Example binding curve of binding compound (BAM) and  
 non-binding compound (2-CP) from individual chemical binding  
 assays plotted as mean values with standard deviations. ....................................................... 34 
	
Figure 2.3. The AR ligand binding domain with the hydrogen bonding  
 network shown for methyltrienolone with threonine (Thr), asparagine  
 (Asn), and arginine (Arg). The crystal structure for the AR binding  
 domain is from Protein Data Bank entry 1E3G. .................................................................... 35 
	
Figure 3.1. Chemical structures of the twenty-one chemicals tested with the  
 estrogen receptor binding assay (ERBA). ............................................................................. 54 
	
Figure 3.2. Examples of binding (DBPN) and non-binding (DCPN) dose  
 response curves. ..................................................................................................................... 62 
	
Figure 4.1. A schematic of the Jordan Lake Business Center on-site  
 reclamation system in Chatham County, NC from which  
 wastewater was collected. ...................................................................................................... 85 
	
Figure 4.2. Diagram of the columns for study 1 packed with layers of  
 (A) 3/8”, (B) 5/16”, and (C) sand-sized Stalite® material for the  
 dose interval studies showing sampling ports 1a-c, 2a-c, and 3a-c.  
 Columns 1 and 3 are kept aerobic and open to the air, while column 2 is  
 kept hypoxic and capped. ...................................................................................................... 86 
	
Figure 4.3. Example YES assay dose-response curves for E2 (ng/well)  
 and a sample extract from T2C3 of the 36h dose interval (L/well). .................................... 100 
	
Figure 4.4. Parity plot of the relationship between YES assay results and  
 LC-MS predicted EEQ values. ............................................................................................ 103 
	
	 xv	
Figure 4.5. Overall removal efficiencies for the five different dosing  
 intervals used in the study as calculated using YES assay derived  
 EEQ values (56). .................................................................................................................. 105 
	
Figure C.1. Diagram of the columns for Trial 1 packed with layers of  
 (A) 3/8”, (B) 5/16”, and (C) sand-sized Stalite® material for the  
 column experiments showing sampling ports 1a-c, 2a-c, and 3a-c. .................................... 152 
	
Figure C.2. Atrazine daily percent removal from column 3 for  
 all dose intervals. ................................................................................................................. 154 
	
Figure C.3. Caffeine daily percent removal from column 3 for all  
 dose intervals. ...................................................................................................................... 155 
	
Figure C.4. Carbamazepine daily percent removal from column 3 for  
 all dose intervals. ................................................................................................................. 155 
	
Figure C.5. DEET daily percent removal from column 3 for all  
 dose intervals. ...................................................................................................................... 156 
	
Figure C.6. 17β-estradiol daily percent removal from column 3 for all  
 dose intervals. ...................................................................................................................... 156 
	
Figure C.7. Nonylphenol daily percent removal from column 3 for all  
 dose intervals. ...................................................................................................................... 157 
	
Figure C.8. Triclosan daily percent removal from column 3 for all  
 dose intervals. ...................................................................................................................... 157 
	
Figure C.9. The TOC percent removal for each time point after column 1  
 for all dose intervals. ........................................................................................................... 158 
	
Figure C.10. The TOC percent removal for each time point after column 2  
 for all dose intervals. ........................................................................................................... 159 
	
Figure C.11. The TOC percent removal for each time point after column 3  
 for all dose intervals. ........................................................................................................... 160 
	
Figure C.12. The DOC percent removal for each time point after column 1  
 for all dose intervals. ........................................................................................................... 160 
	
Figure C.13. The DOC percent removal for each time point after column 2  
 for all dose intervals. ........................................................................................................... 161 
	
Figure C.14. The DOC percent removal for each time point after column 3  
 for all dose intervals. ........................................................................................................... 161 
	 xvi	
Figure C.15. The TN percent removal for each time point after column 1  
 for all dose intervals. ........................................................................................................... 162 
	
Figure C.16. The TN percent removal for each time point after column 2  
 for all dose intervals. ........................................................................................................... 162 
	
Figure C.17. The TN percent removal for each time point after column 3  
 for all dose intervals. ........................................................................................................... 163 
	
Figure C.18. The DN percent removal for each time point after column 1  
 for all dose intervals. ........................................................................................................... 163 
	
Figure C.19. The DN percent removal for each time point after column 2  
 for all dose intervals. ........................................................................................................... 164 
	
Figure C.20. The DN percent removal for each time point after column 3  
 for all dose intervals. ........................................................................................................... 164 
	
Figure C.21. The ammonia concentration in effluent samples from column 1  
 for each time point from each dose interval. ....................................................................... 165 
	
Figure C.22. The ammonia concentration in effluent samples from column 2  
 for each time point from each dose interval. ....................................................................... 165 
	
Figure C.23. The ammonia concentration in effluent samples from column 3  
 for each time point from each dose interval. ....................................................................... 166 
	
Figure C.24. The nitrate concentration in effluent samples from column 1  
 for each time point for each dose interval. .......................................................................... 166 
	
Figure C.25. The nitrate concentration in effluent samples from column 2  
 for each time point for each dose interval. .......................................................................... 167 
	
Figure C.26. The nitrate concentration in effluent samples from column 3  
 for each time point for each dose interval. .......................................................................... 167 
	 	
Figure C.27. The nitrite concentration in effluent samples from column 1  
 for each time point for each dose interval. .......................................................................... 168 
	
Figure C.28. The nitrite concentration in effluent samples from column 2  
 for each time point for each dose interval. .......................................................................... 168 
	
Figure C.29. The nitrite concentration in effluent samples from column 3  
 for each time point for each dose interval. .......................................................................... 169 
	
	 xvii	
Figure D.1. Dissolved organic carbon (DOC) removal percentages  
 measured at each time point (T) and for each column (C) for the  
 wastewater through the 8h saturated dose interval, for example T3C3  
 is time point 2, column 3. .................................................................................................... 175 
	
Figure D.2. Dissolved organic carbon (DOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 8h dose interval. ............................................................................................... 175 
	
Figure D.3. Dissolved organic carbon (DOC) removal percentages measured at  
 each time point (T) and for each column (C) for the wastewater through  
 the 12h dose interval. ........................................................................................................... 176 
	
Figure D.4. Dissolved organic carbon (DOC) removal percentages measured at  
 each time point (T) and for each column (C) for the wastewater through  
 the 24h dose interval. ........................................................................................................... 176 
	
Figure D.5. Dissolved organic carbon (DOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 36h dose interval. ............................................................................................. 177 
	
Figure D.6. Total organic carbon (TOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 8h saturated dose interval. ................................................................................ 177 
	
Figure D.7. Total organic carbon (TOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 8h dose interval. ............................................................................................... 178 
	
Figure D.8. Total organic carbon (TOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 12h dose interval. ............................................................................................. 178 
	
Figure D.9. Total organic carbon (TOC) removal percentages measured  
 at each time point (T) and for each column (C) for the wastewater  
 through the 24h dose interval. ............................................................................................. 179 
	
Figure D.10. Total organic carbon (TOC) removal percentages  
 measured at each time point (T) and for each column (C) for  
 the wastewater through the 36h dose interval. .................................................................... 179 
Figure D.11. Dissolved nitrogen (DN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  





Figure D.12. Dissolved nitrogen (DN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 8h dose interval. ........................................................................................................ 180 
	
Figure D.13. Dissolved nitrogen (DN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 12h dose interval. ...................................................................................................... 181 
	
Figure D.14. Dissolved nitrogen (DN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 24h dose interval. ...................................................................................................... 181 
	
Figure D.15. Dissolved nitrogen (DN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 36h dose interval. ...................................................................................................... 182 
	
Figure D.16. Dissolved nitrogen (TN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 8h saturated dose interval. ......................................................................................... 182 
	
Figure D.17. Dissolved nitrogen (TN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 8h dose interval. ........................................................................................................ 183 
	
Figure D.18. Dissolved nitrogen (TN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 12h dose interval. ...................................................................................................... 183 
	
Figure D.19. Dissolved nitrogen (TN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 24h dose interval. ...................................................................................................... 184 
	
Figure D.20. Dissolved nitrogen (TN) removal percentages measured at  
 each time point (T) for each column (C) for the wastewater effluent  
 of the 36h saturated dose interval. ....................................................................................... 184 
 
Figure E.1 YES Assay Template. ................................................................................................ 195	
 
	 xix	
LIST OF ABBREVIATIONS 
	
AR   Androgen receptor 
ARBA   Androgen receptor binding assay 
ATZ   Atrazine 
BAM    2-bromoacetamide 
BDCM  Bromodichloromethane 
BOD   Biological oxygen demand 
3-BPN   3-bromopropionitrile 
CA   Concentration addition 
CH   Chloral hydrate 
CAF   Caffeine 
chAR   Chimp androgen receptor 
CBZ   Carbamazepine 
CFU   Colony forming units 
CSA   Chlorosuccinic acid 
2-CP    2-chlorophenol 
CPRG   Chlorophenol red-β-D-galactopyranoside 
CW    Constructed Wetland 
CWA   Clean Water Act 
DBAA    Dibromoacetic acid 
DBAN   Dibromoacetonitrile 
DBP   Disinfection by-product 
DBPN   2,3-dibromopropionitrile 
	 xx	
DCAN   Dichloroacetonitrile 
DCBQ   2,6-dichloro-1,4-benzoquinone 
DCP    2,3-dichloropropionamide 
DDT    Dichlorodiphenyltrichloroethane 
 
DHT   5α-dihydrotestosterone 
 
DIAA   Diiodoacetic acid 
 
DN   Dissolved nitrogen 
 
DO   Dissolved oxygen 
 
DOC   Dissolved organic carbon 
 
DTT   DL-dithiothreitol 
 
E2   17β-estradiol 
 
EC50   Effect concentration (50%) 
 
EDCs   Endocrine disrupting compounds 
 
EDSP    Endocrine Disruptor Screening Program 
 
EDSTAC  Endocrine Disruptor Screening and Testing Advisory Committee 
 
EEF   Estradiol effect factor 
 
EEQ   Estradiol equivalents 
 
ER   Estrogen receptor 
 
ERBA   Estrogen receptor binding assay 
 
FWSCWs  Free water surface constructed wetlands 
 
GR   Glucocoriticoid receptor 
 
HAA   Haloacetic acids 
hER   Human estrogen receptor 
	 xxi	
HFCW   Horizontal flow constructed wetland 
HPLC   High performance liquid chromatography 
[3H]-R188h  [17 α-methyl-3H]-methyltrienolone 
HRT   Hydraulic retention time 
IAA   Iodoacetic acid 
IC50   Inhibition concentration (50%) 
JLBC   Jordan lake business center 
LBD   Ligand-binding domain 
LGW   Lab grade water 
MCA   Mucochloric acid 
MPN   Most probable number 
MX    3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone 
NB   Nonbinder 
NDMA   N-nitrosodimethylamine 
4-NP   4-n-nonylphenol 
NPDES  National Pollutant Discharge Elimination System 
 
NR   Nuclear receptor 
 
PCR    Polymerase Chain Reaction  
 
PAO   Phosphorus accumulating organisms 
 
PR   Progesterone Receptor 
 
R1881   Methyltrienolone 
 
RBA   Relative binding affinity 
 
SB   Slight binder 
 
	 xxii	
SFCWs  Subsurface flow constructed wetlands 
 
SPE   Solid phase extraction 
 
TCS   Triclosan 
 
TR   Thyroid receptor 
 
TBNM   Tribromonitromethane 
 
TCAN   Trichloroacetonitrile 
 
TCBQ   3,4,5,6-tetrachloro-1,2-benzoquinone 
 
TCP   2,4,6- trichlorophenol 
 
THMs   Trihalomethanes 
 
TN   Total nitrogen 
 
TOC   Total organic carbon 
 
UPLC-ESI-MS Ultra performance liquid chromatography- electrospray ionization- mass 
spectrometry 
 
U.S. EPA  United States Environmental Protection Agency 
 
VFCWs  Vertical flow constructed wetlands 
 
VFSF   Vertical flow sand filter 
 
YAS   Yeast androgen screen 
 










CHAPTER 1: INTRODUCTION TO ENDOCRINE ACTIVITY IN WATER 
 
1.1. Research Motivations 
	
The human right to water and sanitation was officially recognized by the United Nations 
General Assembly in July 2010 through Resolution 64/292 (1). While the use of chlorine to 
disinfect drinking waters first emerged in 1850 and became widely used in the early 1900’s, 
access to clean drinking water globally has yet to be realized. Even in countries where drinking 
water treatment is commonplace, chemical contaminants in source waters or those produced 
during treatment, such as disinfection by-products (DBPs), undermine what is considered to be a 
safe and clean drinking water. Sanitation, in the form of wastewater treatment, has its own host 
of contaminant concerns including relatively high levels of pharmaceuticals, personal care 
products, DBPs and antibiotic-resistant bacteria, many of which can reach downstream drinking 
water sources (2-6). The confluence of these concerns is that the treatment of our water for 
consumption or our wastewater for release into the environment could still contribute to issues of 
public health. 
In the U.S. providing and maintaining safe drinking water, including preventing 
waterborne outbreaks, is mandated under the Safe Drinking Water Act (SDWA). This act 
regulates over 80 contaminants and requires monitoring hundreds of water quality parameters to 
help provide safe drinking water to nearly 300 million people (7). Disinfectants, such as chlorine 
or chloramine, are used as part of water treatment to meet the SDWA guidelines because they are 
efficient at inactivating disease-causing components often found in source water, including 
Giardia, Campylobacter, and norovirus. As strong oxidants, these disinfectants are also capable 
	 2	
of reacting with natural organic matter from the decomposition of organic material present in 
decaying leaves and other plants, thus forming DBPs (8). Furthermore, because disinfection is 
used in both drinking water and wastewater treatment, these low-level contaminants are found in 
potable water or are released in treated effluent into the environment. These compounds, often 
containing halogens, are comprised of a large variety of structural classes and have generally 
unknown toxicities.  
Despite there being over 800 identified DBPs (9, 10), current United States 
Environmental Protection Agency (US EPA) regulations only address a small subset of them, 
including the sum of four trihalomethanes (THMs) and five haloacetic acids (HAAs), chlorite, 
and bromate (11). Regulations in the European Union and World Health Organization expand 
that list further to include chloral hydrate, dichloroacetonitrile, dibromoacetonitrile, 
trichloroacetonitrile, cyanogen chloride, formaldehyde, and 2,4,6-trichlorophenol (11). 
Epidemiological and laboratory study evidence links the presence of DBPs to a number of 
disease states, including bladder cancer, colorectal cancer, and adverse reproductive outcomes, 
emphasizing the need for a more refined understanding of some of the biological pathways at 
risk (12-16). Of particular concern is whether the DBPs that result from conventional water 
treatment through chlorine or chloramine disinfection can be implicated in endocrine disruption, 
a target system proposed as a potential target of DBPs for these compounds but for which no 
such evaluation exists. Epidemiological studies have suggested that DBPs present in drinking 
water could be the cause of spontaneous abortion (17), as well as cardiovascular defects, low 
birth weight, and neural tube defects (18). Although these chemicals are typically only in the 
µg/L to ng/L range in finished drinking waters (9, 12), their potency has not been measured, 
which would indicate what risk they pose to endocrine disruption. Higher potency chemicals can 
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still be threats at lower concentrations and similarly, mixtures of a large number of low potency 
chemicals even at low concentrations could have a higher overall effect due to the additive effect 
of the mixture (19, 20). In order to understand the risk posed by DBP exposure it is necessary to 
evaluate the interaction of DBPs with endocrine signaling pathways and receptor proteins. An 
amendment to the SDWA in 1996 helped to establish the Endocrine Disruptor Screening and 
Testing Advisory Committee (EDSTAC) through the U.S. EPA (21). The result, the Endocrine 
Disruptor Screening Program (EDSP), is a two-tiered approach to screening pesticides and other 
environmental chemical contaminants for their activity in the estrogen, androgen, or thyroid 
hormone systems.  
While the EDSP requires investigation into whether DBPs are endocrine active, there are 
other common contaminants in waste streams that show activity and present health risks (21). 
These compounds are of concern further in the life cycle of water as they enter the environment 
from wastewater discharges without removal during treatment (22, 23) and then pose a risk to 
aquatic life as well as surface waters (24, 25). A number of common wastewater chemical 
contaminants are known endocrine disrupting compounds (EDCs) and include some pesticides, 
herbicides, and hormonal supplements (15). While conventional wastewater treatment plants 
treat the influent water to remove aggregate indicators of pollution (such as biochemical oxygen 
demand), they are unable to fully remove EDCs (23, 26). Rural populations which usually treat 
their wastewater onsite are, likewise, a source of endocrine activity in the environment because 
of their even more limited approach to EDC degradation, for example through septic systems 
(27). However, alternatives to such systems requiring minimal resources and low costs include 
constructed wetlands (CWs) and these are increasingly common in developing countries where 
large-scale plants are not economically feasible (28-30). In the U.S. CWs are of becoming more 
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commonly considered where wastewater can be reused for landscaping, toilet flushing, and other 
means (31). The use of a CW system to improve wastewater quality before reuse or release into 
the environment allows for passive remediation of anthropogenic contaminants with resulting 
decreased risk to the receiving water body and wildlife (32, 33). Numerous examples have been 
published in the literature on studies examining the use of CWs for various aspects of wastewater 
treatment, including vertical and horizontal flow CWs and biofilters (34) for the removal of 
organic matter, nitrogen content (35, 36), and pharmaceutical contaminants (37). However, there 
has been limited attention paid to the use of CWs for the optimization of the removal of EDCs. 
The U.S. EPA regulates wastewater discharge under the Clean Water Act (CWA) and 
National Pollutant Discharge Elimination System (NPDES), regulations which are designed to 
establish limits on pollution of the nation’s waterways and set water quality standards for surface 
waters. While they help to manage surface water pollution levels in the U.S., they do not address 
the issue of groundwater pollution through the transport of chemicals from decentralized 
wastewater treatment systems, landfill leachates, surface runoff from biosolid applications or 
infiltration from land applications. The water from these sources often contains a diverse group 
of personal care products, hormones, pharmaceuticals, and other chemicals present in households 
which could be transported through the soil to reach groundwater, thus impacting drinking water 
(3, 6, 27). Due to increasing water scarcity, wastewater reuse for non-potable applications is 
employed often without knowing the fate of the chemical contaminants in the water. In one such 
format, constructed wetlands (CWs) are a clear and promising form of green engineering for 
water reuse that are being refined for use in decentralized and developing locations (28, 38, 39). 
These systems not only allow for the treatment of wastewater to generate improved effluent 
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quality, but can also result in treatment of waste streams with lower energy input than 
conventional systems making them a viable alternative treatment technique. 
This dissertation focuses on water quality as it relates to human health, as well as its 
potential impact on the total environment. Through the fundamental study of the endocrine 
activity of DBPs, together with the fate and removal of persistent anthropogenic compounds and 
their endocrine activity during CW treatment of wastewater, an understanding of the endocrine 
activity of drinking water and the removal of activity in wastewater is achieved.  
1.2. Knowledge Gap 
	
Signaling for a number of biological functions in the human body is controlled through 
the master regulatory network known as the endocrine system. This pathway is comprised of a 
group of glands including the adrenal, hypothalamus, ovaries, pancreas, parathyroid, pineal, 
pituitary, testes, thymus, and thyroid, which release hormones to transport signals throughout the 
body. These hormones are used to control gene transcription for a variety of biological functions 
including: sexual development, reproductive health, metabolism, stress levels, and sleep (40). 
The regulation of gene transcription occurs through two main types of hormones: protein 
hormones including peptides and amino acids, and steroid hormones that are produced from 
cholesterol. Targets of steroid hormones include hormone receptors known within the family of 
nuclear receptors (NRs), which are a group of structurally similar transcription factors of which 
48 have been identified in mammals (41, 42). Within NRs, the specific hormone receptors 
include the estrogen receptor (ER), androgen receptor (AR), progesterone receptor (PR), 
glucocorticoid receptor (GR), thyroid receptor (TR), and mineralocorticoid receptor (40). When 
exogenous hormones or hormone analogues are able to interfere with the homeostatic activity of 
these receptors they are known as EDCs. 
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The activity of EDCs as a class, which include interference with every cellular hormonal 
pathway, is an ecological and human health concern because of their ability to inhibit or activate 
the normal gene transcription levels that are controlled by all steroid receptors. The results from 
human exposure to these compounds can vary widely but include biological endpoints such as 
infertility, obesity, altered sexual development, neuroendocrinology, cardiovascular 
endocrinology, and cancer (43, 44). The mechanisms behind these endpoints are not entirely 
understood but there are a few known ways in which EDCs act to interfere with NR signaling. 
Normally, when the endogenous ligand binds to its target receptor it causes a conformational 
change that allows for hetero- or homo-dimerization with another receptor and recruitment of 
coactivators, to allow for binding at DNA promoter sites and the initiation of gene transcription 
(40, 45, 46). For EDCs, however, mechanisms expand to include activation through binding of 
agonists to the NR and initiating recruitment of coactivators that bind to allow for targeted gene 
transcription to begin, or binding of antagonists that prevent coactivator binding and instead 
recruit corepressors to inhibit binding to and transcription of gene targets. Examples of the 
structural changes associated with agonism and antagonism for the androgen receptor, which 
occur in a similar manner for the other nuclear receptors, are shown in Figure 1.1. Alternatively, 
EDCs can interfere by binding to one receptor and initiating cross-talk, in which the bound 
receptor competes for coactivators or for DNA-binding sites with other nuclear receptors (41). 
There can also be disturbances to signaling when the NRs bind to neighboring promoter 
sequences that can cause synergistic or inhibitory activity. Finally, the activation of one NR 
could result in proteasome activation and degradation of the other NR required for dimerization 
(47, 48). An EDC is considered to be any exogenous compound that is capable of acting through 
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one of these means to alter normal signaling, and research to date has shown such chemicals are 
from a number of compound classes.  
A. Agonism     B. Antagonism 
 
Figure 1.1. A) Agonist binding of the EDC (blue and red) is shown with a conformational change 
allowing for the recruitment and association with the coactivator. B) Antagonist binding is 
shown with the EDC (blue and red) preventing the conformational change necessary for the 
coactivator to interact. 
 
 One of the most commonly studied EDCs is bisphenol A, but a variety of other 
environmental contaminants have been shown to have endocrine disruption potential in humans 
and other species, including herbicides and pesticides like atrazine, lindane and 
dichlorodiphenyltrichloroethane (DDT), dioxins, organotin compounds from polyvinyl chloride 
manufacturing, polychlorinated biphenyls, alkylphenols including nonylphenol, and phthalate 
plasticizers (15, 48-50). The nature of endocrine disruption from a particular chemical, however, 
is species-specific which makes them of concern as a health threat for humans and for the total 
environment (51). Besides humans, there have been endocrine effects studied showing weight 





indicate the importance of understanding the potential of endocrine activity (49). To understand 
the variety of endocrine related diseases impacting various species, a number of assays have 
been developed that range from the cellular level to full organism.  
 Assessing endocrine activity in drinking water and wastewater has been approached 
through a battery of receptor, cell, and whole organism tests. Examples include the yeast 
estrogen and androgen screen (YES and YAS, respectively), the E-screen assay with MCF-7 
BUS breast cancer cells, the chemical activated luciferase expression in vitro bioassays 
(CALUX), screening with the 21-day Medaka fish assays, as well as screening using rat models 
(13, 52-55). Each of these assays is useful under different test scenarios, but also have their 
limitations. For example, in vitro assays ignore the potential impact of the target chemicals on 
other cell types that contain different receptor subtypes or membrane proteins, such as cells that 
contain the ERα subtype compared to the ERβ subtype and have different affinities for the same 
EDC (56). Conversely, whole organism experiments do not address the species-specific effects 
that have been observed (42, 54).  
Of the many endocrine pathways mentioned, the primary focus for endocrine disruption 
research has centered on estrogen, androgen, and thyroid activity because of the observed 
biological outcomes associated with EDC exposures and as a result of the EPA screening 
program. Estrogen and androgen receptor binding assays, which were used for the research 
reported in this dissertation, focus on the ability of a chemical to bind at the receptor itself, which 
is one mechanism for endocrine disruption. While these receptor-based assays do not determine 
whether binding translates to altered increased or decreased gene transcription, they do help to 
determine whether a compound has the potential to be endocrine active and if certain chemical 
classes are of greater concern than others. Furthermore, the endocrine activity of environmental 
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pollutants, specifically within the estrogen and androgen pathways, is an active area of interest 
because of their potential to impact a wide variety of species and the range of their biological 
effects in humans (56, 57). Exposure to and disruption from EDCs has been measured in various 
water sources as a number of the chemicals previously listed are released in wastewater effluent, 
while DBPs are formed in both drinking and wastewater (7, 58, 59). For example, herbicides, 
surfactants, antimicrobials, and steroids are among the common wastewater contaminants that 
are of interest in this work that have also been shown to be endocrine active (27, 60, 61). Some 
DBPs have also been implicated as potential EDCs but a large number of them have unknown 
toxicity and endocrine activity (62). The very nature of both wastewater and drinking water 
matrices is that of a complex mixture of low-level chemicals, so an understanding of the effect 
that these mixtures pose on health is of clear need, with some mixtures having been shown to be 
either additive or synergistic (63). Furthermore, the chronic exposure of wildlife and humans to 
EDCs demonstrates an important consideration for public health and environmental chemistry. 
The endpoints tested in most toxicity assays are at high levels but exposure effects have been 
observed at lower environmentally relevant concentrations, which might be due to prolonged 
low-level chemical influences (47, 64). Removal of emerging wastewater contaminants and 
EDCs from wastewater before their introduction into the environment, therefore, is necessary to 
prevent continued exposure to and accumulation of these compounds. 
Since EDCs are persistent contaminants in wastewater and among the so-called 
“emerging contaminants” in drinking water, understanding their implications for human health 
when utilizing water reuse and minimizing the risk of exposure are imperative. Access to 
freshwater is becoming increasingly scarce, with an estimated 700 million people worldwide 
currently affected and 1.8 billion people expected to be impacted by 2030 (65). Furthermore, the 
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majority of the impacted population will be in resource-poor settings. Even within the U.S., 
approximately 80 percent of consumed water is currently being used for agriculture (66). If, 
instead, safe and effective wastewater treatment could produce effluent to be reused for crop 
irrigation, this would help to relieve some of the burden from agricultural use on the drinking 
water supply (67). Utilizing a low-energy engineered design could also allow it to be employed 
in resource-poor settings, as water scarcity becomes a greater issue (28, 38, 68). Understanding 
the level of and removal capability of the system to common anthropogenic contaminants, 
including EDCs, is essential to protecting the overall health of the environment in which the 
treated water is used and to consumers that would be exposed.  
As the hydraulic retention time (HRT) and biodegradation have been shown to be 
important parameters for the removal of EDCs and other pollutants during wastewater treatment, 
optimizing a vertical flow sand filter (VFSF) or constructed wetland are logical approaches for 
an effective low-energy engineering approach (38, 69-72). In particular, one requisite area of 
investigation is determining which batch-loading interval for a VFSF would best remove 
common wastewater contaminants and endocrine active compounds. Examples of common 
wetland designs including surface flow,  horizontal subsurface flow, and  vertical subsurface 
flow, as well as a vertical flow sand filter are shown in Figure 1.2 (38, 73). These designs take 
advantage of different contact times with the substratum and microbial bed, as well as different 
aeration levels due to their flow patterns. Vertical flow filters are particularly useful because they 
require less space and can include pulsed flows as might occur in household use, which alternate 




Figure 1.2. Examples of A) a surface flow-constructed wetland, B) a vertical flow sand filter, C) 
a subsurface flow-constructed wetland, and D) a vertical subsurface flow-constructed wetland. 
 
While sand filters can take a number of forms, they generally function through the 
periodic release of wastewater from perforated pipes along the top of the sand bed. These 
primarily work as aerobic, fixed-film bioreactors that can treat wastewater but have also been 
used for drinking water practices (74). Prior to the release of the wastewater onto the vegetated 
sand bed, a settling tank, such as a septic tank, is used to remove large settleable solids. The 
supernatant liquid then moves to pipes that are spread over the surface of the sand bed and are 
only dosed periodically, which allows for the maintenance of an aerobic and nitrifying biofilm 
and helps to prevent clogging. This biofilm contains heterotrophs that metabolize the carbon 
content of the water as a food source with oxygen, and organic nitrogen that has been hydrolyzed 


























is measured as its biological oxygen demand (BOD) (35, 75). Sand filter designs are efficient 
because they allow for physical separation, both from the settling tank and the pores of the sand 
material, as well as chemically through adsorption of dissolved chemicals and pollutants, and 
biological degradation through the aerobic biofilm. Phosphorus removal in sand filters is 
accomplished largely through adsorption to sites on the porous media surface, which means its 
efficiency is limited and media would sometimes need to be changed to accomplish continued 
removal once these sites are saturated (69, 76, 77). Phosphorus accumulating organisms (PAOs), 
however, could also contribute to removal (78). Biologically, the biofilm does well to manage 
organic carbon and nitrogen removal. The high surface area of sand also allows for colonization 
of microorganisms, which are largely responsible for the water treatment as they use common 
water pollutants, such as nitrate, BOD, NH4+ and organic compounds as nutrients (79). The filter 
bed is lined to prevent leaching while pipes at the bottom of the filter bed exist to collect the 
filtered water, which can then be used for landscaping or other purposes.  
Chemical degradation in sand filters occurs primarily as a result of microorganisms 
through respiration or fermentation, with respiration occurring in oxidized environments with a 
high redox potential (37, 80, 81). It is assumed that most degradation, therefore, occurs in the 
aerobic zone with the chemical contaminants as a carbon source for heterotrophic bacteria, but 
cycling from anaerobic to aerobic to anaerobic stages allows for a higher overall nitrogen 
removal through nitrification and denitrification using a combination of bacteria. Nitrogen 
removal is important as high nitrogen content in environmental waters can lead to harmful algae 
blooms and can be toxic to aquatic life. Different functional classes of microbes are responsible 
for a specific chemical’s degradation and these can be enhanced through augmented operational 
parameters of the sand filter such as adjusting the batch-loading interval to allow for longer 
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periods of unsaturation. Other important factors for activity include pH, salinity, and the 
availability of organic carbon (34). The impact of varying the batch-loading interval on the 
removal of common domestic wastewater contaminants and EDCs in particular, remains an open 
question.  
1.3. Specific Aims 
	
The research reported in this dissertation focused on the use of endocrine activity assays 
for evaluating water quality both in drinking water and wastewater. Prior to this study little was 
known about that activity for the chemical by-products resulting from disinfection, and studies 
measuring the effectiveness of treatment on wastewater effluent quality typically were evaluated 
by the levels of chemicals and pathogenic microbes, not toxicity.  
The known association between contaminants in drinking water and wastewater and 
negative health endpoints has been well established, but the pathways involved specifically 
within the endocrine system are as yet not understood. Furthermore, epidemiological evidence 
suggests an association between consumption of disinfected drinking water and endocrine-
controlled health outcomes, such as premature birth and infertility. The need for a fundamental 
understanding of the structural classes and trends of DBPs that could be the cause of this link is 
necessary in order to address this issue. Specifically, the activity of structurally different DBPs 
with the estrogen or androgen receptors is an important and, as yet, unanswered question for the 
field of environmental toxicology. It was hypothesized that by studying a diverse group of DBPs 
for their ability to bind to these receptors, an understanding of the chemical underpinnings 
involved in the development of these negative health outcomes might be gained. 
In environmental samples, understanding the health risks of exposures must logically 
move towards understanding the behavior of a complex mixture and not just sole chemicals. As 
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environmental samples contain a number of low-level contaminants that might be undetectable 
individually, it is often more logical to evaluate their overall activity. For example, the behavior 
of persistent environmental contaminants including pesticides, herbicides, hormones and 
surfactants need to be understood in relation to how these compounds behave in wastewater and 
how well these compound classes can be removed in rural settings. While there is considerable 
work in the literature to understand specific compound class removal using both constructed 
wetlands and vertical flow filters, there remains a gap in knowledge for how to address overall 
endocrine activity from a diverse set of compounds. The poor removal of endocrine activity in 
large-scale wastewater treatment and the observed estrogenic activity in domestic and rural 
wastewater emphasize this need. By using a bioassay that measures overall estrogenic activity 
through the expression of a reporter gene, it is possible to determine the change in total activity 
and account for chemical transformations that could still contribute even at low levels. In this 
dissertation research, it was anticipated that a vertical flow filter could be optimized for the 
removal of target compounds from major persistent chemical classes in wastewater and for the 
attenuation of endocrine activity.  
 Aim 1: Identify androgen-active chemicals from a group of 21 DBPs that are capable of 
binding to the androgen receptor both individually and in mixtures. 
 Aim 2: Determine which of 21 DBPs can bind to the estrogen receptor both individually 
and in mixtures.  
 Aim 3: Determine the optimal VFSF dose interval for target chemical removal and 
decreased endocrine activity of seven common anthropogenic contaminants, and explore the 
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CHAPTER 2: IDENTIFICATION OF ENDOCRINE ACTIVE DISINFECTION BY-




 Endocrine disrupting compounds (EDCs) are anthropogenic chemicals found in the 
environment that can interact with homeostatic hormone regulation in humans and animals. 
These chemicals are able to modulate the hormone systems that are used for basic physiological 
and developmental control, thus disrupting normal endocrine function (1). Disruption from a 
diverse set of small molecules can occur through a number of actions. One mechanism is that 
exogenous EDCs can mimic endogenous hormones to cause alterations in gene transcription by 
binding to nuclear hormone receptors and initiating signaling pathways. Furthermore, evidence 
of disruption through androgen signaling has been shown in epidemiological studies which 
indicate that chemicals including pesticides and other environmental contaminants are 
responsible for a number of negative health outcomes (2). The androgen system, one of the target 
endpoints highlighted in the 1996 amendment to the Safe Drinking Water Act, remains largely 
unstudied in relation to environmental endocrine disruption. Its biological importance, however, 
includes associated health impacts on male reproductive tract abnormalities, testicular and 
prostate cancer, and altered male sexual differentiation (3-5).  
 While it is understood that androgen signaling is part of male sexual differentiation and 
developmental programing, the effect of environmentally relevant concentrations of EDCs on 
this pathway is relatively unknown. The androgen hormone pathway plays a pivotal role in male 
secondary characteristics, including bone mass, musculature, fat distribution, and hair patterning, 
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among others (6). Androgen hormones primarily modulate the activity of this pathway through 
interaction with the androgen receptor, a 115 - 120 kD modular protein in the nuclear receptor 
superfamily, which is expressed in a number of organs including the hypothalamus, pituitary, 
liver, prostate, and testes (7). Ligand-activated binding occurs with high affinity to two 
endogenous androgens, testosterone and 5α-dihydrotestosterone (DHT), at the ligand-binding 
domain (LBD) (8). Exogenous ligand binding is one known route of androgen disruption and the 
primary target for EDCs, allowing for modulation of the receptor-mediated gene transcription. 
This binding causes a specific conformational change to the receptor depending on whether the 
chemical is an agonist or an antagonist, which then allows for recruitment of coactivators or 
corepressors and thus initiates or suspends gene transcription (9, 10). Understandably, the 
interaction and binding of environmental contaminants to the androgen receptor has the potential 
to modulate the androgen signaling pathway and cause disruptions to regular gene transcription 
levels.  
 Drinking water disinfection is commonly accomplished through the addition of either 
chlorine or chloramine. The reaction of these chemicals with natural organic matter already 
present at very low levels in water results in the formation of DBPs (11, 12). Furthermore, some 
of these by-products have been associated with bladder cancer and infertility (13-15). While 
Watson and colleagues found evidence that the androgenic activity of chlorinated wastewaters is 
partially attributed to DBPs, it has not been fully explained by studies of the currently regulated 
compounds (16). The specific interaction of unregulated DBPs with the androgen receptor and 
signaling pathway, however, remains unknown. Moreover, drinking water contains mixtures of 
DBPs at varying concentrations that should be considered for their potential synergistic, dose 
additive, or antagonistic activity (17). Previous studies have observed a toxicological response 
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for a mixture that is different from the predicted effect based on individual tests and in some 
cases, resultant dramatic biological outcomes are seen, particularly for aquatic species (18, 19). 
The ability of chemical mixtures to have additive binding and disruption abilities even if the 
individual chemicals bind with low affinity is, therefore, of interest.  
Genotoxic and cytotoxic DBPs, such as those containing chlorine-, bromine-, and/or 
nitrogen species, are of concern because of their formation from disinfection practices and at 
concentrations that are dependent on influent water quality. While a few studies have evaluated 
the effects of low-levels of chemical mixtures on the estrogen system, far less work has 
investigated the impact of exogenous chemicals on androgen disruption (20, 21). Competitive 
receptor binding assays, such as the androgen receptor binding assay (ARBA), can establish 
structure-activity relationships that influence trends in activity of EDCs, for both agonistic and 
antagonist chemicals. Such chemicals would then be candidates for a number of future health 
endpoint studies. In the study presented here we set out to identify DBPs that are capable of 
binding to the androgen receptor, and whether they interact and bind differently in more complex 
mixtures. Specifically, the receptor affinity and structural trends of DBPs that are able to bind to 
the androgen receptor individually or in mixtures with the known weakly androgenic chemical, 
4-n-nonylphenol, are identified. The binding nature, as agonists or antagonists, is then assessed 
using an in silico approach. The model of concentration addition (CA) is used to predict the IC50 
value of the binary mixture of compounds when added in equal potency and then compared to 





2.2. Materials and Methods 
	
2.2.1. Chemicals 
Chimp Androgen Receptors (chAR) were supplied by the U.S. Environmental Protection 
Agency (EPA) in TEDG binding buffer and stored at -80 °C. Chemicals purchased from Sigma 
Aldrich (St. Louis, MO) included: methyltrienolone (R1881, 98%), chloral hydrate (CH, >98%), 
DL-dithiothreitol (DTT, >98%), human γ-globulin (>99%), glycerol, dextran-coated charcoal, 
2,6-dichloro-1,4-benzoquinone (DCBQ, 98%), dibromoacetic acid (DBAA, 90%), 
chlorosuccinic acid (CSA, 96%), 2,4,6-trichlorophenol (TCP, 98%), dibromoacetonitrile 
(DBAN, 97%), mucochloric acid (MCA, 99%), 3,4,5,6-tetrachloro-1,2-benzoquinone (TCBQ, 
97%), sodium chloride (NaCl, >99%), 4-n-nonylphenol (4-NP, 98.4%), and absolute ethanol. [17 
α-methyl-3H]-methyltrienolone ([3H]-R1881, 81.2 Ci/mmol) and Opti-Fluor scintillation cocktail 
were purchased from Perkin Elmer (Waltham, MA) while 3-chloro-4-(dichloromethyl)-5-
hydroxy-2(5H)-furanone (MX, 98%) was supplied by Wako (Richmond, VA) and N-
nitrosodimethylamine (NDMA, 100%) was from Supelco (Bellefonte, PA). 2-chlorophenol (2-
CP, 98%), bromodichloromethane (BDCM, >98%), trichloroacetonitrile (TCAN, 98%), and 3-
bromoacetamide (BAM, 98%) were purchased from Acros Organics (New Jersey, USA). 
Dichloroacetonitrile (DCAN, 99.8%) was obtained from Crescent Chemicals (Islandia, NY), 
iodoacetic acid (IAA, 99.5%) from Fluka (Buchs, Switzerland), 2-bromopropionitrile (3-BPN, 
98%) from Alfa Aesar (Lancs, UK), diiodoacetic acid (DIAA, 90+%) from Cansyn Chemicals 
(Ontario, Canada), 2,3-dibromopropionitrile (DBPN, 95+%) from Matrix Scientific (Columbia, 
SC), 2,3-dichloropropionamide (DCP, 97%) from TCI (Tokyo, Japan), and 
tribromonitromethane (TBNM, 95+%) from Orchid Cellmark (Princeton, NJ). Tris base and 
hydrochloric acid (ACS grade) were both purchased from Fisher (Fair Lawn, NJ). 
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2.2.2. Androgen receptor binding assay (ARBA): Single chemical analysis 
The androgen receptor binding assay (ARBA) followed published procedures as 
described by Hartig and colleagues (22). Briefly, initial range finding assays were completed to 
determine the appropriate receptor concentrations, which would result in 5-15% binding. 
Saturation binding and Scatchard analyses were completed to determine the amount of receptor 
that would bind the tritiated methyltrienolone ([3H]-R1881) ligand, showing a dissociation 
constant (Kd) of 10 nM. A control using unlabeled R1881 ligand was included for each day. The 
compound 4-n-nonylphenol (4-NP), a known endocrine disruptor, was used as a positive control 
due to its ability to weakly bind to receptors at levels within the range of the test chemical 
concentrations. TEDG binding buffer (50 mM Tris-HCl, pH 7.4; 2 mM DTT; 10% glycerol; 10 
mg/mL human γ-globulin; 0.8 M NaCl) was prepared and used to dilute receptor and chemical 
stocks. Prior to use, the chARs were diluted 1:100 according to the results of the range finding 
assay, then kept on ice until addition to the assay wells. Test chemicals were prepared in absolute 
ethanol well below their individual solubility at concentrations up to 500 mM and stored in 
amber vials at -20 °C for up to 6 months then vortexed before each use. Unlabeled R1881 was 
run against [3H]-R1881 in the reference assay and [3H]-R1881 was tested for competitive 
binding against varying concentrations of test chemicals in the binding assays. Each assay 
concentration was run in triplicate on the day of the experiment and repeated on at least two 
separate days. 
A 0.1 µM stock of the [3H]-R1881 and a 10 µM stock of the unlabeled R1881 were 
prepared from the neat standards in absolute ethanol, and stored at -20 °C in amber vials. 
Aliquots of each were dried down in borosilicate glass tubes on a SpeedVac (Thermo Scientific 
Savant Model SPD1010; Waltham, MA) then reconstituted in TEDG buffer and 1 µL absolute 
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ethanol to 400 nM R1881 and 8 nM [3H]-R1881. For the assay, 50 µL of working test chemical 
dilutions in TEDG buffer were added to each of three wells in a 96-well plate (Fisher; Fair Lawn, 
NJ) resulting in final concentrations from 2 mM to 0.1 nM following the addition of 25 µL of 8 
nM [3H]-R1881, at a final concentration of 2 nM in the plate. Plates were allowed to gently 
shake (Thermo Scientific Barnstaed Lab Line Rotator; Waltham, MA) for 5 min at 4 °C before 
25 µL of 10,000 cell equivalents chAR was added to all wells. One set of three wells for non-
specific binding was prepared by adding 50 µL of 100-fold excess R1881 over [3H]-R1881 
instead of test chemical; another set of three wells was used to measure total binding by adding 
50 µL of TEDG buffer instead of test chemical. Separately, a 5% dextran-coated charcoal slurry 
was prepared in TEDG buffer. The sealed prepared plates and slurry were placed on a shaker and 
incubated overnight at 4 °C.  
Following incubation, 50 µL of the charcoal slurry was added to each well and the plates 
were sealed and shaken an additional 20 min then centrifuged (International Equipment 
Company; Needham Heights, MA) at 1000 relative centrifugal force (rcf) at 4 °C for 5 min. 50 
µL of the supernatant was removed from each well and placed into a scintillation vial (Fisher; 
Fair Lawn, NJ) containing 4.5 mL Opti-Fluor scintillation cocktail then read on a Packard 1900 
TR scintillation (Palo Alto, CA). 
2.2.3. In silico binding prediction  
 The DBPs were screened for their binding affinity to the receptor using the Endocrine 
Disruptome docking program http://endocrinedisruptome.ki.si/ as previously described (23). The 
software was used to predict the likelihood of whether the compounds would bind in the agonist 
or antagonist confirmation and their free binding energy, shown in kcal/mol. 
	 29	
2.2.4. ARBA binary assay 
 Binary mixtures were prepared by combining equipotent amounts of test chemical and 4-
NP into one stock solution in absolute ethanol. This means that compounds of unequal potency 
would be adjusted in concentration so that their impact on the mixture binding affinity, as 
measured by a sigmoidal dose response curve, could be predicted using the model of 
concentration addition (CA) (24). Working solutions were then prepared and handled as 
described in the previous section. For comparison, the non-binding chemical, mutagen X (MX), 
was added to 4-NP at equal concentration to determine whether a non-binding chemical would 
influence its binding ability.  
2.2.5. Data Analysis 
The data obtained from the scintillation counter (in units of dpm) were analyzed using 
GraphPad Prism 4 software (Version 4.03, La Jolla, CA). Specific binding was calculated for 
each chemical concentration as shown in Equation 2.1 and then plotted against concentration to 
produce dose response curves:  
!"#$%&"' !"#$"#% ! !"#!!"#$%&%$ !"#$"#%
!"#$% !"#$"#%
∗ 100 = 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐵𝑖𝑛𝑑𝑖𝑛𝑔   (2.1) 
Linear regression analysis was used for the dose response curves to examine whether 
each test chemical induced a response that deviated from a mean slope of zero with a p-value 
confidence level of 0.05. Chemicals that showed significant deviation were then fit with a 
log[inhibitor] vs. response (variable slope) curve to determine the chemical’s binding affinity, as 
described by its log(IC50) value, with the bottom constrained to zero. The relative binding 
affinity (RBA) to R1881 was calculated by dividing the IC50 of R1881 by the IC50 of the test 
chemical, and then multiplied by 100 to be expressed as a percent. For R1881, the RBA was set 
to 100%. The IC50 values represent the mean values for a set of test chemical results. Nonbinders 
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(NBs) were determined as those chemicals that did not result in a p<0.05 for the linear regression 
analysis. Slight binders (SBs) were considered to be chemicals whose dose response curves did 
not reach 50% binding at the maximum concentration tested (25). 
Since all of the chemicals tested are assumed to bind at the same active site, the CA 
model as shown in Equation 2.2 was used to determine whether the combination of the chemicals 
enhanced or suppressed the predicted response as measured by IC50 values for the binary 





= 𝑋     (2.2)	
[A] and [B] refer to the concentrations of the test chemical and 4-NP present, 
respectively, in the binary mixture at the designated effect (IC50), [AE] and [BE] refer to the 
concentrations of the individual test chemicals that are required to cause the same 50% binding, 
and X refers to the resulting effect. According to Loewe synergism, additive mixtures have a 
combined effect, X, of 1, synergistic mixtures will have X less than 1, and in antagonistic 
mixtures X will be greater than 1 (26). Effectively, this means that lower concentrations of those 
chemicals in a mixture are required to induce the same effect for synergistic mixtures and higher 
concentrations are required to result in the same effect for antagonistic mixtures (27).  
2.3. Results 
	
2.3.1. Individual chemical binding  
Individual chemical assays were completed for the R1881 standard, the weak androgen 
(4-NP) as the positive control, and the 21 test compounds shown in Figure 2.1, with results 
shown in Table 2.1.  
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Figure. 2.1. Chemical structures of the twenty-one DBPs tested with the androgen receptor 




The log(IC50) for R1881, -8.46 ± 0.22 M, was in close agreement with a previously 
reported value of -9.02 M by Hartig and colleagues (22). The test chemicals that bound to the 
receptors showed dose response curves generally spanning a drop in specific binding from 90% 
to 10% over two orders of magnitude in concentration which, along with the measured R1881 
IC50 value, supports the validity of these findings for a single receptor site competition (28). Of 
the compounds tested, 14 bound to the androgen receptor with one compound, TCBQ, binding 
more strongly than the positive control 4-NP, with log(IC50) values of -4.87 ± 0.293 M vs -4.50 ± 
0.032 M, respectively. DBPN showed a similar binding affinity as 4-NP. An example of a 






























Table 2.1. Androgen receptor-binding assay results for 21 potential DBPs, the positive control  
4-n-nonylphenol (4-NP), and the androgen standard, R1881, n=3.  










R1881 284.39 -8.46 ± 0.219 9.86E-04 100 
TCBQ 245.88 -4.87 ± 0.293 3.31 0.026 
4-NP 220.35 -4.50 ± 0.032 7.01 0.011 





-4.38 ± 0.154 





DBAN 198.84 -3.80 ± 0.085 31.4 0.002 
IAA 185.95 -3.81 ± 0.104 28.9 0.002 
TBNM 297.73 -3.71 ± 0.007 58.7 0.002 
DCAN 109.94 -3.63 ± 0.397 25.9 0.001 
BAM 137.96 -3.58 ± 0.042 36.4 0.001 
TCP 197.45 -3.36 ± 0.022 87.2 0.001 
DCP 141.98 -2.73 ± 0.047 2.65E02 0.0002 
DBAA 217.84 -2.41 ± 0.168 8.50E02 SBd, 0.0001 
(29.1) 
 
CSA 152.53 -2.69 ± 0.444 3.09E02 SBd, 0.0002 
(29.1) 
 
DIAA 311.85 -1.91 ± 0.750 3.84E03 SBd, 0.00003 
(24.4) 
 
MX 217.43 NBd NBd NBd 
CH 165.4 NBd NBd NBd 
BDCM 163.8 NBd NBd NBd 
2-CP 128.56 NBd NBd NBd 











a. See Figure 2.1 for identity of chemical acronym.  
b. SD = standard deviation. 
c. RBA = relative binding affinity. 
d. NB = nonbinder, SB = slight binder. 
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Figure 2.2. Example binding curve of binding compound (BAM) and non-binding compound (2-
CP) from individual chemical binding assays plotted as mean values with standard deviations. 
 
The only tested chemicals that did not show a significant deviation from linearity and 
were, therefore, not able to bind to the androgen receptor at the concentrations tested were MX, 
CH, BDCM, 3-BPN, 2-CP, NDMA, and TCAN. Binding affinities for the other compounds 
tested ranged in log(IC50) concentrations from -4.38 ± 0.154 M for MCA to -1.91 ± 0.750 M for 
DIAA. The IC50 values for the compounds tested did not follow a pattern based on molecular 
weight, halogen type or abundance, or relative size. It is, however, expected that these 
compounds bind to the threonine (Thr877), asparagine (Asn 705), and arginine (Arg752) 
residues in the ligand-binding domain as shown in Figure 2.3, competitively against [3H]-R1881, 




















Figure 2.3. The AR ligand binding domain with the hydrogen bonding network shown for 
methyltrienolone with threonine (Thr), asparagine (Asn), and arginine (Arg). The crystal 
structure for the AR binding domain is from Protein Data Bank entry 1E3G. 
 
Using the groupings originally described by Fang et al., chemicals that bound were 
compared to R1881 based on their RBA values and considered as either a strong binder (RBA > 
1), a moderate binder (1 > RBA > 0.01), or a weak binder (0.01 > RBA > 0.0001) (25). Of the 21 
chemicals tested, there were no strong binders but there was one moderate binder, TCBQ (RBA 
= 0.026%), in addition to the positive control, 4-NP (RBA = 0.011%). Ten of the chemicals were 
considered weak binders, namely DBPN (RBA = 0.009%), DCBQ (RBA = 0.006%), MCA 
(RBA = 0.008%), DBAN, IAA, and TBNM (RBA 0.002% each), DCAN, BAM and TCP (RBA 
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= 0.001% each), and DCP (RBA = 0.0002%). While DBAA and CSA had weak RBA values 
(0.0001% and 0.0002%, respectively), they did not reach 50% inhibition over the concentrations 
tested (29.1% binding response induced for each), and were, therefore, categorized as slight 
binders. DIAA showed some displacement of R1881 (24.4%) but had an RBA of 0.00003%.  
2.3.2. In silico binding predictions 
 The results from the Endocrine Disruptome molecular docking predictions are shown in 
Table 2.2. The predictions indicate favorable antagonistic binding for all of the chemicals that 
bound, denoted by an asterisk, to the receptor except IAA, but also suggested potential 
antagonistic binding for the chemicals that did not bind across the tested concentration range. 
















Table 2.2. Binding predictions for the 21 DBPs as antagonists or agonists to the Androgen 
Receptor using Endocrine Disruptome. (*) indicates favorable binding.  
DBP AR Agonism 
Free Binding Energy 
(kcal/mol)  
AR Antagonism 
Free Binding Energy 
(kcal/mol) 
TCBQ -6.1 -5.8* 
DBPN -3.7 -3.7* 
MCA -4.9 -4.4* 
DCBQ -5.5 -5.6* 
DBAN -3.3 -3.2* 
IAA -3.4 -3.1 
TBNM -4.4 -4.3* 
DCAN -3.3 -3.3* 
BAM -3.5 -3.5* 
TCP -5.4 -5.7* 
DCP -4.3 -4.3* 
DBAA -3.8 -3.7* 
CSA -4.7 -4.5* 
DIAA -3.8 -3.6* 
MX -6.2 -5.9* 
CH -4.6 -4.7* 
BDCM -3.2 -3.1 
2-CP -5.3 -5.7* 
TCAN -3.9 -3.8* 
NDMA -3.5 -2.8 
3-BPN -3.3 -3.1 
	
2.3.3. Binding as mixtures 
 The androgenic activity of eight of the chemicals tested from the individual assays, seven 
of the strongest binding affinities in the individual assays and one non-binder, were evaluated in 
binary mixtures with 4-NP using the CA model. This chemical was chosen as the positive control 
because it is known to be a weakly androgenic chemical and a source of environmental 
endocrine disruption. When placed in a binary mixture with one of the test chemicals that are 
equipotent or weaker binders for the androgen receptor, it was expected that changes in the 
binding affinity for the 4-NP would be due to the presence of the new chemical. Using 
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equipotent mixtures meant that compounds were added at concentrations that should produce the 
same effect as each other, as measured by their IC50 values from the individual chemical assays. 
When compounds act independently but with similar modes of action, such as binding to the 
same active site of a receptor, the results should be additive because one compound could 
essentially replace the other in the mixture, thus behaving as if it were the same compound. Each 
experiment was run as a mixture of one test compound with 4-NP across the same concentration 
range as the individual assays and the resulting data are presented in Table 2.3. The IC50 values 
were all in the micromolar range, from approximately 31.5 µM for TCBQ with 4-NP to 178 µM 
for BAM with 4-NP. To determine the effect of one chemical on the binding affinity of the other 
in the mixture, (X in equation 2), the CA model was used on the mean (n=3) IC50 concentrations 
(27, 29). While the model from the mean values shows enhanced and suppressed binding affinity 
of these compounds in mixtures, when the standard deviation of the individual and binary assay 
results are considered, none of the mixture results for CA model are statistically significant for 
Loewe synergism. The trend in the mean values, however, indicates that this warrants further 















Table 2.3. Equipotent binding assays presented as mean values of log(IC50) and standard 
deviation (SD), individual concentrations at mixture IC50, potency ratio, and result of the 
concentration addition test, n =3. 
DBP +      
4-NP 













-4.42 ± 0.147 
 
3.38 3.93 1.12:1 1.12 
IAA -4.11 ± 0.168 
 
12.2 2.62 5.5:1 0.79 
DBAN -3.98 ± 0.272 
 
17.3 3.99 4.8:1 1.12 
DBPN -4.29 ± 0.405 
 
6.50 4.48 1.1:1 1.40 
TCBQ -4.50 ± 0.573 
 






-3.75 ± 0.038 
 
-4.10 ± 0.291 
 





















a. Chemical mixture tested as negative control by using 1:1 concentration ratio. 
b. Represents the concentration of the contributing chemical in that mixture at the IC50. 




 Of the over 800 DBPs that have been identified in various types of drinking water, the 
vast majority have unknown biological activities, which has spurred the need to understand how 
exposure to these chemicals may impact human health (30). Endocrine disruption due to 
chemicals in the environment highlights the ability of low-level and chronic exposures to 
influence gene activity through chemical binding to receptors in a myriad of systems, sometimes 
with non-monotonic responses, and induce a variety of diseases (31). The results of this study 
showed that 14 of the 21 tested DBPs could bind to the androgen receptor, with some trends 
within structural classes but not between them, and that they had comparable binding affinities to 
the observed results for other active chemicals and known endpoints (32). Chemicals that were 
found to bind individually were then tested in binary mixtures, since environmental exposures 
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are not to single compounds but complex mixtures such as through consumption of drinking 
water. The additive effect observed for the tested binary mixtures is consistent with other 
published reports, and supports the impetus for evaluating chemical mixtures in water for their 
influence on endocrine activity, beyond the currently regulated 11 chemicals (33). In particular, 
further exploration into the structure-activity relationships with the androgen receptor and DBPs 
should be evaluated.  
For the tested chemicals, ring structures showed favorable binding with interactions that 
are generally through hydrophobic residues. Possible limitations to binding could be based on 
steric hindrance, as in the case of DCAN binding (log(IC50) of -3.63 M) compared to TCAN 
which did not show any binding affinity. Similarly, IAA was a moderate binder (log(IC50) of -
3.81 M), while DIAA was only a slight binder (log(IC50) of -1.91 M). For planar molecules the 
trend appears to reverse, as the more halogenated structures showed stronger binding affinities, 
which is similar to the toxicity trend that has been previously observed for quinones (34). For 
example, TCP (log(IC50) of -3.36 M) bound more strongly than 2-CP, a non-binder, and TCBQ 
(log(IC50) of -4.87 M) bound more strongly than DCBQ (log(IC50) of -4.24 M). These results are 
likely because of the large size of the binding pocket, which favors phenolic structures but 
accommodates a variety of small molecules through its hydrogen bonding network (9). For the 
androgen receptor, the binding site of the ligand binding domain (LBD) is comprised of a similar 
structural motif to other nuclear receptors, including the estrogen receptor. The LBD consists of 
the helices 3, 5, 7 and 10, and β1, which provide hydrogen bonding networks and hydrophobic 
interactions for androgens (35). Once the ligand binds, a conformational change is induced that 
forms a hydrophobic cleft from the movement of helix 12 (36). It is expected that the chemicals 
that bound were able to interact through this hydrogen bonding network when present 
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individually. The predicted docking position for each chemical in Endocrine Disruptome 
indicates that these chemicals will bind in the antagonist conformation, and thus likely 
correspond to decreased gene transcription, as was shown for some flame retardants (37). None 
of the compounds tested were predicted to bind as agonists. 
Two of the three chemicals capable of binding to the androgen receptor with the strongest 
affinity in the individual assays, TCBQ and DCBQ, belong to the emerging class of DBPs 
known as haloquinones (HQs), which occur in treated waters at nanogram per liter levels and 
have been implicated as potential bladder carcinogens (38). In one study, DCBQ was present in 
all of the aqueous samples tested (4.5 to 274.5 ng/L), with the highest median concentrations of 
the tested HQs at 23.0 ng/L, but over 100 ng/L in 5 of the 16 tested samples (39). Using a 
quantitative structure-toxicity relationships analysis as well as toxicological and occurrence data, 
HQs were predicted to be important potential carcinogens with toxicity levels as high as 1000 
times those of the currently regulated DBPs (40). Furthermore, the use of chloramines for 
disinfection favors the formation of haloquinones, such as TCBQ, as a result of its reaction with 
naturally occurring organic compounds including lignins, tannins, or catechol (12). The 
relatively strong affinity of TCBQ and DCBQ for the androgen receptor, and their known 
influence in other disease states, indicates that these compounds should be included in more 
widespread occurrence surveys. For example, halobenzoquinones have shown cytotoxicity to 
T24 bladder cancer cells in the micromolar range (41). Also of concern, dibromoacetic acid 
(DBAA) has been shown to have liver and testes toxicity, bromodichloromethane (BDCM) is 
listed as a probable human carcinogen and shown to produce liver and kidney tumors in rats as 
well as alter sperm motility (42-44). Dibromoacetonitrile (DBAN) has shown a number of 
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negative outcomes including DNA damage in mammalian cell assays and altered hepatic activity 
(45). 
In occurrence studies, the tested DBPs have generally been found in the µg/L to ng/L 
range in drinking water. Tribromonitromethane (bromopicrin) was found at the highest levels 
within the class of nine different halonitromethanes, which were detected at 0.1 – 5 µg/L in the 
U.S. Nationwide DBP Occurrence Study (17, 46). Iodoacetic acid, identified in drinking water 
from high bromide/iodide source water that was disinfected with chloramines and found at low 
parts per billion (ppb) levels in some cities, is another example of an individual DBP that could 
contribute to the overall endocrine activity of a finished water (47). Haloamides, including 
bromoacetamide, were detected in distribution system samples at up to 7.6 µg/L. Similarly to 
iodo-acids, there is some evidence that indicates haloamides form more preferentially with the 
use of chloramine disinfectant. Haloacetonitriles (HANs), including DBAN, DCAN and TCAN, 
as well as others, have been detected in U.S. and Canadian drinking waters at up to 41.0 µg/L 
(48, 49). These occurrence levels in conjunction with the measured androgen binding affinities 
from this study indicate that it is important to consider the impact of more complex mixtures of 
compounds. The observed binding across structural classes further indicates the importance of 
assessing how a mixture in different waters could influence androgen disruption. 
Although the compounds were tested mostly at concentrations above environmentally 
relevant levels, their ability to bind to the receptors at all lends credence to their potential as 
endocrine disruptors, particularly when occurring in more complex mixtures. The persistence of 
the compounds in disinfected drinking water is also of note, as these exposures occur over the 
long-term at low-levels instead of at acute high-levels. In drinking or recreational waters there is 
a much more complex mixture of a large number of compounds, which means that compounds 
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that are able to bind but are present at what would be weak acute individual effect levels (below 
their IC50 level) could combine to induce an endocrine response (50). Furthermore, drinking 
water regulations for DBPs currently set a maximum contaminant level (MCL) for only a small 
subset of all DBPs, including the sum of four trihalomethanes (including the listed BDCM tested 
in this study), the sum of five haloacetic acids, and bromate, and all at sub-micromolar levels.  
2.5. Conclusions 
	
As this study has shown, a number of known and suspected DBPs that are not currently 
regulated are capable of binding to the androgen receptor including haloquinones, 
haloacetonitriles, haloacids, and halofuranones. The structural diversity of these chemicals 
together with their demonstrated CA binding indicates that chemicals present beyond those 
currently regulated need to be considered when assessing potential health effects, particularly 
endocrine disruption. While the MCL concentrations for regulated DBPs are well below the 
reported IC50 for androgen receptor activity, the ability of these compounds to bind at all is still 
of concern. For comparison, flame-retardants well below no observed adverse effect levels from 
toxicological studies result in adverse health effects when low-level chronic exposures occur 
(51). Further experiments are required to not only understand the behavior of mixtures with 
biological systems, but also what altered physiological states result from low-level binding to the 
androgen receptor and whether the active DBPs detected here are cause for greater concern. 
These results indicate that a wide variety of DBPs are capable of binding to the androgen system 
preferentially as antagonists and that this pathway should be investigated more as cause of the 
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  Most conventional water treatment in the U.S. is accomplished through the use of 
disinfectants including chlorine and chloramine that inactivate bacteria and pathogens, but also 
react with low-levels of natural organic matter and form disinfection by-products (DBPs) (1). 
While this practice is used for both drinking and wastewater, laboratory-based and 
epidemiological studies have shown that there is an established link between exposure to 
disinfected water and a number of toxicological outcomes, including bladder cancer and 
impaired reproductive health (2). Endocrine disruption, a primary toxicological endpoint of 
concern, is the result of non-hormonal compounds interfering with normal hormonal signaling 
processes through receptor binding and other mechanisms (3, 4). Exogenous compounds, that are 
able to bind to these receptors or otherwise interfere with normal signaling levels, are known as 
endocrine disrupting compounds (EDCs) (5). The environmental impact of EDCs as estrogen 
active compounds is particularly important for public health as improper estrogen signaling is 
linked to a number of negative public health outcomes including infertility, breast cancer, and 
obesity (6, 7). This is due to the fact that estrogens cause cellular changes that influence 
reproduction, bone development, impaired cognition, stress responses and cardiovascular health 
and are, therefore, prone to cause a number of diseases when disrupted in either males or females 
(8). Due to the importance of the estrogen signaling pathway in the development and control of 
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such diverse outcomes, the ability of both regulated and unregulated DBPs to act as EDCs is an 
important and as yet unresolved question.  
Estrogenic disruption in humans occurs primarily through nuclear hormone receptors (5). 
Two major estrogen receptor subtypes, ERα and ERβ, exist in humans as coded by the ESR1 and 
ESR2 genes, respectively, and act in tissue-dependent roles (8). These variances mean that EDCs 
which interact with the estrogen system may not show the same affinity for each receptor 
subtype and, as a result, the binding of EDCs with one subtype over another could be more 
indicative of a specific disease response (8-10). For example, ERα is found in the mammary 
glands, kidney, lung bronchi, and gonads and promotes cell proliferation, whereas ERβ has an 
anti-proliferative effect in mammary tissues and is found primarily in bone, lung alveoli and 
prostate tissues (4, 8, 9). Furthermore, within the family of nuclear receptors, ERs are known to 
have highly flexible and large binding pockets that lack specificity and are thus able to bind 
ligands in multiple orientations, which then act as agonists, partial-agonists, or antagonists (11). 
These variances are due to the structural changes that result at the ligand binding domain, which 
change the conformation of the receptor and its recruitment for co-regulator proteins (3, 12). It 
should be mentioned that these structural changes are tissue-specific, which help to determine the 
role of the estrogen receptor in subsequent pathways and its involvement in different diseases 
(13). These receptors are found in the nucleus of the cell and once bound to a hormone or EDC 
will bind to the estrogen response element and begin gene transcription, thus imparting 
physiological changes. 
 As a result of the promiscuous nature of estrogen receptors, the number and variety of 
anthropogenic compounds that can bind to them and cause disruption is extensive and include 
phthalates, phytoestrogens, pesticides, polycyclic aromatic hydrocarbons, and plasticizers (7). 
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Molecular docking studies have shown that even other steroids are able to bind at the ligand 
binding domain of ERs in multiple orientations, in part because of their symmetry, which makes 
it more difficult to predict whether specific chemicals will be estrogen binders (10).  
One area of human exposure to EDCs that has garnered little attention is through 
consumption of drinking water much of which is disinfected with chemicals that react with the 
background natural organic matter to produce DBPs. There is increasing evidence that some of 
the over 800 DBPs identified to date are EDCs, and comprise a group of structurally diverse 
compounds that often contain halogens and aromatic ring structures (14). Currently, only 11 of 
these DBPs are regulated in the United States while the European Union and World Health 
Organization have expanded the list to include an additional 7 compounds (15). Previous 
research has exposed a gap between the observed toxicity of the regulated DBPs and the overall 
activity of drinking water, which suggests that unregulated compounds are involved but their 
identity remains largely unknown. For example, studies of some of the unregulated DBPs have 
shown higher genotoxicity than their regulated counterparts (16). Furthermore, the potential 
ability of DBPs to bind to the estrogen, androgen, or thyroid nuclear hormone receptors (ER, 
AR, TR, respectively) and initiate transcription of downstream gene targets was raised in the 
1996 amendment to the Safe Drinking Water Act (17). As a result of the already observed 
estrogenic activity of disinfected wastewaters and finished drinking water (18) and the known 
promiscuity of ERs, it is important to determine which DBPs are contributing to this activity and 
whether a particular type of disinfection might need to be reconsidered. Due to the differences in 
the formation of DBP classes and their related genotoxicities as a result of the disinfectant type, 
the influence that treatment type could have on estrogenic activity should also be evaluated (19).  
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In this study, a group of 21 structurally diverse DBPs, shown in Figure 3.1, were tested 
for their ability to bind to the human estrogen receptor (hER) as measured by their half inhibitory 
concentration (IC50) in a competitive binding assay. These chemicals were also tested using an in 
silico binding approach to determine whether their binding activity or conformation could be 
predicted. A subset of 7 of the active compounds was then tested in binary mixtures containing 
the known water contaminant and weak endocrine disruptor, 4-n-nonylphenol, to determine 
whether their behavior is dose-additive. The behavior of these compounds in mixtures is of 
particular importance because environmental exposures occur to mixtures of EDCs, such as 
those found in drinking water, and understanding whether their toxicity as a mixture can be 







Figure 3.1. Chemical structures of the twenty-one chemicals tested with the estrogen receptor 
binding assay (ERBA). 
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3.2. Materials and Methods 
	
3.2.1. Chemicals 
Recombinant human Estrogen Receptors-α (hER-72) were supplied by the U.S. 
Environmental Protection Agency (EPA) in TEDG binding buffer and stored at -80 °C. 
Chemicals purchased from Sigma Aldrich (St. Louis, MO) were: bovine serum albumin (BSA), 
phenylmethyanesulfonyl fluoride (PMSF, 98%), sodium molybdate dehydrate (>95%), 17β-
estradiol (E2, >98%), chloral hydrate (CH, >98%), DL-dithiothreitol (DTT, >98%), 
ethylenediaminetetraacetic acid (EDTA), glycerol, dextran-coated charcoal, 2,6-dichloro-1,4-
benzoquinone (DCBQ, 98%), dibromoacetic acid (DBAA, 90%), chlorosuccinic acid (CSA, 
96%), 2,4,6-trichlorophenol (TCP, 98%), dibromoacetonitrile (DBAN, 97%), mucochloric acid 
(MCA, 99%), 3,4,5,6-tetrachloro-1,2-benzoquinone (TCBQ, 97%), sodium chloride (NaCl, 
>99%), 4-n-nonylphenol (4-NP, 98.4%) and absolute ethanol. [3H]-17β-estradiol ([3H]- E2, 140 
Ci/mmol) and Opti-Fluor scintillation cocktail were purchased from Perkin Elmer (Waltham, 
MA) while 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX, 98%) was supplied by 
Wako (Richmond, VA) and N-nitrosodimethylamine (NDMA, 100%) was from Supelco 
(Bellefonte, PA). From Acros Organics (New Jersey, USA) the chemicals 2-chlorophenol (2-CP, 
98%), bromodichloromethane (BDCM, >98%), trichloroacetonitrile (TCAN, 98%), and 2-
bromoacetamide (BAM, 98%) were purchased. Dichloroacetonitrile (DCAN, 99.8%) was 
obtained from Crescent Chemicals (Islandia, NY), iodoacetic acid (IAA, 99.5%) from Fluka 
(Buchs, Switzerland), 2-bromopropionitrile (3-BPN, 98%) from Alfa Aesar (Lancs, UK), 
diiodoacetic acid (DIAA, 90+%) from Cansyn Chemicals (Ontario, Canada), 2,3-
dibromopropionitrile (DBPN, 95+%) from Matrix Scientific (Columbia, SC), 2,3-
dichloropropionamide (DCP, 97%) from TCI (Tokyo, Japan), and tribromonitromethane 
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(TBNM, 95+%) from Orchid Cellmark (Princeton, NJ). Potassium chloride (99%), Tris base and 
hydrochloric acid (ACS grade) were purchased from Fisher (Fair Lawn, NJ). 
3.2.2. Estrogen receptor binding assay (ERBA): Single chemical analysis 
The estrogen receptor binding assay (ERBA) followed published procedures as 
previously described for the androgen receptor, with some modifications (20). Briefly, initial 
range finding assays were completed to determine the appropriate receptor concentrations, which 
would result in 5-15% binding. Saturation binding and Scatchard analyses determined the 
dissociation constant (Kd) of the receptor to the potent tritiated 17β-estradiol ([3H]-E2) ligand, 
resulting in a value of 1.0 nM, which corresponds well to the literature value (21). For each set of 
competitive binding assays, an unlabeled E2 control ligand was included along with tests for 
non-specific and total binding of the [3H] ligand to the receptor. The known endocrine disruptor 
and weak binder, 4-NP, was used as a positive control for test chemicals to show a measurable 
affinity at the test concentrations. TEDG binding buffer (10 mM Tris-HCl, pH 7.4; 1 mM DTT; 
10% glycerol; 10 mg/mL bovine serum albumin; 400 mM KCl; 1 mM PMSF; 1mM sodium 
molybdate; 1.5 mM EDTA) was prepared and used to dilute receptor and working chemical 
stocks. Prior to use, the hERs were gently mixed by pipette and diluted to 625 cell eq/ml 
according to the range finding assay, then kept on ice until addition to the assay wells. All assays 
were kept on ice during use and sealed with plate-sealing film during overnight shaking and 
mixing. Test chemicals were prepared in absolute ethanol well below their solubility 
concentrations and stored in amber vials at -20°C for up to 6 months. These were vortexed 
briefly before use in the assay. Unlabeled E2 was run against [3H]-E2 in the reference assay and 
[3H]-E2 was tested for competitive binding against varying concentrations of test chemicals in 
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the binding assays. Each assay concentration was run in triplicate on the day of the experiment 
and repeated on at least two separate days. 
Stocks of 0.1 µM [3H]-E2 and 10 µM unlabeled E2 were prepared from the neat 
standards and stored at -20 °C in amber vials. Aliquots of unlabeled 10 µM E2 and 0.1 µM [3H]-
E2 were dried down in borosilicate glass tubes on a SpeedVac (Thermo Scientific Savant Model 
SPD1010; Waltham, MA) then reconstituted in TEDG buffer and 1 µL absolute ethanol prior to 
addition to the plates. For the assay, 50 µL of freshly prepared working test chemical were added 
to each of three wells in a 96-well plate (Fisher; Fair Lawn, NJ) resulting in final concentrations 
from 2 mM to 0.1 nM following the addition of 25 µL of 8 nM [3H]-E2, at a final concentration 
of 2 nM in the plate. Prepared plates were allowed to gently shake (Thermo Scientific Barnstaed 
Lab Line Rotator; Waltham, MA) for 5 min at 4 °C before 25 µL of the prepared hER was added 
to all wells. One set of three wells for non-specific binding was prepared by adding 50 µL of the 
400 nM unlabeled E2 which is equivalent to a 100-fold excess E2 compared to [3H]-E2 instead 
of test chemical; another set of three wells was used to measure total binding by adding 50 µL of 
TEDG buffer instead of test chemical. Separately, a 5% dextran coated charcoal slurry was 
prepared in TEDG buffer. The sealed prepared plates and slurry were placed on a shaker and 
incubated overnight at 4 °C.  
Following incubation, 50 µL of the charcoal slurry was added to each well and the plates 
were sealed and shaken an additional 20 min. They were then centrifuged (International 
Equipment Company; Needham Heights, MA) at 1000 relative centrifugal force (rcf) at 4 °C for 
5 min, placed on ice, and then 50 µL of the supernatant was removed from each well and placed 
into a 20 mL scintillation vial (Fisher; Fair Lawn, NJ) containing 4.5 mL Opti-Fluor scintillation 
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cocktail. The vial was then briefly shaken and read on a Packard (Palo Alto, CA) 1900 TR 
scintillation counter. 
3.2.3. In silico binding predictions 
 The quick and efficient docking program, Endocrine Disruptome 
(http://endocrinedisruptome.ki.si/), was used as previously described to determine the likelihood 
of DBP binding to the estrogen receptor subtypes and their other nuclear receptor counterparts 
(22). The program utilizes previously published crystal structures of the nuclear receptors and 
AutoDock Vina molecular docking software to determine the potential for the ligands to bind as 
agonists and antagonists. The likelihood of binding is indicated by an asterisk (*) for favorable 
binding, and then their free binding energy (kcal/mol) is calculated (23).  
3.2.4. ERBA binary assay 
 For the binary binding assays, mixtures were prepared by combining equipotent amounts 
of test chemical and 4-NP into one stock solution in absolute ethanol. This means that 
compounds of unequal potency would be adjusted in concentration so that their impact on the 
mixture binding affinity, as measured by a sigmoidal dose response curve, could be predicted 
using the model of concentration addition (CA) (24). Working solutions were then prepared and 
handled as described in 3.2.2. 
3.2.5. Data Analysis 
Data obtained from the scintillation counter (in units of dpm) were analyzed by first 
calculating the specific binding and comparing that to the test concentration. Specific binding 
was calculated for each chemical concentration as shown in Equation 3.1 and then plotted 
against concentration using GraphPad Prism 4 software (Version 4.03, La Jolla, CA): 
!"#$%&"' !"#$"#% ! !"#!!"#$%&%$ !"#$"#%
!"#$% !"#$"#%
∗ 100 = 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐵𝑖𝑛𝑑𝑖𝑛𝑔   (3.1) 
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Using a p-value confidence level of 0.05 to determine whether each DBP was able to 
displace [3H]-E2, a linear regression analysis was fit to each response curve to examine whether 
the slope deviated from a mean of zero. Chemicals without a significant p-value (> 0.05) were 
considered to be non-binding (NB), while a slight binder (SB) refers to a chemical that did not 
reach 50% binding over the tested concentrations (25). Chemicals that showed significant 
deviation were then fit with a log[inhibitor] vs. response (variable slope) curve to determine the 
chemical’s binding affinity, as described by its log[IC50] value, with the bottom constrained to 
zero. The relative binding affinity (RBA) to E2 was calculated by dividing the IC50 of E2 by the 
IC50 of the test chemical, and then multiplied by 100 to be expressed as a percent. For E2, the 
RBA was set to 100%. IC50 values that are smaller indicate more potent binding of the chemical 
to the receptor and, therefore, a larger RBA to E2.  
The CA model as shown in Equation 3.2 was used to determine whether the combination 
of the two chemicals was synergistic, antagonistic, or dose-additive as compared to the IC50 for 





= 𝑋     (3.2)	
In this equation, [A] and [B] refer to the concentrations at the IC50 of the test chemical 
and 4-NP present, respectively, in the binary mixture, [AE] and [BE] refer to the concentrations of 
the individual test chemicals that are required to cause the same 50% binding, and X refers to the 
resulting effect. According to Loewe synergism, if the chemical mixture is additive then the 
combined effect, X, will be 1, if it is synergistic X will be less than 1, and if it is antagonistic 
then X will be greater than 1 (24, 26). Effectively, this means that lower concentrations of those 
chemicals in a mixture are required to induce the same effect for synergistic mixtures and higher 




3.3.1. Individual chemical binding  
 Competitive binding curves were completed for 21 structurally diverse DBPs with ERα, 
shown in Figure 3.1, to concentrations up to but below their solubility limit. The measured IC50 
values for the individual ERBA experiments showed that 9 of the tested DBPs were able to 
weakly bind to the receptor. The results from these assays along with the affinities measured for 
the weak estrogen (4-NP) and natural ligand (E2) are reported in Table 3.1. These binding 
chemicals were TBNM, BDCM, DBPN, TCBQ, DBAN, CSA, TCP, BAM, and 2-CP, with 
log[IC50] values ranging from -3.83 ± 0.064 M for TBNM to -2.19 ± 0.216 M for 2-CP, 
compared to the weak positive control 4-NP that had a log[IC50] of -5.67 ± 0.346 M. The 
measured log[IC50] of E2 was -9.13 M, or an IC50 value of 7.46 E-10 ± 0.636 E-10 M, was in 
close agreement to the published value of 8.77 E-10 (28). Chemicals that bound showed a drop 
from 90% to 10% inhibition over two orders of magnitude, which confirms the expectation that 



















Table 3.1. Estrogen receptor-binding assay results for 21 test compounds, the positive control 4-
n-nonylphenol (4-NP), and the estrogen standard, E2. NB = nonbinder, SB = slight binder.  











E2 284.39 -9.13 ± 0.197 2.12E-04 100 
4-NP 220.35 -5.67 ± 0.346 0.547 0.0331 
TBNM 297.73 -3.83 ± 0.064 44.1 0.0006 





-3.23 ± 0.075 





DBAN 198.84 -2.84 ± 0.328 351 0.0001 
CSA 152.53 -2.83 ± 0.092 228 SB, 0.0001 
TCP 197.45 -2.73 ± 0.021 371 SB, 0.00004 
BAM 137.96 -2.41 ± 0.107 540 SB, 0.00002 
2-CP 128.56 -2.19 ± 0.216 886 SB, 0.00001 
IAA 185.95 NB NB NB 
MCA 168.96 NB NB NB 
NDMA 74.08 NB NB NB 
DCAN 109.94 NB NB NB 
TCAN 144.39 NB NB NB 
MX 217.43 NB NB NB 
CH 165.4 NB NB NB 
DCP 141.98 NB NB NB 
DIAA 311.85 NB NB NB 












 The DBPs CSA, TCP, BAM, and 2-CP were classified as slight binding chemicals 
because they did not reach at least 50% inhibition over the tested assay concentration ranges, 
with relative binding affinities of 0.0001%, 0.00004%, 0.00002% and 0.00001%, respectively. 
TBNM had a RBA of 0.0006%, BDCM had an RBA of 0.0002%, and DBPN, TCBQ, DBAN, 
and CSA had RBA values of 0.0001%. Groupings of RBA values defined by Fang and 
colleagues, classify these DBPs as weak binders because they showed relative binding affinities 
(RBA) of less than 0.001% when compared to the IC50 of E2 (25). Of the chemicals tested, 12 
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were not able to bind to the estrogen receptor as determined by the fact that their dose addition 
curves did not depart from linearity with a p ≤ 0.05 over the concentration range tested which 
was depending on compound solubility. The non-binding chemicals included IAA, DIAA, MCA, 
NDMA, DCAN, TCAN, MX, CH, DCP, DBAA, DCBQ, and 3-BPN. An example of a binding 
































Figure 3.2. Examples of binding (DBPN) and non-binding (DCPN) dose response curves.  
 
3.3.2. In silico binding predictions 
 The results from the molecular docking predictions to ERα and ERβ as agonists and 
antagonists are shown in Table 3.2 indicating likely binding probability, denoted by an asterisk, 
and the free binding energy presented in kcal/mol. The in silico molecular docking predictions 
for these compounds suggest a low probability of binding for all 21 tested DBPs to the receptors, 
including the known weak estrogen 4-NP, which is why none of the results have been marked 
with an asterisk. The software used for these predictions allows for ligand flexibility but limited 
receptor flexibility, which is primarily restricted to receptor side chains, and could account for 
difference in the observed binding for the individual assays but not in the molecular docking 
predictions. This is attributed to the well-established binding pocket flexibility of ERs, which is 
especially influential for estrogen receptor binding as the pocket is known to be highly 
promiscuous.  
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Table 3.2. The results of the molecular docking predictions for the 21 DBPs and weak positive 
control with the ERα and ERβ as agonists and antagonists, with all indicating low probability 
and the free binding energy indicated in kcal/mol.  
 Free Binding Energy (kcal/mol) 
DBP ERα agonist ERα antagonist ERβ agonist ERβ antagonist 
4-NP -6.8 -7.0 -7.1 -7.0 
TBNM -3.5 -3.6 -4.0 -3.6 
BDCM -2.9 -2.9 -3.0 -3.0 
DBPN -3.1 -3.1 -3.2 -3.2 
TCBQ -5.8 -5.4 -5.8 -5.9 
DBAN -3.0 -2.9 -3.1 -2.9 
CSA -3.8 -4.1 -4.4 -4.1 
TCP -5.2 -5.4 -5.3 -5.4 
BAM -3.4 -3.4 -3.4 -3.3 
2-CP -5.4 -5.1 -5.1 -5.1 
IAA -3.0 -2.8 -3.3 -2.9 
MCA -4.4 -4.2 -4.5 -4.1 
NDMA -2.8 -2.5 -3.1 -2.5 
DCAN -3.1 -2.8 -2.9 -3.1 
TCAN -3.1 -3.1 -3.3 -3.2 
MX -5.7 -5.2 -5.5 -5.3 
CH -3.9 -3.9 -4.0 -3.9 
DCP -4.2 -4.1 -4.3 -4.0 
DIAA -3.3 -3.5 -3.5 -3.4 
DBAA -3.5 -3.3 -3.8 -3.3 
DCBQ -5.2 -5.1 -5.4 -5.3 
3-BPN -3.0 -2.9 -3.0 -3.0 
 
3.3.3. Binding as binary mixtures 
 Of the 21 initial DBPs tested, 6 chemicals that were able to bind in the individual 
competitive binding assays and one nonbinding chemical were then examined in binary mixtures 
with 4-NP. Equipotent mixtures were used to determine whether, at concentrations equal to their 
relative activity, the chemicals would be additive, synergistic or antagonist to binding. These 
chemicals included BAM, TCP, 2-CP, TCBQ, DBPN, TBNM, and the non-binding chemical 
DIAA, and their results are presented in Table 3.3. The exception was for DIAA, which was a 
non-binding chemical and was added at equal concentrations to the 4-NP. The RBA values 
showed that all of the chemicals could be classified as weak binders, as expected based on the 
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individual assay results. The concentration addition values were additive according to the CA 
model when the standard deviation of the individual and binary assay concentrations were taken 
into account (27). 
Table 3.3. Equipotent binding assays presented as log(IC50), IC50, RBA, potency ratio, and result 
of the concentration addition test.  
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 DBPs are structurally diverse, often halogenated, structures that form in a highly 
dependent matter based on source water quality and disinfectant type during drinking water 
treatment (15). In order to determine which structural classes are the most potent potential 
estrogens, a subset of 21 DBPs was evaluated that included regulated DBPs, haloacids, 
haloaldehydes, halofuranones, cyanogenic compounds, and by-products that are predicted based 
on the structure of natural organic matter in water. The high number of DBPs identified thus far, 
coupled with the observed estrogenic activity and endocrine disrupting potential of 
conventionally disinfected waters, suggest a need to explore the identity or type of DBP 
responsible for this activity so that they can be mitigated (14, 18, 29). In this work, nine DBPs 
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formerly uncharacterized for endocrine activity, were shown to weakly bind to the estrogen 
receptor and it was demonstrated that they behave in an additive manner when in mixtures with 
4-NP, a known weak endocrine disruptor that is found as a surfactant degradation product in 
some surface waters. This supports the notion that estrogenic activity in waters disinfected with 
chlorine or chloramine could, in part, be attributed to DBPs. For example, BAM and DBAN both 
bound to the receptor and have been found to form in some drinking waters containing bromide 
with chloramination. TBNM, another weak binder, can form under multiple disinfection 
scenarios using chlorine, chloramine, ozone-chlorine, or ozone-chloramine (15). While all of 
these DBPs were only able to bind to the receptor weakly when compared to 17β-estradiol, their 
ability to bind at all indicates their potential to disrupt the long-term balance of the endocrine 
system. A number of diseases have already been associated with chronic exposure to low-level 
contaminants in the environment and as these chemicals have been shown to influence gene 
expression, at times with non-monotonic responses (30). The additive effect of these DBPs 
further supports the need to identify which emerging contaminants that can bind to the estrogen 
receptor and, therefore, interfere with the homeostatic balance of the estrogen pathway and those 
pathways in which it is involved (6, 31). Due to the extensive number of DBPs formed during 
disinfection, the ability of these DBPs to bind at all despite being at such low-levels is an 
important finding for understanding the estrogenic nature of this class of compounds. 
 The 9 DBPs that were able to bind to the estrogen receptor in this study ranged in IC50 
concentrations from 44.1 mg/L for TBNM to 886 mg/L for 2-CP. While these concentrations are 
clearly above the sub- to low-µg/L levels occurrence levels detected in drinking waters (15, 32) 
they still indicate the ability of the chemicals to bind to the estrogen receptor and the 
implications of chronic exposures are unknown. Five of the nine binding compounds were 
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bromine-containing species, which is consistent with previously published work that suggests 
higher toxicity for brominated DBPs. Neither of the iodinated compounds were able to bind 
despite the observation that they are the most genotoxic of the halogenated DBPs (33). Bromide 
and iodide concentrations in influent water enhance the formation of bromine- or iodine-
containing DBPs relative to those containing just chlorine as the halogen (15). When considering 
toxicity, the predominant estrogen affinity observed for bromine-containing DBPs supports the 
claim that higher levels of these compounds could lead to greater toxicity (34). The most potent 
DBP in this study, TBNM, was found at levels from 0.1 to 5 µg/L in the U.S. Nationwide DBP 
Occurrence Study, which were the highest levels within the class of 9 different 
halonitromethanes (32, 35). BAM, a chemical in the class of haloamides and another emerging 
class of DBPs, was detected in distribution system samples at concentrations up to 7.6 µg/L (35). 
TCBQ, which was able to bind despite DCBQ being unable to, has also been detected in drinking 
water samples at ng/L levels and is part of the class of halobenzoquinones which are suspected 
bladder carcinogens (36). Effectively, the generally low-levels of individually detected DBPs can 
logically be considered to contribute to a higher concentration of the total DBP presence in 
disinfected waters.  
Limited structural trends were observed between the DBPs tested, with no trends 
appearing based on molecular weight or size. This is most likely due to the large and 
accommodating binding pocket, which is able to accept ligands in multiple binding modes (4). 
NDMA, a commonly studied emerging contaminant and a chloramine byproduct, also showed no 
binding affinity. Aromatic ring structures, with the exception of DCBQ, were all able to bind 
which is a common outcome with these chemicals because they are more structurally similar to 
the aromatic rings of the natural estrogens, such as E2 and estrone. 
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 The group of chemicals selected for this study was based on their structural diversity as 
well as suspected reproductive and other toxicity endpoints. For example, BDCM, a regulated 
DBP, was shown to induce a toxicogenomic response in embryo development specifically in the 
estradiol pathway, at ppb (µg/L) levels when the exposure occurred during embryo development. 
TCP has been shown in previous studies to cause disruption through the retinoid X receptor, 
which is another member of the same nuclear receptor superfamily as the estrogen receptor (37). 
2-CP, which was the weakest binder of the estrogen active compounds in this study, has been 
shown to have dose-dependent toxic and genotoxic effects in bacteria, fish and human cell lines 
previously (38). Another chemical with established toxicity is DBAN, shown in this study to 
have a log[IC50] value of -2.84 ± 0.328 M and has been identified as capable of inducing DNA 
damage and altering tumor-initiating genes causing hepatotoxicity (39). In all of these instances, 
the measured estrogenic activity of the individual compounds adds to the body of knowledge of 
the overall risk to these specific DBPs, as these chemicals are shown to induce multiple toxicity 
pathways. 
 As binary mixtures with 4-NP these chemicals showed binding affinities in the range of 
1880 µM for TBNM to 3.7 µM for DIAA. The concentration addition values, which crossed 
from below 1 (synergistic) to above 1 (antagonistic) when standard deviations of the individual 
and binary IC50 values were taken into account, support the assumption of additive activity with 
these compounds to the receptor. The mixtures here are particularly important since 4-NP has 
been detected in waterways as a byproduct of surfactant degradation and largely recalcitrant in 
treatment processes (18, 29). Additionally, drinking water regulations are set as a maximum 
contaminant level for groups of a subset of the known DBPs, such as sum of the concentration of 
the four trihalomethanes (including the listed BDCM), the sum concentrations of 5 haloacetic 
	 68	
acids, and bromate, and all at sub-micromolar levels. The ability of 7 of the tested, but 
unregulated, DBPs to bind to the estrogen receptor in an additive manner suggests that 
unregulated compounds even well below their IC50 concentrations in water, could still account 
for some of the observed estrogenic activity. 
This study identified new DBPs capable of targeting the estrogen receptor both 
individually and in mixtures.  These compounds have previously been shown to be toxic for 
other endpoints and, therefore, their ability to also impact the estrogen pathway further 
emphasizes the risk from exposure. Additional work needs to be completed, however, to show 
how the binding of DBPs to the estrogen receptor will influence gene transcription in a tissue-
specific manner, as the binding nature with the estrogen receptor has been established as variable 
and dynamic (4). Specifically, chronic low-level environmental exposure to these compounds is 
also of concern, and their implications on long-term gene transcription and disease progression 
should be investigated. Other chemicals, such as flame-retardants, have been shown to have 
similarly safe levels in toxicological studies but result in adverse health effects when long-term 
exposures occur (40). Future research should include an expansion of the structural groups in this 
study to include other compounds from the most potent groups identified, namely 
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CHAPTER 4: OPTIMIZATION STUDIES FOR ENDOCRINE ACTIVITY REMOVAL 




Wastewater treatment is designed to remove the biological activity and chemical 
contaminants inherently present. The treatment steps vary depending on the nature of the influent 
and the capabilities of the system, with the goal of producing effluent water that can be released 
back into the environment without causing harm. As water scarcity increases, however, efforts to 
expand the reuse of this treated wastewater are being developed (1). In designs for decentralized 
domestic wastewater treatment systems, the removal of chemical and microbial contaminants 
would have to be considered if the water is to be reused for agricultural or other purposes (2). 
Vertical sand filters and constructed wetlands are two types of treatment that can be applied in 
rural settings and evaluated for potential reuse (3-6).  
Common contaminants found in wastewater treatment plant and septic tank effluents, 
receiving streams, and stormwater runoff include personal care products, pesticides, and 
hormones (7). Many of these compounds are recalcitrant and can, therefore, persist in the 
environment into which they are disposed, potentially causing harm to aquatic life or entering 
drinking water treatment plants downstream (8). Although at low micro- or nanomolar levels in 
wastewater (in the microgram to nanogram per liter range) these compounds are environmental 
contaminants of concern because of their chronic exposure to aquatic organisms or humans (9-
12). In particular, endocrine disruption is a known area of concern for both raw and treated 
wastewater (11, 13, 14). Endocrine disruptors, which include hormones, plasticizers, and 
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pesticides, are able to mimic natural hormones and influence signaling and gene transcription, 
resulting in diseases such as breast and prostate cancer as well as infertility (15-17). The risk of 
exposure to these compounds also exists for aquatic life where intersex, fecundity, and birth 
defects are of concern (15, 18).  
Besides the sand filter design mentioned in Chapter 1, section 1.2, other onsite 
constructed wetland wastewater treatment options include subsurface flow (SFCWs), free water 
surface (FWSCWs), and vertical flow constructed wetlands (VFCWs). SFCWs and FWSCWs 
have a tendency towards anaerobic conditions while VFCWs have a larger aerobic zone (19). 
These Hybrid Constructed Wetland systems utilize multiple treatment environments to enhance 
wastewater treatment, with various goals and related performances. Generally, constructed 
wetlands contain shallow ponds or beds in which emergent wetland vegetation grows, and a 
constant water level can be maintained. Similar to vegetative sand filters, the microbes present 
will be attached to the root structure of vegetation or soil and help to increase the aerobic area of 
treatment depending on the depth, saturation, and other factors, while the plants can also uptake 
contaminants. Loading rates and hydraulic retention times can be tailored depending on the types 
and concentrations of contaminants. FWSCWs have inflow into a basin, generally 2-3 ft or up to 
4 ft deep, which is planted with dense vegetation from which the treated water is released after 
about 3 days. The major difference between vegetative sand filters and CWs is the water level, 
which changes how the aerobic portion is maintained and the biological oxygen demand (BOD), 
and subsequently how effectively the carbon and nitrogen are treated. To maintain some level of 
aeration, SFCWs and FWSCWs require large amounts of land to be in contact with air, which is 
a limitation of their use when compared to vegetative vertical flow sand filters. While these 
systems receive spaced doses of water and rely on that spacing to keep some dissolved oxygen 
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from the air in the upper levels of the system, CWs use plant systems and dissolution into the 
water layer to maintain an aerobic portion, which is where aerobic microbes exist and are needed 
for nitrification. Anaerobic portions of both CWs and vegetative sand filters are where 
denitrification occurs by heterotrophic bacteria, but this is most effective when there is enough 
organic content present. In both types of systems, recirculation of effluent allows for 
denitrification followed by nitrification (breaking down organic carbon and ammonia), then 
denitrification again to remove the remaining N by releasing N2 (19). Alternating between 
aerobic and anaerobic stages, which is increasingly common in hybrid systems, significantly aids 
in nitrogen removal and, therefore, is becoming a more widely used process (19, 20).  
VFCWs are also highly efficient at removal of emerging contaminants because they 
operate under aerobic conditions and require less space as a result (21). Because VFCWs operate 
with a similar dosing scheme to vegetative sand filters, the hydraulic retention time is only a few 
hours compared to a few days for horizontal flow constructed wetlands (HFCWs), like those 
discussed above. In a study by Matamoros and colleagues, VFCWs were compared to unplanted 
sand filters (SFs) and flooded systems, such as HFCWs, for their ability to remove 
pharmaceuticals (22). HFCWs, including SFCWs and FWSCWs, have lower levels of oxygen 
than VFCWs or vegetative sand filters and, therefore, require a longer contact time for pollutants 
to be degraded by microbial communities since a smaller population of aerobic microbes and 
smaller concentration of O2 for consumption will exist (22). The researchers found that the 
VFCW was more robust over time, with less impact caused by overloading conditions, and that 
the presence of vegetation and a specific hydraulic loading rate were crucial for the removal of 
pharmaceuticals and personal care products, BOD5, and ammonia from the wastewater (22). 
Overall, VFCWs have also been shown to be more effective for wastewater treatment than other 
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constructed wetland configurations, including SFCWs and unplanted sand filters. Ultimately, 
introduction of aerobic periods by maintaining a specified hydraulic loading rate and retention 
time that alternates with anaerobic periods is understood to be important for the treatment of 
chemicals of emerging concern. These periods allow for changes in the microbial communities, 
dissolved oxygen (DO) concentration, and the time that compounds are in contact with the 
microbial communities themselves, which make VFCWs and vegetative sand filters possibly 
more efficient for emerging contaminant treatment than traditional HFCWs or FWSCWs.  
The Jordan Lakes Business Center (JLBC) is a small business park that includes a school 
and totals around 60 people in Apex, North Carolina, in which a vegetated sand filter connected 
to a greenhouse is used to treat its domestic wastewater. This site is designed to include a 
sedimentation tank, from which the wastewater flows into the anaerobic zone of a vegetated sand 
filter and is allowed to move down through the soil before being collected and reapplied to the 
aerobic zone (23). The water then passes through the anaerobic zone again before being pumped 
to the greenhouse, which grows tropical plants, before disinfection and reuse for toilet flushing 
and landscaping. This system, which includes combinations of vegetated sand filters and 
subsurface flow constructed wetlands, is the reference site for this study and includes a 
combination of treatment types that provide a range of physical, chemical, and biological 
processes. While primarily aerobic vegetated sand filters are effective for nitrification, 
phosphorus storage, and the oxidation of organic compounds, constructed wetlands can be 
hypoxic or anaerobic and are instead useful for denitrification, physical removal, and the 
anaerobic metabolism of organic compounds (24, 25). The domestic wastewater at this hypbrid 
wetlands site was used for the duration of this work, after it had passed through the anaerobic- 
aerobic-anaerobic stages of circulation of the vegetated sand filter but before it has been 
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disinfected or reached the greenhouse. The addition of wastewater to this system occurs in 
pulses, which aids in the dispersion of oxygen in the aerobic layer and helps to prevent clogging 
from excessive exopolymeric substances, which are produced by the biofilm present on the 
packing material (26).  
The use of vertical flow filters for wastewater treatment has been well studied, as 
discussed in Chapter 1, section 1.2, but the optimization of these systems for the removal of a 
range of persistent pollutants has not yet been accomplished. At the JLBC, the system uses 
Stalite as the packing medium. Stalite is a lightweight, expanded-slate aggregate that has a high 
porosity allowing for biofilm formation with the potential to act as a suitable packing material in 
a vertical flow filter, as an alternative to commonly used substrates such as gravel and soil.  It is 
an example of a locally sourced, cheap material that can serve as a guide for expanding on the 
materials used in constructed wetlands for wastewater reuse. In this study, varying sizes of this 
material were packed into three sequential columns for the treatment of a domestic wastewater 
collected from the JLBC. The removals of seven persistent wastewater pollutants that are also 
commonly found in surface waters were measured using liquid chromatography- electrospray 
ionization-mass spectrometry (LC-ESI-MS), along with the effects on endocrine activity. The 
concentrations of the target chemicals were elevated through the addition of standards at the start 
of experiments in order to allow for their detection after treatment. The target chemicals in this 
study were selected to represent a wide range of wastewater pollutants with varied degradation 
pathways. Included were the herbicide atrazine, the stimulant caffeine, the anti-epileptic 
carbamazepine, the insect repellent DEET, the hormone 17β-estradiol, the surfactant degradation 
product nonylphenol, and the antimicrobial agent triclosan. These compounds are found in 
microgram to nanogram per liter ranges in wastewater effluent, have varied known degradation 
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pathways, and are considered emerging contaminants of concern. Some of these chemicals are 
also known to cause endocrine disruption, with 17β-estradiol acting as a particularly potent 
estrogen.  
To determine the most effective treatment for this column system, wastewater was dosed 
with the target chemicals and added at unsaturated dose intervals of 8, 12, 24, 36, 48, and one 
saturated 8h interval. These experiments varied the amount of water added to each column based 
on that time period, and were tested using the three sequential columns acclimatized for more 
aerobic and more hypoxic levels of oxygen, then run in the order of hypoxic-aerobic-hypoxic 
and aerobic-hypoxic-aerobic. The optimal dose interval of a Stalite-packed vertical flow filter 
was determined based on the overall removal of the target chemicals and the measured reduction 
in estrogenic activity. 
4.2. Materials and Methods 
	
4.2.1. Chemicals 
 Atrazine (99.1%), DEET (98.1%), anhydrous caffeine, and D(+) glucose were purchased 
from Fluka (St. Louis, MO). From Sigma Aldrich (St. Louis, MO), citric acid monohydrate, ACS 
grade methyl-tert-butyl ether (≥99%), chlorophenol red-β-Dgalactopyranoside, cupric sulfate 
pentahydrate, thiamine, erythromycin, pyridoxine, D-pantothenic acid hemicalcium salt, 
potassium hydrogen phthalate (99.95%), 4-nonylphenol (technical grade), 17β-estradiol (98.1%), 
and triclosan were acquired. Potassium dihydrogen phosphate, potassium hydroxide pellets, 
liquid ammonium hydroxide (ACS grade), casamino acids, agarose, anhydrous dextrose, Luria-
bertani (LB) powder, and ethanol (absolute) were purchased from Fisher Scientific (Fair Lawn, 
NJ). From MP Biomedicals (Santa Ana, CA), atenolol, iron(III) sulfate, L-aspartic acid, and the 
FastDNA Spin Kit for Soil were purchased. L-threonine, magnesium sulfate septahydrate, 
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inositol, carbamazepine (99%), and adenine sulfate were from Acros Organics (New Jersey, NJ), 
and biotin was from Kodak (Rochester, NY). Ammonium sulfate was from Mallinkrodt (Paris, 
KY), adenine from Alfa Aesar (Ward Hill, MA), and bacto agar and Difco yeast nitrogen base 
from BD (Sparks, MD). ACS grade methanol was from Honeywell Burdick & Jackson 
(Muskegon, MI), potassium nitrate was from EM (Gibbstown, NJ), and laboratory grade water 
(LGW) (> 17 MΩ) prepared using a Dracor (Durham, NC) system that passes chlorinated tap 
water through ion exchange resins and activated carbon before 0.2 µm filtration. HPLC grade 
methanol was purchased from VWR (Radnor, PA). SYBR SAFE DNA Gel Stain (Invitrogen, 
Carlsbad, CA), agarose (Fisher, St. Louis, MO), and some tests for the MP Biomedicals 
FastDNA Spin Kit for Soil (Santa Ana, CA) were generously provided by Dr. David Singleton.  
4.2.2. Solid Phase Extraction (SPE) 
SPE was used to concentrate the analytes in effluent samples for chemical and endocrine 
activity. This was completed for all column 3 and the final column 1 and 2 time points for each 
study, as previously described (27). Briefly, to concentrate the target analytes, 200 mg/6 mL 
Strata-X, 500 mg/3 mL Strata-SAX, and 200 mg/3 mL Si-1 cartridges (Phenomenex, Torrence, 
CA) were used. The Strata-X cartridges were conditioned with 3 mL methyl tert-butyl ether, 3 
mL methanol, and 6 mL LGW, while the Strata-SAX cartridges had an additional wash of 3 mL 
of 0.2 M citric acid and were connected to the top of the Strata-X cartridges. Each new JLBC 
unspiked wastewater was measured into 250 mL volumes and spiked with increasing 
concentrations (5 – 150 µg/L) of each of the target analytes using the standards from the column 
study to obtain a standard addition calibration curve. 250 mL, in duplicate for each sample, of 
the filtered wastewater samples were spiked with either 50 or 100 µg/L atenolol internal standard 
(consistently between dose interval extraction) and then passed over the conditioned cartridges 
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on a vacuum manifold at a flow of less than 8 mL/min. The SAX cartridges were then discarded 
and the Strata-X cartridges were washed with 3 mL of 40% HPLC grade methanol in LGW, 3 
mL of LGW, and 3 mL of 10% HPLC grade methanol and 2% ammonium hydroxide in LGW, 
then dried under vacuum for 1 h. Additionally, 200 mg/3 mL Si-1 cartridges were conditioned 
with 2 mL of ACS grade methyl tert-butyl ether: HPLC grade methanol (9:1) and then the Strata-
X cartridges were eluted slowly with 5 mL of the same mixture directly onto the Si-1 cartridges 
and collected directly into conical vials. These vials were subsequently placed on a heating block 
at 40 °C and the extracts blown down to dryness under a gentle flow of high purity N2 (Airgas, 
Radnor, PA) using a Pierce (Rockford, IL, USA) Reacti-Vap Model 18780. Samples were 
reconstituted into 2 mL HPLC grade methanol for chemical analyses. Samples that were to be 
used for both chemical and estrogenic activity analyses were split equally following elution and 
then blown down separately in order to reconstitute in 1 mL of methanol for chemical analysis 
and 1 mL of ethanol for estrogenic activity analysis, and stored at -20°C in 2 mL amber vials 
(Fisher, St. Louis, MO).  
4.2.3. Chemical Analysis 
Reconstituted SPE extracts were diluted by pipetting 20 µL into 1 mL HPLC grade 
methanol containing 100 µg/L of erythromycin and analyzed using reverse phase liquid 
chromatography with a 3.0mm x 50 mm x 1.7µm ACQUITY UPLC CSH (Charged Surface 
Hybrid Particle) column (Waters, Milford, MA) connected to a Thermo Scientific (Waltham, 
MA) TSQ Quantum Ultra triple-quadrupole mass spectrometer (LC/MS). Compound detection 
was achieved via electrospray ionization for ion transitions in positive mode for atrazine (m/z: 
216 è 146), caffeine (m/z: 195 è  138, 195 è  110), carbamazepine (m/z: 237 è  194), 
DEET (m/z: 192 è  119), and transitions in negative mode for 17β-estradiol (m/z: 271 è  145), 
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nonylphenol (m/z: 219 è  133), and triclosan (m/z: 287 è  142).  The column temperature was 
maintained at 30 °C and the flow rate was kept at a constant 0.20 mL/min. A gradient elution 
was employed with the mobile phase initially consisting of 99.9% of a 0.05% ammonium 
hydroxide solution in LGW water and 0.1% HPLC grade methanol, the latter then increased to 
5% by 0.3 minutes and held for 1.4 minutes, then increased to 50% over 1 minute and held for 
1.5 minutes. The methanol concentration was then increased to 80% over 1.7 minutes and held 
for 1.6 minutes, increased again to 99.9% over 1.4 minutes and held for 5 minutes. At this point, 
the methanol was decreased to 0.1% over 0.7 minutes and then held, amounting to a total method 
run time of 21 minutes. 
4.2.4. Yeast Estrogen Screen 
 Estrogenic activity of the ethanol-reconstituted SPE extracts was measured using the 
yeast estrogen screen (YES) assay. These were brought to room temperature and diluted into 
10% ethanol in LGW and run on the assay as previously described (28) and given in Appendix 
E, with the following changes. LGW was filtered sterile prior to its use for preparing 
chlorophenol red-β-D-galactopyranoside (CPRG), the 10% ethanol solution, and chemical stocks 
because of prior issues with microbial contamination. Yeast colonies were grown on solid Ura-
Trp agar plates to prevent contamination of this yeast strain because it is differential and 
selective and will not allow for the growth of non-targeted strains. The column-treated 
wastewater samples that were tested were the source (unspiked), spiked, early, mid, and final 
time points. The early, mid and final time points are relative for each study due to the difference 
in the total number of collected samples; for example, the 36h study has fewer samples than the 
8h study due to the longer dose interval.  
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The cytotoxicity absorbance (620 nm), which is a measure of the turbidity of the 
suspension, from the negative control (10% ethanol), and the cytotoxicity absorbance (620 nm) 
measured at each concentration in the assay were subtracted from the absorbance reading (540 
nm) that resulted from estrogenic chemicals. The estrogenic samples bound to the estrogen 
receptor in the nucleus of the yeast, which then bound to the estrogen response element and 
allowed for transcription of lac-Z, the reporter gene. Lac-Z causes the expression of β-
galactosidase, which hydrolyses the galactosidic bond in CPRG, causing a color change from 
yellow to red, which can be measured by absorbance at 540 nm. Duplicate absorbance 
measurements of each well from the samples and the positive control (E2) standard plates were 
graphed using GraphPad Prism 4.3 (GraphPad Software, La Jolla, CA). The corrected 
absorbance values were plotted against the volume of extract added to each well and fitted with a 
sigmoidal dose curve (variable hillslope), which gives an EV50 (effect concentration at 50% 
activation) in terms of liters of sample added per well. The E2 standard was prepared in 10 % 
ethanol and diluted across 11 wells which, after processing, generate absorbance values which 
are plotted against concentration in terms of ng/well, producing an EC50 value (ng/well). Results 
of analyses are presented as an estradiol equivalent factor (EEF), shown in Equation 4.1 (29). 
Samples were run in triplicate and results are presented as the mean ± standard deviation.  









    (4.1) 
 The results of the YES assays, presented as estradiol equivalents (EEQs) (ng/L), were 
then compared to results of predicted EEQs, which are the result of the potency of each 
individual compound (measured by EEF) multiplied by the concentration of that compound 
obtained from the chemical analysis in that sample (see Equation 4.2). These comparisons are 
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used to indicate the difference between the measured estrogenic compounds and the observed 
estrogenic activity of the wastewater. 
          𝐸𝐸𝑄 =  𝐸𝐸𝐹!!!!! ∙ [𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛]!       (4.2) 
4.2.5. Other Analyses 
Ammonia, nitrate, and nitrite measurements used Hach® kit methods numbers 64, 60, 
and 54, respectively (Hach; Loveland, CO). Samples were first filtered using a Whatman GF/D 
(Little Chalfont, UK) (2.7 µm, 4.7 cm) glass fiber filter stacked on top of a Whatman GF/D 
(Little Chalfont, UK) 934-AH (1.5 µm, 5.5 cm) glass fiber filter in a vacuum filtration apparatus, 
then the filtrate was filtered again using a 0.45 µm, 47 mm nylon filter (Fisher, St. Louis, MO). 
The final filtrate was then diluted by pipette into LGW to fall within the kit concentration range 
and protocols for the kits were followed. For TOC, TN, DOC, and DN measurements, samples 
were diluted by pipette with LGW into an estimated range of 0.5 – 10 mg/L as C or N as 
appropriate based on a reading of the source wastewater. Standards of 0.5, 5, and 10 mg/L as 
carbon and nitrogen were prepared from 1,000 mg/L stock solutions of potassium hydrogen 
phthalate as C, and potassium nitrate as N. These stocks were stored for up to 2 months at 5 °C. 
The samples and standards were acidified to pH 2-2.5 using 2N HCl and measured using a TOC-
V organic carbon analyzer and TNM-1 total nitrogen measuring unit (Shimadzu; Atlanta, GA). 
Total coliform and Escherichia coli were measured as colony forming units (CFU) for 
the source wastewater and final effluent from each study using IDEXX Colilert Quanti-Tray kits 
(Westbrook, ME). Unfiltered samples were diluted 1:10 into LGW, combined with the Colilert 
chemical indicator, and poured into 96 well trays which were then incubated (Thermo Electron 
Corporation, Marietta, Ohio) for 24 h at 37 °C. Wells that turned yellow were considered 
positive for total coliform and those that were yellow and then fluoresced blue under UV light 
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were considered positive for Escherichia coli by the IDEXX protocol and converted into CFU 
using the IDEXX most probable number (MPN) table. 
4.2.6. Column Study 
4.2.6.1. Column Setup  
 The columns used in this study were filled with wastewater collected from the JLBC, 
which is a small (~60 person) site that contains a school and small businesses with onsite 
wastewater treatment through a constructed wetland. A schematic of the JLBC treatment setup is 
shown in Figure 4.1, which includes treatment with stacked vegetated filters and anaerobic 
wetlands. The wastewater for use in this study was collected in batches of 20 - 50 L from after 
the VSFs and anaerobic wetlands after partial treatment, which included passage through a 
settlement tank and vegetated constructed wetland, then was stored at 5 °C for use in the column 
study. It still had biological activity, organic matter and nitrogen content, but because of low or 
non-detectable levels of our target compounds the water was spiked with a mixture of these 
chemicals before use. It was expected that the small size of this site would allow for fairly 





Figure 4.1. A schematic of the Jordan Lake Business Center on-site reclamation system in NC 
from which wastewater was collected.  
 
In this study, three 110 cm x 10 cm stainless steel columns were packed with 3/8”, 5/16”, 
and ‘sand-sized’ Stalite (Gold Hill, NC) sizes according to Figure 4.2. Each was equipped with 
ports at the bottom of the column to drain effluent and three ports along the sides of the column 
from which to collect core samples. To prevent biofilm growth in the column effluent during the 
experiments, the columns were wrapped with heat tape and insulation to maintain a temperature 
of 18-20 °C, then kept in a cold room at 5 °C. The cooled constant temperature room allowed for 
the collection of effluent from the columns directly into flasks that were kept cold during the 
period of the experiments and maintained the integrity of the sample without promoting further 
bacterial growth or chemical degradation in the water held outside the columns. 
The wastewater was periodically changed by draining the columns and refilling with new 
wastewater over the course of more than four months to allow for the formation of a biofilm 
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and second round (study 2) of experiments. The column order for study 1 is presented in 
Appendix C, Figure C.1. For study 2, the order of the columns were run as presented in Figure 
4.2, with the first and third columns aerobic and the second hypoxic.  
 
Figure 4.2. Diagram of the columns for study 1 packed with layers of (A) 3/8”, (B) 5/16”, and 
(C) sand-sized Stalite® material for the dose interval studies showing sampling ports 1a-c, 2a-c, 
and 3a-c. Columns 1 and 3 are kept aerobic and open to the air, while column 2 is kept hypoxic 
and capped.  
 
After inoculation of the columns with periodically changed wastewater, bacterial 
presence on the Stalite was tested by taking sterile swabs of the tops and mid-points of each of 
the columns and inoculating them in LB broth overnight at 35 °C. Cloudiness, which indicated 




























bacterial growth, was observed in all samples and, therefore, study 1 was started. After 
inoculation with wastewater following study 1, it was necessary to confirm whether there was 
still a biofilm present on the Stalite in the columns. Core samples of about 25 g were removed 
from ports 1a-c, 2a-c, and 3a-c with a stainless steel coring device that was wiped with ethanol 
between each sample and the core samples frozen overnight at  -80 °C. The samples were 
allowed to thaw before DNA was extracted using the MP Bio FastDNA Spin Kit for Soil 
according to the protocol provided by the manufacturer and included in Appendix E. The 
extracts were then run on a 1% agarose gel and compared to a DNA ladder to determine whether 
any genomic DNA was present.  
In a preliminary set of dose interval experiments, referred to as study 1, the columns were 
set to mimic an operating constructed wetlands field site in Chatham County, NC that alternates 
between zones in the order hypoxic-aerobic-hypoxic. The dose intervals in study 1 were each run 
for 14 days to allow for the establishment of a period in which the columns gave consistent 
removal of the target compounds, which were analyzed as previously described in section 4.2. 
This study was done in preparation for later work that would utilize the column study data. 
However, due to a change in the field site a second set of dose interval experiments, study 2, was 
undertaken. The primary difference between the two studies can be described as follows. In 
study 1, the wastewater at the field site was dosed to the wetland midway through the bed 
material in a hypoxic zone and then recirculated to dose a vegetated vertical flow filter before 
passing through the hypoxic zone for a second time, allowing for better removal of nitrogen 
species. In study 2, the wastewater was introduced to the vegetated vertical flow filter first, 
which is aerobic, before passing through a hypoxic zone and then recirculated.  
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4.2.6.2. Dose Intervals 
 The target chemicals were prepared as 1 g/L stock solutions in either HPLC grade 
methanol or LGW, depending on solubility, and then stored in amber vials at 5 °C for up to 5 
months. The relevant properties of these chemicals are presented in Table 4.1, and they were 
spiked into the wastewater at 100 µg/L and mixed for each dose immediately prior to adding the 
water to column 1 for each time point during each dose interval. To ensure low oxygen levels in 
the hypoxic column 2, the effluent from column 1 was flushed with high purity argon (Airgas, 
Durham, NC) through a stainless steel transfer line for 30 min prior to addition to column 2, 
while the doses to be added to columns 1 and 3 were flushed with industrial grade air connected 
to a stainless steel transfer line (Airgas, Durham, NC) to increase the oxygen content. This 
procedure was done exactly the same for study 1, except that the doses to be added to columns 1 
and 3 were flushed with high purity argon (Airgas, Durham, NC), while the dose to be added to 










































































a Handbook of Data on Organic Compounds, 1994. (30) 
b Handbook of Aqueous Solubility Data Second Edition, 2010. (31) 
c United States Environmental Protection Agency, 2009. (32) 
d CRC Handbook of Chemistry and Physics 95th Edition, 2015. (33) 
e CRC Handbook of Chemistry and Physics 88th Edition, 2008. (34) 
f Hawley’s Condensed Chemical Dictionary 15th Edition, 2007. (35) 
g The Merck Index – An Encyclopedia of Chemicals, Drugs, and Biologicals. 2006. (36) 
 
A summary of the dose interval experiments is shown in Table 4.2. For all intervals 
except the 8h saturated, the columns were allowed to drain freely from the port on the bottom of 
OH
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the column into 2 L collection flasks after dosing. For the 8h-saturated interval, which 
represented a flooded wetland, the column ports were closed for the duration of each dose period 
and then allowed to drain before the addition of the next 8h dose. The intervals maintained a 1.61 
L addition per 24 h period, which is the equivalent of 2 gal/ft2/day for dose interval studies 8, 12, 
and 24 h but 1.61 L for the 36 or 48 h dose intervals. 
Table 4.2. The batch loading intervals and volumes used for each of the column studies.  
Dose Interval 
(h) 









8 Saturated 1.61  ✓ 100 0.537 
8 1.61 ✓ ✓ 100 0.537 
12 1.61  ✓ 100 0.805 
24 1.61 ✓ ✓ 100 1.610 
36 1.61a ✓ ✓ 100 1.610 
48 1.61a ✓  100 1.610 
aVolume added at the period of each interval, every 36h or 48h, respectively. 
  
 The doses were added in sequence, with the collected effluent from column 1 being 
added to column 2 and effluent from column 2 being added to column 3 at each dose time point. 
For study 1, the first and third columns were hypoxic, while column 2 was aerobic, as shown in 
Appendix C. This preliminary study was run for 14 days to measure the efficacy of the columns 
for removing the target chemicals. For study 2, the length of the study was shortened to 9 days 
based on the time period observed in study 1 to reach consistent measurements of the target 
compounds. Study 2, which mimics the JLBC constructed wetlands and the field site ultimately 
used for other parts of a larger study, was run with columns 1 and 3 as aerobic while column 2 
was hypoxic. Sample doses were added slowly by funnel to the center of the column over 3-4 
min in order to minimize potential boundary flow effects. Due to the size of the Stalite gravel 
compared to the column diameter and the slow rate of dose addition it is expected that there was 
minimal impact from boundary effects. 
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The entire sample volume from column 3 was collected while 50 mL aliquots were 
collected from columns 1 and 2 for each day and from all three columns in full for the final day 
of each dose interval. The effluent from column 3 for each time point was collected as an 
aggregate of all doses that combined for a full 1.61 L dose; for example, three 8 h dose points or 
two 12 h dose points. Due to the difference in time intervals and the lag time from collecting a 
full 1.61 L from column 3, the collected samples are labeled as time point (T) and column (C); 
for example, T2C3 is time point 2 column 3 effluent. The effluents that correspond to the final 
time points are labeled as TFinal because of the difference, again, in the time for the first full dose 
to exit column 3. These effluent samples were filtered using two Whatman GF/D (2.7 µm pore 
size, 4.7 cm diameter) and 934-AH (1.5 µm pore size, 5.5 cm diameter) glass fiber filters (Little 
Chalfont, UK) placed together, in line, in a vacuum filtration apparatus, and the filtrate 
subsequently filtered using a 0.45 µm pore size, 47 mm diameter nylon filter (Fisher, St. Louis, 
MO). Filtered samples were then used for their dissolved organic carbon (DOC), dissolved 
nitrogen (DN), ammonia, nitrate, nitrite analyses as well as for solid phase extraction (SPE) of 
the for target analytes and estrogenic activity. Unfiltered samples were used for the total organic 
carbon (TOC) and total nitrogen (TN) analyses. Raw unspiked wastewater was treated the same 
as samples for each interval for comparison. Samples were stored at 5 °C in amber bottles until 
analyses, which occurred during the week following the conclusion of each dose interval 
experiment. 
4.2.6.3. Stalite Extractions and Estrogenic Activity 
 Core samples of an estimated 30 g Stalite were removed from column ports 1a-c, 2a-c, 
and 3a-c after the final dose interval of study 2 was completed. The Stalite was allowed to dry 
overnight at room temperature and then 20 g of each sample was weighed and crushed to a 
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coarse powder with a mortar and pestle. The loose powder was then transferred to a beaker, 10 
mL of HPLC grade methanol was mixed in and the contents sonicated (Fisher Scientific, St. 
Louis, MO) for 45 min. The sample was allowed to settle and the supernatant liquid was 
transferred by pipette to a new flask. The process was repeated on the solid with another 10 mL 
of methanol. The methanol aliquots were combined and blown down to dryness under a gentle 
flow of high purity N2 (Airgas, Radnor, PA) using a Pierce (Rockford, IL, USA) Reacti-Vap 
Model 18780 while on a heating block at 40 °C. The samples were then reconstituted in 1.5 mL 
of absolute ethanol and used for the yeast estrogen screen assay as previously described. A 
control sample of unadulterated Stalite (20 g) was extracted in the same manner to measure any 
background estrogenic activity that could be attributed to the solid itself. 
4.2.7. Batch Study 
 To evaluate the contribution of sorption to the bed material as compared to 
biodegradation from the biofilm for the removal of the target chemicals, a batch study was 
undertaken. Stalite was first inoculated with JLBC wastewater and and aerated using Top Fin 
Aquarium air pumps (Petsmart, Phoenix, AZ) for 3 months in a large glass canister kept inside 
an incubator at 25 °C (Fisher Scientific, St. Louis, MO) with periodic recharges of the 
wastewater in order to allow for a biofilm growth. Two pairs of 1L acid-washed amber bottles 
were then filled with 120 g of Stalite, then with 600 mL of JLBC wastewater, to which 100 µg/L 
of the 7 target chemicals were added and mixed. One pair of bottles was then flushed with 
industrial grade air (Airgas, Radnor, PA) for 30 min to achieve aerobic conditions while the 
other was flushed with high purity argon (Airgas, Radnor, PA) for 30 min to decrease the 
dissolved oxygen to approach a hypoxic environment. The hypoxic bottles were then capped and 
sealed with Teflon tape. To determine adsorption effects only, another pair of amber bottles with 
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autoclaved wastewater (600 mL) was first autoclaved then prepared with autoclaved Stalite (120 
g) from the same inoculation with wastewater as the aerobic and hypoxic bottles batch to 
determine sorption to the biofilm. These were then spiked at the same 100 µg/L concentrations as 
the previous bottles. A final pair of bottles contained autoclaved Stalite (120 g) and LGW (600 
mL) along with 100 µg/L of each of the 7 target compounds for comparison of removal by 
sorption to colloidal carbon in the wastewater. All bottles were stored in an incubator at 25 °C on 
a slow shaker at ~60 rpm (Lab-Line Instruments, Melrose Park, IL) for the duration of their time 
points. At 1h, a bottle from each pair was sacrificed and another set after 30 h. The samples were 
immediately filtered and then processed with SPE for chemical analyses as described in sections 
4.3.4 and 4.3.5, respectively. A second batch study was run with 600 g of Stalite in contact with 
600 mL JLBC wastewater, containing 100 µg/L spikes of the target chemicals with sampling 
time points at 1h and 24 h for the hypoxic and aerobic wastewater samples and 24h for the LGW 
and autoclaved wastewater samples. The 1h point was to determine whether there was any rapid 
degradation or sorption to the Stalite, while the 24h time point represented the full contact time 
of the 8h saturated dose interval, which was the longest contact time in the column study.  
4.3. Results and Discussion 
	
4.3.1. Column Study  
Prior to running the dose intervals for the column studies, a biofilm was confirmed on the 
Stalite packing material from DNA extractions of inoculated Stalite using the FastDNA Spin Kit 
for Soil. The first extraction showed genomic DNA present in the samples collected from ports 
3b and 3c, while a second extraction after further wastewater inoculation showed genomic DNA 
in all of the remaining ports except 3a. At this point, the columns were considered conditioned 
and ready for the dose experiments. One notable difference between the column systems and the 
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field sites in studies 1 and 2 is that the bed material in the columns is not vegetated, which is due 
to the limitations of running a laboratory-scale column system in a cold room. The cold 
temperature (5 °C) of the room was necessary to prevent further bacterial growth in the column 
effluent collection vessels, but the lack of fresh air, sunlight, and warm temperatures along with 
the limited surface area of the top of the column (10 cm) prevented planting.  
4.3.1.1. Study 1 
Briefly, the results from study 1, which are presented in Appendix C, show consistently 
high removal of the target compounds from the wastewater effluent for caffeine, 17β-estradiol, 
4-nonylphenol, and triclosan often to below their limit of quantitation (10 µg/L). The total 
percent removal of all chemicals for the final time points of each dose interval after columns 1, 
2, and 3 treatment along with the average of the percent removals after column 3 for all of the 
time points are presented in Table C.1. The overall removals observed for each time point of 
each compound are presented in Figures C.2- C.8. In these figures, the consistency of the 
removal of the target compounds in each study is shown for all of the target compounds in the 
effluent samples except for atrazine and carbamazepine, which appear to be recalcitrant. In the 
literature, reports for the behavior of these compounds in wastewater in relation to sorption, 
biodegradation, and photolysis indicate that these results are consistent with what has previously 
been observed (37, 38) and are discussed in more detail for study 2. The results for the 
compounds atrazine and carbamazepine, which showed inconsistent removal in the effluent after 
column 3 throughout each dose interval, are presented in Appendix C, as well. The consistency 
between the target chemical removal and TOC (Figures C.9 – C.11) removal of each of the time 
points in all of the dose intervals indicated that these experiments could be shortened from 14 
days for study 2. The results for TN, DN, and DOC, indicated that the length of each dose 
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interval could be changed to 9 days, which is the point at which the measurements of these 
parameters had become stable. The 9 day dose interval is also similar to the length of other 
studies measuring target contaminant removal (37). The poor consistency between samples and 
low overall removal for atrazine, carbamazepine, and DEET for the 48 h dose interval combined 
with the high removal observed for the shorter dose intervals resulted in this experiment being 
replaced in study 2. To determine whether saturated conditions in the columns instead of free 
flowing from them would result in better removal, the best dose interval from study 1 was 
selected as both an 8 h as before and as an 8 h saturated interval.  
In vertical flow filters as well as wetlands, organic contaminants can be removed or 
treated through four primary mechanisms: volatilization, sorption, biodegradation, and photolysis 
(38). In this study, the columns are made of stainless steel and kept in a dark room while 
running, which limits the potential contribution of photolysis, and the compounds tested for 
removal are non-volatile which is one reason they persist in wastewater. This leaves 
biodegradation and sorption as the primary potential removal mechanisms in the column studies 
and the results presented show that both of these mechanisms contribute to the observed removal 
in the dose interval experiments. 
4.3.1.2. Study 2 
Due to the results of the stabilization period observed for study 1, which was run for 14 
days, study 2 was shortened to 9 days, which is similar to that used for previous studies of this 
nature (37). In study 2, the analytical limit of detection for triclosan increased during analyses, 
which precluded calculations of its removal during treatment. The results of the chemical 
analyses for study 2 are summarized in Table 4.3, below. The source wastewaters used for each 
dose interval had concentrations of the target analytes that were below the limit of quantitation (5 
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µg/L). From this method, the percent recovery for the compounds, calculated by comparing the 
concentrated standard extracts to the standards spiked into solvent at the same concentration 
factor, are 53% for atrazine, 49% for caffeine, 77% for carbamazepine, 30% for DEET, 10% for 
17β-estradiol, and 81% for 4-nonylphenol.  
Table 4.3. Cumulative removal of target chemicals after each column in study 2 measured for 
each dose interval from columns 1 (n=2) and 2 (n=2), and column 3 (n as indicated) presented as 
mean ± standard deviation.  












TFinalC1 38 33 18 55 > 95# > 95 
TFinalC2 -1.6 > 95 0.6 > 95 > 95 92 





> 95 5.9 
± 5.8 
> 95 > 95 > 95 
8 
TFinalC1 20 42 -11 55 84 > 95 
TFinalC2 27 > 95 0.2 > 95 > 95 > 95 





> 95 1.9 ± 
3.7 
> 95 > 95 89 ± 13 
12 
TFinalC1 4.1 51 -40 53 73 > 95 
TFinalC2 13 > 95 -33 91 > 95 > 95 





> 95 -24 ± 11 > 95 > 95 > 95 
24 
TFinalC1 11 14 -15 26 66 74 
TFinalC2 24 66 -15 75 > 95 94 
TFinalC3 56 91 -4.1 > 95 > 95 > 95 
C3 (Avg) 
n=12 
46 ± 18 82 ± 5.7 17 ± 25 79 ± 9.5 > 95 95 ± 3.8 
36 
TFinalC1 -14 11 -20 41 48 94 
TFinalC2 19 77 18 62 > 95 > 95 
TFinalC3 18 85 20 78 > 95 > 95 
C3 (Avg) 
n=8 
30 ± 10 94 ± 7.1 31 ± 8.2 91 ± 9.4 > 95 > 95 
# LOQ = limit of quantitation for analytes is 5 µg/L. Percent removals reported as >95% for 
concentrations below that limit. 
 
These results show that 17β-estradiol, 4-nonylphenol, DEET, and caffeine are 
consistently well removed (≥ 95%) by the time they exited the final column for the 8 h saturated, 
8 h, and 12 h studies. 4-nonylphenol, the product of the environmental degradation of 
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nonylphenol ethoxylate surfactants, was known to readily sorb to the biofilm of streambeds (39). 
It was also observed as somewhat recalcitrant for anaerobic degradation but that could be 
enhanced with increased temperature or shaking, or decreased in the presence of metals, with the 
overall half-life measured to be between 23.9 to 69.3 days (40), compared to 0.9 to 13.2 days for 
aerobic conditions (41). The observation that 4-nonylphenol was more likely to biodegrade under 
aerobic settings corresponds well with the observed removal from column 1 with little 
enhancement coming from column 2 in this study (42). For comparison, wastewater treatment 
plants have shown 4-nonylphenol to primarily be removed through biodegradation, with physical 
treatment having less of a contribution to the overall removal (43). It should be noted, however, 
that this column study used a mixture of 4-nonylphenol isomers, which was similar to what 
would exist in a wastewater treatment plant but has also been observed to have isomer-specific 
biodegradation, particularly under aerated conditions, with chain length and degree of branching 
both considered contributing factors (41).  
17β-estradiol, the potent estrogen and known endocrine disruptor, was well removed in 
this study. Chemical analyses showed linearly improved removal from the longest dose interval 
to the shortest for column 1, with the 8h saturated interval showing a removal of ≥ 95%. The 
consistently high removal of 17β-estradiol for the overall effluent from column 3 at each time 
point was in line with the literature assertion that 17β-estradiol removal in wastewater treatment 
was primarily accomplished through biodegradation and sorption (44). The saturated interval, 
which had the highest removal from C1, will have the longest residence time with the biofilm 
compared to the other dose intervals (45). Loss of these compounds from volatilization was 
unlikely, as steroid estrogens including 17β-estradiol and its metabolites have low vapor 
pressures, ranging from 2.3 E-10 to 6.7 E-15 mmHg (46). Consistently high removal of 17β-
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estradiol from these systems mirrors previous studies that observed that 17β-estradiol and its 
metabolite, estrone, could biodegrade under aerobic, anoxic and anaerobic conditions, although 
with enhanced degradation under aerobic conditions (45). Furthermore, the logKow of 17β-
estradiol is 4.01, which suggests it was likely to be removed through sorption to Stalite, would 
also enhance removal (45, 46).  
The widely used stimulant caffeine, which is frequently detected in wastewater and 
streams, has been established as an organic contaminant that is easily biodegraded, which is the 
dominant method of removal for this analyte in wastewater treatment (47-50). Additionally, in a 
similar unsaturated column test published in 2017 (51), caffeine was not observed in any of the 
column effluent, which further supports the assertion that it was easily removed from wastewater 
and, therefore, less of an environmental concern. Sorption also contributed to immediate 
removal, which was observed as a fast initial sorption velocity (2055 µg kg-1 h-1) in one recent 
study (51). The efficiency of caffeine removal in these previous studies corresponds well to the 
observed results here, which showed high overall removals for the shorter dose intervals. Drying 
out of the column bed material, which might occur during the longer dose intervals, could 
contribute to the lower removal in those experiments in addition to the effect of the higher dose 
volume, which would result in a larger mass of caffeine added at one time that might overwhelm 
the microbial communities.  
DEET, an insecticide, is widely used in the United States with domestic usage estimated 
to be 1800 tons annually (52), resulting in its frequent detection in streams, often at the low 
parts-per-billion levels. DEET was well removed overall, but showed the highest percentage 
removal in the 8 h and 8 h saturated intervals. Both aerobic and anaerobic removal was observed, 
as column 2 showed similar net percentage removals from its influent to column 1 effluent 
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relative to its influent levels. Previous studies have shown that some removal from anaerobic 
degradation was possible but that there was a slightly enhanced removal when in an aerobic 
system (52, 53). 
The herbicide atrazine and anti-epileptic carbamazepine were mostly recalcitrant, with 
inconsistent removal observed for the time point effluent samples from each dose intervals and 
when the overall removals from each dose interval were compared. This inconsistency was 
attributed to a few factors, including sorption and desorption of the compounds throughout the 
course of the study because they did not easily biodegrade. Samples that showed a negative 
percent removal was likely to be the result of desorption of the chemical that had previously 
accumulated on the column substrate; this was specifically evident for carbamazepine and 
atrazine, which were not known to degrade well in the environment. For example, 
carbamazepine has been classified as “no removal” in activated sludge since the biodegradation 
rate is < 1 g L-1 h-1 (48). It was also observed at higher concentrations in wastewater treatment 
plant effluent compared to plant influents, which is attributed to either the release of the 
compound from sludge, as those particles are degraded by microbes and the compound is 
released (54), or reconversion of metabolites into the parent compounds by the biofilm (55). 
Another source of its removal was transformation into epoxy-carbamazepine, which was 
previously observed as a product of incomplete biodegradation and could be due to 
overwhelming the biomass at this dose concentration (47).   
4.3.1.3. Yeast Estrogen Screen 
 The estrogenic activity of the estrogenic standards, and the column treated wastewater at 
early, mid and final time points from each of the dose intervals was measured using the yeast 
estrogen screen (YES) assay and portions of that data are part of another thesis (56). Due to the 
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different times required to collect samples at a full time point from column 3, the points were 
described as time point (T) and then column (C) instead of as days or hours. The full list of time 
points and their corresponding hours are listed in Appendix D. Examples of a dose-response 
curve for 17β-estradiol and for one of the sample extracts are presented in Figure 4.3. 
	
Figure 4.3. Example YES assay dose-response curves for E2 (ng/well) and a sample extract from 
T2C3 of the 36h dose interval (L/well).  
 
  Of the seven target chemicals monitored in this study only three (17β-estradiol, 4-
nonylphenol, and atrazine) showed estrogenic activity within their aqueous solubility. The 
estrogenic activities measured by the YES assay are shown in Table 4.4 and represent the mean 
and standard deviation of the EC50 curves for each chemical, as well as the EEFs normalized by 
the EC50 of 17β-estradiol, which make the EEF of 17β-estradiol 1. The activity for the column 
effluent samples are presented in Table 4.5. These EC50 values each correspond well with the 
values from the literature for the YES assay of 0.2 – 2.5 nM for 17β-estradiol, and 0.35 – 210 
µM for 4-nonylphenol (57). Although atrazine has not been tested individually with the YES 
assay, it has shown activity in other estrogen-dependent cell lines for gene expression including 









































Table 4.4. Summary of analysis of dose response curves for the most estrogenically active 
among the target chemicals.  
 E2 (n=54) 4-NP (n=4) ATZ (n=5) 
Average EC50 (M) 5.39E-10 6.98E-07 3.99E-05 
Standard Deviation (M) 1.90E-10 1.03E-07 1.68E-05 
EEF 1.00 0.000771 0.000013 
 
The data for the column samples represent the concentrations after accounting for the 
concentration factor of 125, from the method described in section 4.2.3. In the spiked 
wastewater, the predicted EEQ should be 12.5 mg/L, based on 100 µg/L spikes of the target 
compounds and the concentration factor. The stronger potency of 17β-estradiol, as shown in 
Table 4.4, made it the dominant source of estrogenic activity in the wastewater, so the EEQ in 
the spiked and subsequent samples was primarily influenced by the concentration of 17β-
estradiol or its potent transformation products. The EEQ values measured for the samples, 
presented in Table 4.5, indicate consistent removal trends compared to the chemical analyses, 
with the best removal observed for the shorter dose intervals. Notably, there was still estrogenic 
activity present in samples where the more potent active target compounds in this study, 17β-
estradiol and 4-nonylphenol, were at or below their detection limit. Furthermore, even when 
measurable quantities of atrazine are still present, the contribution from this least potent target 
chemical is not significant enough to account for the observed estrogenic activity as shown by 
the predicted EEQs. This implies that these compounds have either been transformed into other 
estrogenic compounds, such as estrone or estriol from 17β-estradiol, or that other estrogenic 
compounds were present in the wastewater that were not targeted in the chemical analysis. The 
difference between the measured estrogenic activity and the activity predicted by the LC-MS 
measurements is presented as a parity plot in Figure 4.4, which clearly shows that there is not a 
linear association between the measured and predicted values.  
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Table 4.5. Experimental, predicted and percent accounted for of EEQs (ng/L) calculated for 
samples from the column study,*denotes a statistically significant difference between predicted 
and observed. n= 3 except as noted.  
Dose Interval  
(h) Sample 







for by LC-MS 
8 
Saturated 
Source 0.336 µg/L  0.861 µg/La 39 
Spiked* 1.26 mg/L 128 ± 14.9 µg/L >100 
T1C3 1.10 µg/L 5.07 ± 7.07 µg/L 22 
T3C3* 0.224 µg/L 13.2 ± 1.56 µg/L 1.7 
T8C3* 0.146 µg/L 2.40 ± 0.344 µg/L 6.1 
T8C1* 1.31 mg/L 1.67 ± 0.494 mg/L 79 
T8C2* 0.529 µg/L 4.82 ± 3.17 µg/L 11 
8 
Source* 0.00 2.63 ± 0.437 µg/L <1.0 
Spiked* 1.26 mg/L 6.20 ± 1.92 mg/L 20 
T1C3 0.058 µg/L 3.77 ± 5.83 µg/L 1.5 
T3C3 5.35 µg/L 7.12 ± 4.14 µg/L 75 
T6C3 0.772 µg/L 1.09 ± 1.06 µg/L 71 
T8C3 0.0696 µg/L 4.19 ± 4.10 µg/L 1.7 
T8C1* 217 µg/L 2.40 ± 0.443 mg/L 9.0 
T8C2* 0.0689 µg/L 7.13 ± 2.34 µg/L <1.0 
12 
Source* 0.683 µg/L  1.99 ± 0.755 µg/L 3.4 
Spiked* 1.26 mg/L 693 ± 86.6 µg/L >100 
T1C3 0.080 µg/L 4.43 ± 6.70 µg/L 1.8 
T3C3 0.0941 µg/L 0.684 ± 0.234 µg/L 14 
T5C3 0.0955 µg/L 1.81 ± 2.17 µg/L 5.3 
T7C3* 0.0109 µg/L 13.0 ± 2.52 µg/L <1.0 
T7C1* 319 µg/L 3.99 ± 2.53 mg/L 8.0 
T7C2* 0.0832 µg/L  243 ± 4.88 µg/L <1.0 
24 
Source* 0.23 µg/L  2.2 ±0.8 µg/L 11 
Spiked* 1.26 mg/L 8.11 ± 4.37 mg/L 16 
T3C3 104 µg/L 185 ± 86 µg/L 56 
T5C3* 10.6 µg/L 185 ± 86.1 µg/L  5.7 
T7C3 1.04 µg/L 92.9 ± 119 µg/L 1.1 
T9C3* 12.1 µg/L 210 ± 110µg/L 5.8 
T9C1* 430 µg/L 3.59 ± 0.4 mg/L 12 
T9C2* 693 µg/L 1.12 ± 0.181 mg/L 62 
36 
Source* 0.00155 µg/L  2.16 ± 0.801 µg/L <1.0 
Spiked* 1.26 mg/L 6.20 ± 1.92 mg/L 20 
T1C3* 0.055 µg/L 10.5 ± 8.05 µg/L <1.0 
T2C2* 0.046 µg/L 31.0 ± 22.9 µg/L <1.0 
T3C3* 0.057 µg/L 2.29 ± 2.72 µg/L 2.5 
T4C3* 0.0347 µg/L 309 ± 102 µg/L <1.0 
T4C1 6.79 mg/L 5.29 ± 0.608 mg/L 13 
T4C2 0.0437 µg/L  1.25 ± 0.283 mg/L <1.0 
an = 2, no standard deviation 
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Figure 4.4. Parity plot of the relationship between YES assay results and LC-MS predicted EEQ 
values.  
The predicted EEQs of the samples as derived by the chemical analysis data are also 
presented in Table 4.5, along with the percent difference between the experimental and predicted 
EEQ, part of which is part of another thesis (56). The results showed a statistically significant 
difference between the predicted EEQ value using the chemical analyses and the experimentally 
observed value from the YES assay for 26 of the 39 samples. The differences observed in the 
predicted and experimental wastewater extracts could be due to a number of factors, including 
metabolites of our target compounds, untargeted compounds already present in the wastewater, 
and colloidal carbon preferentially binding the hormones, as discussed below.  
As mentioned previously, the predicted values were calculated based on the target 
chemical concentrations but do not take into account other chemicals that were present in the 
wastewater. The estrogenic activity measured for the source water, however, suggests that other 
chemicals were present that could influence the assay, including both agonists that increase 
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activity and antagonists that decrease it, because of the deviation between the predicted chemical 
activity and the measured activity from the bioassay. Similarly to the degradation of 4-
nonylphenol isomers, the degradation of unknown chemicals in the mixture could bias the 
activities measured and these unknowns also might degrade differently in the columns. For 
example, antagonists would decrease the estrogenic activity in the spiked source water, which 
would result in a dampened spiked extract. These chemicals could, however, degrade 
preferentially in the columns over other agonists, thus resulting in an enhanced effluent activity 
as has been seen previously in a soil-aquifer treatment study using the YES assay (59). The same 
could also be observed for agonist degradation, which emphasizes the utility of using a bioassay 
to assess overall wastewater quality when chemical analyses might not capture all of the active 
components. 
Another factor contributing to the difference could be the presence of colloidal organic 
matter, which has been previously observed to decrease the free aqueous concentrations of 
hormones and nonylphenols in batch studies (60-62).  In that instance, the colloidal particles 
cannot be filtered from the wastewater but could sorb 17β-estradiol, of which even a small loss 
would cause significant impact on the activity due to its potency (5.39 E-10M). Furthermore, 
estrogens binding to colloids have been estimated to be in the range of 4 – 31% in wastewater 
(63), and up to 60% in one study (60), which could cause a significant impact on the results. 
An additional factor was likely to be the formation of estrogenic metabolites through the 
biodegradation of any of the target compounds or others present in the source water, for example 
the formation of estrone and estriol from 17β-estradiol (45). 17β-estradiol was well removed in 
the columns, and often found below the quantitation limit, but incomplete biodegradation could 
result in activity from its metabolites. 4-Nonylphenol, the second most potent estrogen of our 
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target compounds, may also contribute to the poor correlation between the predictions and the 
measured EEQ, as different isomers have been shown to have different estrogenic activity (64) 
and different propensities for biodegradation (41), so the measured concentrations of total 4-
nonylphenol would not necessarily correspond to the actual activity from that mix of isomers.  
 The removal efficiency, which compared the EEQ concentrations of the final column 3 
samples to those of the 100 µg/L spiked source wastewater, allowed for comparison between the 
dose intervals. The efficiencies, shown in Figure 4.5 for the total removal, indicated that the 
shorter the interval the better the removal of estrogenic activity. The chemical analyses showed 
similarly high removals, as previously described. 
 
Figure 4.5. Overall removal efficiencies for the five different dosing intervals used in the study 
as calculated using YES assay derived EEQ values (56).  
 
4.3.1.4. Other Analyses 
 The spiked chemicals were prepared in methanol, with the exception of caffeine, because 
of solubility limitations for making concentrated stocks. The addition of 0.6 mL of methanol/L of 
wastewater, equivalent to 178 mg of carbon, resulted in elevated organic carbon levels in the 


























because of the potential for even very small differences in 17β-estradiol concentrations to 
considerably impact the estrogen activity measurements. However, because the wastewater 
collected from JLBC for this study was already partially treated before use, the additional TOC 
from the methanol in the spike solutions brings the concentration to levels within a normal 
untreated wastewater range (65). The source wastewater TOC, DOC, TN, and DN concentrations 
and the corresponding concentrations with the chemical spikes are presented in Table 4.6, along 
with the DOC/DN ratio. While the mean TOC of the spiked wastewater was greater than the 
DOC, the standard deviation qualifies this as not a statistically significant difference. TOC, 
DOC, TN, and DN as the percent removal for the final time points and as an average of the 
percent removal of each time point for each column are presented in Table 4.7. Full graphs of 
individual points for TOC, DOC, TN, and DN are presented in Appendix C for study 1 and 
Appendix D for study 2. Although Hach kit readings were taken, and are presented in Table 4.8, 
it was not possible to do a mass balance for nitrogen due to limitations for the instrumental 
method. Similarly to the chemical analyses, shorter intervals showed better removal for these 
target indicators. These results suggest that the drying period that exists between dose intervals 
might contribute to this trend, either through physical disruption of the biofilm and greater 
sloughing off of the biofilm containing both organic material and sorbed compounds, or an 
oversaturation of the biofilm as the longer dose intervals also correspond to a higher dose 









Table 4.6. Wastewater carbon and nitrogen concentrations before and after adding the target 
chemical spikes. (n=2).  


















38 ± 13 36 ± 9.9 1.1 210 ± 50 36 ± 8.5 5.9 
 
Table 4.7. The total percent removal results for the TOC, DOC, TN and DN measurements of 
effluent after each of the columns, relative to the spiked wastewater, at the final time point and as 

























C2 97 95 ± 3.7 98 
98 
± 0.2 98 
95 
± 4.9 97 
94 
± 6.1 



















± 2.7 95 
90 
± 5.2 
C3 >98.5 99 ± 0.4 >98.5 >98.5 76 
74 






































































 Concentrations of ammonia, nitrate and nitrite (mg/L) and pH for each of the final time 
points for each column and as averages from those column effluent for the period of the study 
are presented in Table 4.8. The influent nitrate values, however, were likely elevated because of 
nitrate residual on the acid-washed glassware because one reading was particularly high, 112 
mg/L, which indicated contamination of the sample. This nitrate reading was well above the total 
nitrogen measured for the same source water. These results show the measured value for the 
effluent from each of the three columns as well as the average for the influent from each column 
over the course of each dose interval. The pH of the effluent from each column remained steady 
throughout the course of each study. The removal of the other wastewater indicators presented in 
Table 4.8 again show the best removal for the shorter dose intervals, but a slightly enhanced 
























Table 4.8. Analysis of inorganic nitrogen and pH for each of the final time points and the 
average for all time points from each column compared to column 1 influent levels. N/A = not 













Final Avg. Final Avg. Final Avg. Final Avg. 





N/A 6.8 ± 0.1 
8 
Saturated 







C2 0.0 0.1 ±0.0 8.0 
13 





C3 0.0 0.1 ±0.0 8.0 
30 


















































C1 2.7 1.6 ± 1.8 3.0 
1.8 






































± 0.8 7.1 
7.2 ± 
0.2 
a Experimental contamination resulted in n=1 as a reference but is comparable to study 1 
readings.  
 
Removal of total coliform and E. coli as measured by IDEXX Colilert Quanti-trays, 
indicated nearly complete removal for each of the dose intervals. No total coliform was detected 
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in either the 8h or 8h saturated tests, while the 12h had 63 colony forming units per 100 mL, the 
24h sample had 41 colony forming units per 100 mL, and the 36h samples had 10 colony 
forming units per 100 mL, compared to 750 colony forming units per 100 mL for the source 
wastewater. It was not unexpected that these levels were low compared to a raw wastewater, as 
the source water used in this study was already partially treated through a constructed wetland 
and total coliform levels vary considerably in wastewater, with one study showing variations of 0 
to 10, 000 CFUs over the course of a year (66). The log removal values (LRV) of total coliform 





Table 4.9. Log removal values of total coliform from the dose intervals compared to the source 
water.  
 Dose Interval 
8h 8h Saturated 12h 24h 36h 
LRV >10 >10 1.0 1.3 1.9 
	
4.3.1.5. Stalite Extraction 
To approximate the loss of estrogenic compounds to sorption on the Stalite an extraction 
was done on 20 g core samples removed from each of the column ports at the end of the study, 
on source Stalite that had not been in contact with wastewater, and on Stalite onto which 2 µl of 
the 1 g/L stocks was spiked. The results for the extract of target chemicals from Stalite core 
samples and subsequent YES analysis are shown in Table 4.10, below. Due to the low measured 
activity, further analyses of core samples taken in between the dose interval experiments were 
not evaluated as these consisted of 10x less Stalite by mass and were unlikely to show a 
response. An extraction of the source Stalite, done in the same manner as the core samples, that 
had not been in contact with wastewater did not result in a measurable EC50 so the material itself 
is not expected to leach estrogenic compounds. An extraction of the chemicals spiked directly 
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onto the Stalite showed a low recovery of 3%, compared to its predicted EEQ, which was likely 
due to strong sorption of the estrogenic compounds to the Stalite (63). This was a similar value to 
some of the observed percentages from the predicted EEQs and the experimental YES extract 
values.    
Table 4.10. Estrogenic activity of extracted core samples from column 1, 2, and 3.  
 EEQ ± Std Dev  
(ng/L) 
Source Stalite 8.10 ± 4.99 
Spiked Stalite 3.1E4 ± 5.1E4 






a 4.3 ± 6.1 0.6 ± 0.9 12 ± 2.3 
b 0.5 ± 0.6 1.0 ± 0.9 4.0 ± 5.5 
c 0.6 ± 0.9 1.3 ± 0.9 3.9 ± 1.7 
 
 Extraction of the column core samples showed low-level (ng/L) estrogenic activity, 
shown in Table 4.10, and did not reach full dose response curves, and were also well below the 
values observed for the effluent extracts. However, the low recovery from this extraction 
contributed to the low readings from the column extracts, indicating that these numbers 
underestimated the actual loss to sorption. Column 3 showed a statistically significant difference 
between sorption to the 3a core sample compared to all other core samples, but none of the other 
ports were statistically different from one another. These results indicated that sorption is a 
contributing factor to the removal of the estrogenic compounds in the mixture but because of 
conversion between 17β-estradiol and other estrogenic compounds, it was not possible to say 
whether the activity was coming from 17β-estradiol or an accumulation of its metabolites or 
other low-level wastewater contaminants. Furthermore, a limitation of this approach is that it 
only looks at the accumulation of 3 points within the columns but it was possible that there was 
sorption at the top layer which first came in contact with the spiked wastewater or at the bottom 
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of the columns by the exit port, which had a much more prolonged interaction with the 
wastewater.  
4.3.2. Batch Study 
 The batch results from both studies are presented in Table 4.11. The 30h time point was 
chosen to allow for maximum chemical removal in the study so as to be able to measure a 
difference in effect between biological (microbial degradation) and physical (sorption) removal 
from the wastewater. This was also in a timeframe similar to that used in the column study, in 
which the wastewater had a maximum contact time of 24 h between the three columns, which 
was for the 8h-saturated dose interval. There was removal of each compound after 30h but they 
were not significantly different between the conditions in the first batch study, which used a 
lower Stalite mass (120 g for 600 mL JLBC wastewater (WW), 100 µg/L target compounds). 
The removal levels in the first study indicated that the substrate:solute ratio might have been too 
low resulting in a limited amount of removal from either biodegradation or soption to the bed 
material for a difference to be observed. The second batch study, which used 600 g of Stalite for 
600 mL (100 µg/L added target compounds) (samples 3 and 4) showed enhanced removal by 
biodegradation for 17β-estradiol, which was below the detection limit in the 24h samples for 
both the aerobic and hypoxic trials. Atrazine showed slightly elevated removals for the aerobic 
(33% in sample 3) and hypoxic (34% in sample 4) trials compared to the sorption in the 
autoclaved wastewater sample (25% in sample 2), which supported the column study results and 
previous literature findings (38). The higher ratio of Stalite to wastewater in batch study 2 also 
enhanced removal of atrazine, supporting the column study data and previous literature that 
sorption is an important removal mechanism. Surprisingly, caffeine had a low removal observed 
through biodegradation, which could be attributed to its fast sorption velocity mentioned 
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previously. Similarly, carbamazepine, which had a logKow of 2.25, was also expected to adsorb 
to the biofilm on the bed material but was unlikely to be biodegraded at that point, which could 
explain the inconsistency between the time points and condition results (67). DEET showed 
enhanced removal in the second batch study compared to the first, with higher removal in the 
hypoxic system than the aerobic, and removal efficiencies similar to what has been observed at 
treatment plants (68). 4-nonylphenol was well removed in both batch studies but showed an 
enhanced removal in batch study 1, which could be in part due to the presence of colloidal 
carbon as previously described. The generally enhanced removals observed for the higher Stalite 
to solute ratio indicated the importance of chemical access to the packing material and on 
limiting the amount of liquid added in order to allow for efficient removal. In a column or field 
system, this would equate to a shorter dose interval where smaller volumes of wastewater are put 























Table 4.11. Batch study results for percent removal of target compounds with two 
substrate:solute ratios and four conditions, including 1) LGW with autoclaved Stalite, 
2)Autoclaved JLBC wastewater with autoclaved Stalite, 3) Aerobic wastewater with an active 
biofilm, and 4) Hypoxic wastewater with an active biofilm. NM = not measured. 
 Stalite : Wastewater (g : mL) 
 120:600 600: 600 
Target 
Compound Sample 











1 -19 -1 NM 29 
2 -2.2 -4.9 NM 25 
3 -0.7 -1.1 22 33 
4 -12 4.3 35 34 
CAF 
1 1.7 17 NM 25 
2 22 14 NM 24 
3 15 13 21 29 
4 5.8 18 25 23 
CBZ 
1 -8.5 -8.8 NM -2.5 
2 -0.8 3.7 NM -3.5 
3 -3.8 -5.4 -1.3 5.8 
4 -6.8 1.3 7.9 -6.8 
DEET 
1 -18 -33 NM 62 
2 -36 -36 NM 55 
3 -53 -13 39 39 
4 -4.4 -34 45 57 
E2 
1 12 41 NM 17 
2 28 26 NM 35 
3 23 47 -5.9 > 90a 
4 27 40 77 >90a 
4-NP 
1 33 54 NM 28 
2 52 65 NM 37 
3 48 84 38 30 
4 53 59 38 28 
a >90% removal or below 10 µg/L. 
4.4. Conclusions 
	
The removal of emerging contaminants and their estrogenic activity from wastewater was 
not considered in the design and operation of conventional treatment plants, leading to their 
presence in receiving water bodies (69). In a recent nationwide study it was shown that 
estrogenic activity is measured consistently in river waters, with 34 of 35 test sites across the 
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U.S. showing agonistic responses, which means an increase in gene transcription targets from the 
estrogen receptor (70). Furthermore, the results of that study indicated a linear correlation 
between the concentrations of individual steroidal estrogens and the observed in vitro estrogenic 
activity, after correcting for the potency of each compound (70). Beyond endocrine disruption, 
the contamination from mixed organic contaminants of anthropogenic origins coming from 
runoff and wastewater is well documented in surface waters (70-73). Clearly, reuse of 
wastewater also needs to consider the fate of these chemicals if the technology is to be expanded 
into areas that currently use drinking water and where human and ecosystem exposure could 
occur (74).  
The operational parameters of alternating between aerobic, hypoxic, and aerobic zones 
while utilizing different dosing intervals tested in this study with Stalite, clearly indicated that 
shorter periods between doses and smaller volumes were preferred for the removal of estrogenic 
compounds. The removal of recalcitrant chemicals was inconsistent and suggests that only 
partial removal can be achieved under any of these conditions but that sorption is likely to 
dominate. The removal of estrogenic activity for the tested dose intervals followed the same 
trends as the removal of the target chemicals. A notably dampened effect, however, was 
observed when the predicted EEQs calculated from the most potent estrogenic chemicals in the 
treated water were compared to the observed estrogenic activity. This is likely due to antagonists 
in the mixture, the formation of untargeted potent estrogenic transformation products, or the 
increased sensitivity for the bioassay compared to chemical analyses. The source wastewater 
itself also had measurable estrogenic activity, a common occurrence, and supports the need for 
further optimization of on-site treatment systems to address endocrine activity (69, 70). In each 
of the dose interval studies, the removal was above 90% by column 3 but the activity that 
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remained was at a similar level to the background originally present in the raw wastewater. 
Importantly, the YES assay results were able to bridge the gap between the detection limitations 
of chemical analyses and the actual estrogenic activity as they measured reproducible activity in 
samples that were below the detection limit for the test chemicals in the instrumental analysis. 
However, further work could be undertaken to develop an extraction process to capture a wider 
array of compounds and, therefore, potentially recover more of the estrogenic chemical 
contaminants for comparison to the bioassay. 
 Target chemical removal in “green” engineered, on-site treatment systems is an active 
area of study as environmental professionals look to wastewater reuse to accommodate water 
shortages (75). The benefits of being able to reuse wastewater puts a decreased burden on the 
drinking water system, but requires high quality treated wastewater effluent. Of concern is how 
to remove common organic contaminants from wastewater to a point where the effluent does not 
pose an environmental risk if reused. The target chemicals in this study have varied degradation 
pathways that have been studied extensively, under abiotic and biotic conditions (6, 76-79). The 
most efficient way to enhance removal in rural wastewater treatment settings is to utilize these 
results when designing a passive treatment system, like a vertical flow filter or constructed 
wetland. In the results presented in this study, clear trends in chemical removal show enhanced 
removal for shorter dose intervals for 17β-estradiol, 4-nonylphenol, caffeine, and DEET. These 
results correspond well to both the removal of organic carbon and organic nitrogen, as well as to 
other nitrogen species. The enhanced removal at shorter intervals could likely be due to lower 
ratio of target compound to biofilm, which would prevent over-saturating the bacterial 
community with target compounds to degrade. If this were the case, it would also support the 
results from the batch study, which showed little difference in the removal of the target 
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compounds between the active biofilm and inactive (autoclaved) samples. The spike 
concentration of the compounds, which was chosen to mimic the concentration spiked into the 
column wastewater samples to allow for other measurements, might have already saturated the 
bed material in the system. The compounds carbamazepine and atrazine, which were not 
expected to biodegrade, showed varied removal that was likely due to sorption and desorption to 
the Stalite, observations that are seen in streambeds (6, 80, 81).  
 Due to the elevated levels at which these compounds were spiked, it is not possible to say 
how efficient this system would be at removing compounds in the low microgram to nanogram 
per liter levels at which they are typically found in the environment. The trends in removal, 
however, would indicate that shorter dose intervals should still be applied when the primary 
concern is treatment of estrogenic activity or biodegradable compounds. For recalcitrant 
compounds the dose interval seems to be less important, as there is not a direct correlation 
between this operational parameter and their overall removal.  
A limitation of this study is that the doses were studied at such elevated chemical levels. 
Therefore, future work should evaluate source wastewater with the 8h and 8h saturated intervals 
to determine the removal efficiency of emerging contaminants and estrogenic activity when at 
lower levels. The YES assay has been demonstrated to be suitable for evaluating wastewater 
treatment as it relates to endocrine activity and would provide useful insight into those low-level 
studies because of its sensitivity. Furthermore, the ability of the YES assay to detect estrogenic 
activity when the analytical method for individual chemicals did not detect any target 
compounds supports the assertion that future studies on the treatment of estrogenic activity in 
wastewater would be better served by bioassays to first identify activity and treatment 
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CHAPTER 5: CONCLUSIONS 
	
5.1. Summary of Motivation 
	
 Water treatment, whether for waste- or drinking water, is concerned with the 
mitigation of contaminants that can be harmful to the consumer or the receiving water 
body. Specifically, the primary concern is the inactivation of pathogens in order to 
produce a safe effluent. Generally, conventional drinking water treatment plants employ 
steps including sedimentation, flocculation, filtration and disinfection to remove 
biological and chemical contaminants of concern. It has been well established, however, 
that the conventional treatment of drinking and wastewater has unintended consequences 
for consumers and the environment. Low-level contaminants produced in the process of 
treating drinking water, and contaminants that accumulate through household chemical 
use and agricultural runoff in wastewater, are of particular concern because of their far-
reaching health implications. In particular, it is unclear how habitual exposure to these 
chemicals can impact the health of drinking water consumers. It is, however, clear that 
some of the contaminants that can be found in treated wastewater are of toxicological 
concern. As drinking water sources become scarcer, wastewater reuse is being expanded 
for purposes such as golf courses, landscaping, agriculture, and toilet flushing (1). 
Furthermore, if future reuse is to be extended to replace the more demanding potable 
water consumption of crop irrigation, then it is necessary to evaluate the efficacy of 
treatment in removing a wide range of pollutants and their biochemical activity. The 
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focus of this dissertation was to evaluate both drinking water and wastewater treatment in 
terms of the mitigation of emerging contaminants and endocrine disruption.  
While drinking water disinfection is necessary to inactivate harmful pathogens, 
these strong oxidants react with organic matter and produce disinfection by-products 
(DBPs) of which over 700 unique chemicals have been identified (2). The toxicological 
behavior of these low-level contaminants in humans is not well understood, but 
epidemiological and lab-based studies have indicated an association between exposure 
and the development of several negative health outcomes, including bladder cancer and 
infertility (3, 4). Among the pathways of concern that have been implicated from those 
results are the ones that make up the endocrine system, because of their involvement with 
female and male hormone signaling. Although many environmental pollutants have been 
identified as endocrine active substances, including pesticides, plasticizers, and 
surfactants, it remains unclear whether DBPs have endocrine activity (5-7). To date, the 
structure-activity relationships and the overall toxicological activities of the vast majority 
of DBPs for the estrogen and androgen signaling pathways are unknown. Despite 
evidence to suggest that chronic low-level exposure to these chemicals may be harmful to 
human and ecosystem health, the specific areas of concern have yet to be identified and 
the compound classes of interest remain unclear.  
Unlike drinking water, the estrogenic activity of wastewater and the identification 
of some chemicals that contribute to it are already well established (8-11). The removal 
of this biological activity is vital if wastewater reuse is to be applied in certain settings 
such as agricultural use, because of the potential for these contaminants to accumulate in 
the environment, including crops, or cause disruption to other species (12-15). The issue 
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of mitigating endocrine disruption, however, is an ongoing challenge for both 
conventional wastewater treatment systems and onsite treatment systems alike (10, 16, 
17). Add-on processes to septic systems for on-site wastewater treatment include sand 
filters and constructed wetlands that may assist towards this goal and their application in 
reuse is an active area of investigation (15, 17, 18). Furthermore, optimization of these 
systems to directly address estrogenic activity is an important but as yet underexplored 
area for rural wastewater treatment.  
Specifically, the goals for this dissertation were to identify estrogenic and 
androgenic DBPs individually, in binary mixtures, and in silico, from a subset of 
compounds that have been previously identified in structure-activity studies as potentially 
disruptive to the endocrine system. The remediation of estrogenic activity in relation to 
target common wastewater pollutants was then addressed through a systematic column 
study of varying dose intervals to determine the optimal operational conditions that could 
ultimately be transferred to full scale constructed wetlands treatment.  
5.2. Major Findings 
	
 The primary findings from these studies were the identification of estrogenic and 
androgenic DBPs using competitive binding assays and the determination of the best dose 
interval for wastewater addition to a vertical flow filter for estrogenic activity removal.  
Specifically, the results from Aim 1 found that 14 of 21 tested DBPs were able to 
bind to the androgen receptor in a competitive binding assay over the range 13.5 µM for 
3,4,5,6-tetrachloro-benzoquinone to 1.86 mM for 2,3-dichloropropionamide. Seven of 
these active compounds were found to follow concentration addition when in binary 
mixtures with a known, weak endocrine disruptor, 4-n-nonylphenol. Steric hindrance 
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showed some influence on binding, with dichloroacetonitrile able to bind when 
trichloroacetonitrile could not, and iodoacetic acid binding more strongly than 
diiodoacetic acid. Planar molecules showed the reversed trend, with more halogenated 
structures showing stronger binding affinities for the receptor. Using in silico predictions, 
it was determined that all but one of these compounds was likely to bind as an antagonist, 
therefore potentially decreasing androgen-related gene transcription. These results 
indicate that DBPs are a potentially important chemical class of newly identified 
androgen disruptors and that they could contribute to some of the negative health 
outcomes already associated with exposure to disinfected water. Furthermore, the 
identified compounds represent a wide range of structural groups, which indicates the 
importance of performing further structure-activity studies into the activity of other 
potentially androgen-active DBPs. 
The results from Aim 2 identified 9 of the selected 21 DBPs as estrogen-binding 
compounds when in an estrogen receptor competitive binding assay individually, with 
IC50 values found in the concentration range of 148 µM for bromopicrin to 6.46 mM for 
2-chlorophenol. In binary mixtures with the known weak endocrine disruptor, 4-n-
nonylphenol, the compounds again followed the concentration addition model, 
suggesting that their effects would be additive in mixtures like those found in drinking 
water. Despite having IC50 values that are above occurrence levels in drinking water, the 
ability of DBPs to bind to the estrogen receptor and the chronic low-level exposures to 
which humans are exposed, cannot be ignored because of the potential for cumulative 
effects. The variety of active compounds in this study indicate that DBPs are indeed a 
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contributing factor to the observed biological activity of disinfected waters and that 
estrogen disruption is a pathway of interest. 
In Aim 3, a reporter gene assay was used to measure the estrogenic activity of 
column-treated wastewater samples, in terms of their estradiol equivalents (EEQs). The 
findings determined that for the dose intervals of 8 h, 8 h saturated, 12 h, 24 h, and 36 h, 
the removal of both estrogenic activity and anthropogenic chemicals was enhanced as the 
dose interval became shorter and contact time became longer. For recalcitrant target 
compounds, such as atrazine and carbamazepine, variability measured for the removal 
within the dose interval time points and between the dose interval experiments suggested 
that these compounds are likely sorbing and desorbing to the bed material throughout the 
course of the studies. It was observed that the removal of 17β-estradiol and 4-
nonylphenol responded well to shorter intervals, as well as to the increased contact time 
of the saturated 8h interval. The shorter dose intervals also correlated well to the removal 
of organic carbon and nitrogen measured in the column effluent. While the target 
compounds and overall estrogenic activity were well removed, the chemical analysis did 
not account for a significant portion of the observed estrogenic activity in some of the 
samples. This discrepancy could be attributed either to the possible formation of estrogen 
active metabolites from 17β-estradiol or other compounds present in the wastewater, or to 
the preferential degradation of antagonists in the columns such as some 4-nonylphenol 
isomers. Overall, the vertical flow filter column design in this study was effective for the 
removal of the estrogenic activity that is attributed to surfactant degradation products and 
hormones, and was best attained through shorter dose intervals and longer contact times 
with the filter bed material (Stalite) that was used. The yeast estrogen screen assay was 
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determined to be an effective tool to measure the estrogenic activity of complex mixtures 
and a complementary technique to targeted chemical analyses, which is particularly 
important for the analysis of complex environmental samples. 
5.3. Future Work 
	
The results from these studies provoke several interesting research questions that 
could be explored in future work. While it was determined that DBPs were capable of 
binding to both the estrogen and androgen receptors, and the nature of that binding was 
predicted by in silico means, a more complete analysis of the agonist or antagonist nature 
of their activity could be undertaken using spectroscopic or polymerase chain reaction 
(PCR) array analyses. Furthermore, the impact of long-term, low-level exposure to these 
compounds could begin to be addressed using controlled exposures to model organisms 
such as Zebrafish or Medaka fish. Finally, while the results from Aim 3 suggest shorter 
dose intervals are best for the remediation of estrogenic activity and the degradation of 
these target compounds, a more complete study could include isotope-labeled standards 
and subsequent microbial analyses to determine the microbial communities responsible 
for the degradation in these columns. These results are also specific to a column study 
that uses equal dose addition periods for each of the column stages, but altering the 
retention time or the order of the columns should be evaluated to determine whether all of 
these stages are necessary for estrogen activity remediation. The results were also 
specific to Stalite, which may have a higher adsorption capacity, and in turn could cause 
the system to fail by clogging. Additionally, a non-targeted analysis of dose intervals 
with raw, unspiked, wastewater that is already inherently estrogenic could be used to 
determine the remediation of estrogenic compounds and activity at environmentally 
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relevant levels. Other studies could include an analysis of the other endocrine endpoints 
of concern, including the androgen and thyroid signaling pathways, or a comparison 
between wastewater types, such as those from agricultural runoff, large scale animal 
operations, or hydraulic fracturing effluent. These other types of wastewater may have 
attributes that alter the ability of the columns to remove estrogenic activity, such as their 
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APPENDIX A: DETAILED METHODS FOR CHAPTER 2 
 
A.1. Solution preparations  
 
TEDG Binding Buffer Preparation:  
 
To make 100 ml of TEDG ARBA binding buffer, the following are added in order.  
  
  40 ml ddH2O 
  40 ml of 2 M NaCl 
  5 ml of 1 M Tris-HCl 
  10 ml of glycerol 
  31.2 mg DTT 
  1.0 g human γ-globulin 
 
Mix components and adjust the solution to pH 7.4 using 1N NaOH. The final 
concentrations will be: (50 mM Tris-HCl, pH 7.4; 2 mM DTT; 10% glycerol; 10 mg/mL 
human γ-globulin; 0.8 M NaCl) 
Unlabeled R1881 preparation: 
 
 The unlabeled R1881 is supplied as a powder. To 20 mg add 5 mls 100% ethanol; 
this gives you 14.08 mM stock. Measure 14.2 µl and add to 20 ml 100% ethanol; this 
gives you 10 µM or 10-5 M stock. Store at -20°C until ready to use. 
0.1 µM [3H]-R1881 solution preparation: 
 Prepare a 0.1 µM or 10-7M stock by adding by pipette 1 µl of the original 1.0 
mCi/ml stock solution for every specific activity unit (Ci/mmol) and diluting this to 10.0 
mls with ethanol. Thus, when the [3H]-R1881 stock is 85.1 Ci/mmol specific activity, you 
should pipette 85.1 µL into a vial containing 9.914 ml of ethanol. Invert this to mix. This 
is the 0.1 µM stock, store at -20°C. 
Chemical Stock Preparations: 
The stock solutions of chemicals to be tested are made by first preparing a 500 
mM stock. This is diluted to varying concentrations, depending on the chemical tested. 
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The unlabeled-R1881 stocks were made by first preparing a 1 mM stock, then diluting to 
the following concentrations. 
 
R1881 Standard Curve 
Stock [ ] Final [1x] in experiment 
30 µM  100 nM 
10 µM  33 nM 
3 µM  10 nM 
1 µM  3.3 nM 
300 nM 1 nM 
100 nM 0.33 nM 
30 nM  0.1 nM 
3 nM  0.01 nM 
 
Androgen Receptor Solution: 
To make an adequate solution of androgen receptor, based on the results from the range 
finding study, 1342 µL of the thawed original 1:50 dilution from 1,000,000 cell 
equivalents/mL (20,000 cell eq/mL stock) were diluted in 3358 µL of TEDG ARBA 
buffer and gently mixed by pipette. This solution is made the day of use and kept on ice. 
 
A.2.Chimp androgen receptor range finding assay procedure 
 
Day 1:  
  
The specific activity of the [3H]-R1881 ligand was 85.1 Ci/mmol. In a 20 ml scintillation 
vial add 4.5 ml of opti-fluor scintillation cocktail and 10 µl of 0.1 µM [3H]-R1881 
solution.  Read on scintillation counter and complete the following calculation to 
determine volume needed for assay: 
2.22 * 1012 dpm/Ci * specific activity = dpm/pmole 
2220 * 85.1 Ci/mmol = 188922 dpm/pmole  (insert your spec. activity from 
supplier) 
188922 * 0.004 pM = 755.7 dpm/ul 
 
For a 1.3 ml sample: 755.7 dpm/µl * 1300 µl = 1616160 dpm’s needed to give 1 nM  
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in the well. 
1616160 dpm in 1.3ml/ your dpm reading from scint. Counter = volume in µl  
needed for each sample. 
Example: 1616160 dpm in 1.3 ml/22,808 dpm/µl = 70.9 µl of [3H]-R1881 used 
 
The desired dpm reading in the well for total added was 30,000 – 40,000 dpm; both of 
these considerations were taken into account in the androgen range finding calculations.  
In a 20 ml scintillation vial, add 4.5 ml of opti-fluor scintillation cocktail and 10 
µl of 0.1 µM [3H]-R1881 solution.  Read on scintillation counter and complete the AR 
range finding calculation. Adjust the desired dpm reading to 30,000- 40,000 dpm in order 
to give a more consistent reading with lower noise on the scintillation counter. 
 
To two borosilicate glass culture tubes:  
 For total binding, add 369 µl of [3H]-R1881 (10-7 M solution) 
For NSB, add 369 µl of [3H]-R1881 (10-7 M solution) and 369 µl of unlabeled 
R1881 (10-5 M solution). 
Dry down on the speed vac. for 20 min at 45°C, setting 5.1. Once dry, reconstitute in 4.7 
ml of HSB + BSA. Vortex briefly (about 30 seconds) to mix.  
Into a 96-well, round-bottom plate, add: 
 50 µl of HSB + BSA (TEDG buffer) to all wells 
 25 µl of [3H]-R1881 to total binding wells 
 25 µl of unlabeled E2 + [3H]-R1881 mix to NSB wells 
Shake for 5 min at 4°C. 
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To three 20 ml scintillation vials, add 25 µl of [3H]-E2 and store at 4 °C overnight. These 
are for the ‘total added’ measurement. 
Make receptor dilutions once chAR receptor is fully thawed on ice and gently mixed 
(lightly by pipette or slow inversion): 
Stock (1:50 of 1,000,000) cell equivalents/ml à  
(A)  1:10 dilution by adding 44 µl stock to 400 µl TEDG à 
 (B)  1:20 dilution by adding 220 µl to 220 µl TEDG à 
 (C)  1:40 dilution by adding 220 µl to 220 µl TEDG à 
 (D)  1:80 dilution by adding 220 µl to 220 µl TEDG à 
 (E)  1:160 dilution by adding 220 µl to 220 µl TEDG à 
 (F)  1:320 dilution by adding 220 µl to 220 µl TEDG  
 
Add 25 µl of each concentration to corresponding row, cover with plate-sealing film, and 
shake overnight at 4°C. 
Weigh 0.25 g dextran coated charcoal and transfer to a 50 ml falcon tube containing 5 ml 
of TEDG buffer.  Flip at 4°C overnight. 
Day 2: 
 
Remove 96-well plate and charcoal slurry from shaker. Add 50 µl of charcoal 
surry to all wells using a repeat pipette. Shake plate, sealed with plate-sealing film, at 4°C 
for 10 min. Centrifuge plate at 1000 rpm, 4°C, for 5 min.  
Add 4.5 ml scintillation cocktail to labeled 20 ml scintillation vials. Tilt plate to 
45 degrees on ice and pipette 25 µl of sample from well into the correspondingly labeled 
scintillation vial. Swirl to mix the vial. Read all vials on scintillation counter for 3H, with 
2 min run times and 2 runs per sample (protocol 13).  




[3H]-R1881 Solution Preparation: 
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 Using the calculation from the range finding assay, 369 µl of 10-7M [3H]-R1881 
stock solution is added by pipette to a borosilicate glass tube. This is dried down on the 
speed vac. for 20 min at 45°C, setting 5.1. To this, 4.7 ml of ARBA TEDG binding buffer 
is then added and the solution is vortexed then kept on ice during use. This will result in a 
final concentration of approximately 1 nM in the well. 
 
Unlabeled R1881 Solution for Non-Specific Binding (NSB) Preparation: 
From the 1 x 10-5 M stock in ethanol, 4 µl are added by pipette to a borosilicate 
glass tube and dried down on the speed vac. for 20 min at 45°C, setting 5.1. This is 
reconstituted with 200 µl of ARBA TEDG binding buffer and 1.3 µl of 100% ethanol. 
This solution is vortexed to mix and kept on ice during use. 
 
Chemical Stock Preparations: 
The stock solutions of chemicals to be tested are made by first preparing a 500 
mM stock and then making a total of 10 dilutions, all in 100% ethanol, based on the 
solubility of the chemical. The stocks were stored at -20°C in sealed amber vials until 
further use. 
From each of these stock solutions in the assay, 1.1 µl was added by pipette to a 
borosilicate glass tube containing 166 µl of ARBA TEDG binding buffer, on ice. These 
working stocks were then covered with parafilm and briefly mixed by vortex, then kept 
on ice until use.  
 
R1881 Standard Curve Preparation: 
From a 1mM stock of R1881 solution in 100% ethanol, the following dilutions are 
made. Each concentration is diluted in 100% ethanol and then briefly mixed by vortex. 
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Following the stock preparation, 1.1 µl of each stock is added by pipette into a 
corresponding borosilicate glass tube containing 166 µl of TEDG binding buffer. This is 
then briefly mixed by vortex and kept on ice until use. All stocks in ethanol are stored in 
amber vials at -20 °C until further use. 
 
R1881 Standard Curve 
Stock [ ] Final [1x] in experiment 
30 µM  100 nM 
10 µM  33 nM 
3 µM  10 nM 
1 µM  3.3 nM 
300 nM 1 nM 
100 nM 0.33 nM 
30 nM  0.1 nM 
3 nM  0.01 nM 
 
Androgen Receptor Solution: 
The range finding assay showed that a receptor dilution of 1342 µl of 1:50 diluted 
chAR stock mixed into 3358 µl ARBA TEDG binding buffer would give around 10% 
binding. The chAR was thawed on ice and then gently mixed by pipette before use. This 
working solution was kept on ice during use, as well.  
 
Plate Preparation Procedure: 
While on ice, the following solutions are added to a 96-well, round bottom plate. 
For the total binding wells, add 50 µl of ethanol and TEDG binding buffer (made by 
added 1.3 µl of 100% ethanol to 200 µl TEDG binding buffer and mixing) to each of 
three wells. 
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For the non-specific binding wells, add 50 µl of unlabeled R1881 solution to each of the 
three wells. For all chemical dilution wells, add 50 µl of the working stock solution to 
each of three wells per dose.  
Using a repeat pipette, add 25 µl of the 4x [3H]-R1881 stock solution to each well. Add 
25 µl to each of three scintillation vials as well, for the ;total added to each well’ 
calculation. Keep this at 4°C until use on day 2. 
Shake the plate lightly on speed 2.5 for 10 minutes at 4 °C. 
Using a repeat pipette, gently add 25 µl of the diluted 4x receptor stock solution to each 
well. Cover the plate with plate sealing film and lightly shake the plate on setting 2.5 
overnight, at 4°C. 
Solutions are added in the following scheme to the 96-well plate. 
Table A.1. Diagram of the competitive binding 96-well plate.  
 1 2 3 4 5 6 7 8 9 10 11 12 




MA 10 nM 
B R1881 33 nM NSB R1881 DCAN 0.1 nM MA 3.3 nM 
C R1881 10 nM DCAN 330 nM DCAN 0.033 
nM 
MA 1 nM 
D R1881 3.3 nM DCAN 100 nM DCAN 0.01 
nM 
MA 0.33 nM 
E R1881 1 nM DCAN 33 nM BLANK MA 0.1 nM 
F R1881 0.33 nM DCAN 10 nM MA 330 nM MA 0.033 nM 
G R1881 0.1 nM DCAN 3.3 nM MA 100 nM MA 0.01 nM 
H R1881 0.01 nM DCAN 1 nM MA 33 nM BLANK 
Example DBPs: DCAN = dichloroacetonitrile; MC = mucochloric acid 
 
5% Dextran Coated Charcoal Solution Preparation: 
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The dextran coated charcoal solution is prepared by suspending 0.325 g of 
dextran-coated charcoal in 6.5 mls of TEDG binding buffer in a 50 ml falcon tube. This is 
capped and then placed on a rotary mixer overnight at 4 °C. 
 
Day 2: 
To harvest the receptors, the plate and charcoal slurry are removed from the cold 
room. To each well, 50 µl of the charcoal solution is added using a repeat pipette. The 
plate is then returned to the shaker for 30 minutes at 4 °C. During this time, 4.5 mls of 
opti-fluor scintillation cocktail is added to each scintillation vial labeled to correspond 
with each well on the plate, as well as to the three ‘total added’ vials prepared on day 1. 
The plate is then removed and centrifuged at 1000 rcf, 4 °C, for 5 minutes. With the plate 
at a 45-degree angle, 25 µl of each sample is removed and added by pipette to the 
corresponding scintillation vial. These are briefly swirled to mix and the outside of the 
vials is wiped with methanol to prevent misreading on the scintillation counter. 
The vials are then read on the scintillation counter for 3H, with 2 min run times 
and 2 runs per sample (protocol 13), to determine the androgenic activity of each of the 
two test chemicals, as compared to the standard R1881 curve. The curves are plotted 
again using GraphPad prism 4 software.  
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APPENDIX B: DETAILED METHODS FOR CHAPTER 3 
 
B.1. Solution preparations  
 
TEDG ERBA Binding Buffer preparation: 
 To make 100 ml of TEDG binding buffer, the following are added in order.  
  
  77.15 ml ddH2O 
  10 ml of 4 M KCl 
  1 ml of 1 M Tris-HCl 
  10 ml of glycerol 
  0.1 ml of 1 M sodium molybdate 
  0.75 ml of 200 mM EDTA 
  1.0 ml 100 mM PMSF 
  15.4 mg DTT 
  1 g Bovine Serum Albumin (BSA) 
 
 Mix and adjust the solution to pH 7.4 using 1N NaOH. The final concentrations 
will be: (10 mM Tris-HCl, pH 7.4; 1 mM DTT; 10% glycerol; 10 mg/mL BSA; 400 mM 
KCl; 1 mM PMSF; 1 mM sodium molybdate; 1.5 mM EDTA) 
 
Unlabeled 17β-estradiol preparation: 
 The unlabeled E2 is supplied as a powder. Weigh out 2.72 mg of E2 and add to 1 
ml 100% ethanol. This is a 10 mM stock solution. Dilute this 1:1000 to get 10 µM or 10-5 
M stock. Store at -20°C until ready to use. 
 
0.01 µM [3H]-E2 solution preparation: 
 Prepare a 0.1 µM or 10-7M stock by pipetting 1 µl of the original 1.0 mCi/ml 
stock solution for every specific activity unit (Ci/mmol) and diluting this to 10.0 mls with 
ethanol. Thus, when the 3H-E2 stock is 140 Ci/mmol specific activity, you should pipette 
140 µL into a vial containing 9.86 ml of ethanol. Invert this to mix. This is the 0.1 µM 
stock, store at -20°C. 
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B.2. Human Estrogen receptor range finding assay procedure 
 
In a 20 ml scintillation vial, add 4.5 ml of opti-fluor scintillation cocktail and 10 µl of 0.1 
µM [3H]-E2 solution.  Read on scintillation counter and complete the following 
calculation to determine volume needed for assay: 
 
2.22 * 1012 dpm/Ci * specific activity = dpm/pmole 
2220 * 140 Ci/mmol = 310800 dpm/pmole  (insert your spec. activity from 
supplier) 
310800 * 0.004 pM = 1243.2 dpm/ul 
 
For a 1.3 ml sample: 1243.2 dpm/µl * 1300 µl = 1616160 dpm’s needed to give 1 nM  
in the well. 
1616160 dpm in 1.3ml/ your dpm reading from scint. Counter = volume in µl  
needed for each sample 
 
Example: 1616160 dpm in 1.3 ml/22,808 dpm/µl = 70.9 µl of [3H]-E2 used 
 
To two borosilicate glass culture tubes:  
 For total binding, add 70.9 µl of [3H]-E2 (10-7 M solution) 
For NSB, add 70.9 µl of [3H]-E2 (10-7 M solution) and 70.9 µl of unlabeled E2 
(10-5 M solution). 
 
Dry down on speed vac. For 20 min at 45°C, setting 5.1. Once dry, reconstitute in 1.3 ml 
of HSB + BSA. Vortex briefly (about 30 seconds) to mix.  
Into a 96-well, round-bottom plate, add: 
 50 µl of HSB + BSA (TEDG buffer) to all wells 
 25 µl of [3H]-E2 to total binding wells 
 25 µl of unlabeled E2 + [3H]-E2 mix to NSB wells 
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Shake for 5 min at 4°C. 
 
To three 20 ml scintillation vials, add 25 µl of [3H]-E2 and store at 4 °C overnight. These 
are for the ‘total added’ measurement. 
 
Make receptor dilutions once receptor is fully thawed on ice and gently mixed (lightly by 
pipette or slow inversion): 
 
Stock 1,000,000 cell equivalents/ml à  
(A)  1:10 dilution by adding 44 µl stock to 400 µl TEDG (1,000,000 cell 
eq./ml)     
2500 cell eq. in assay à 
 (B)  1:20 dilution by adding 220 µl to 220 µl TEDG (50,000 cell eq./ml) 1250 
cell eq. in assay à 
 (C)  1:40 dilution by adding 220 µl to 220 µl TEDG (25,000 cell eq./ml) 625 
cell eq. in assay à 
 (D)  1:80 dilution by adding 220 µl to 220 µl TEDG (12,500 cell eq./ml) 312 
cell eq. in assay à 
 (E)  1:160 dilution by adding 220 µl to 220 µl TEDG (6,250 cell eq./ml) 156 
cell eq. in assay à 
 (F)  1:320 dilution by adding 220 µl to 220 µl TEDG (3,125 cell eq./ml)    78 
cell eq. in assay 
 
Add 25 µl of each concentration to corresponding row and shake overnight at 4°C. 
 
Weigh 0.25 g dextran coated charcoal and transfer to a 50 ml falcon tube containing 5 ml 
of TEDG buffer.  Flip at 4°C overnight. 
 
Range Finding Day 2 
 
Remove 96-well plate and charcoal slurry from shaker. Add 50 µl of charcoal surry to all 




Add 4.5 ml scintillation cocktail to labeled 20 ml scintillation vials. Tilt well to 45 
degrees and pipette 25 µl of sample from well into the correspondingly labeled 
scintillation vial. Swirl to mix the vial. Read all vials on scintillation counter for 3H, with 
2 min run times and 2 runs per sample (protocol 13). 
 
B.3. Estrogen Receptor Binding Assay (ERBA) 
 
Day 1: 
[3H]-E2 Solution Preparation: 
 Using the calculation from the range finding assay, 114.1 µl of 10-7M [3H]-E2 
stock solution is added by pipette to a borosilicate glass tube. This is dried down on the 
speed vac. for 20 min at 45°C, setting 5.1. To this, 2.7 ml of TEDG binding buffer is then 
added and the solution is vortexed then kept on ice during use. This will result in a final 
concentration of 1 nM in the well. 
 
Unlabeled E2 Solution for Non-Specific Binding (NSB) Preparation: 
From the 1 x 10-5 M stock in ethanol, 4 µl are added by pipette to a borosilicate glass tube 
and dried down on the speed vac. for 20 min at 45°C, setting 5.1. This is reconstituted 
with 200 µl of TEDG binding buffer and 1.3 µl of 100% ethanol. This solution is 
vortexed to mix and kept on ice during use. 
Chemical Stock Preparations: 
The stock solutions of chemicals to be tested are made by first preparing a 1 mM stock. 







Stock [] Final [1x] in experiment 
100 µM 330 nM 
30 µM  100 nM 
10 µM  33 nM 
3 µM  10 nM 
1 µM  3.3 nM 
300 nM 1 nM 
100 nM 0.33 nM 
30 nM  0.1 nM 
10 nM  0.033 nM 
3 nM  0.01 nM 
 
From each of these stock solutions, 1.1 µl added by pipette to a borosilicate glass tube 
containing 166 µl of TEDG binding buffer, on ice. These working stocks are then briefly 
mixed by vortex and kept on ice until use. The stock chemical solutions in ethanol are 
stored at -20 °C until further use. 
E2 Standard Curve Preparation: 
From a 1mM stock of E2 solution in 100% ethanol, the following dilutions are made. 
Each concentration is diluted in 100% ethanol and then briefly mixed by vortex. 
Following the stock preparation, 1.1 µl of each stock is added by pipette into a 
corresponding borosilicate glass tube containing 166 µl of TEDG binding buffer. This is 
then briefly mixed by vortex and kept on ice until use. All stocks in ethanol are stored at -












E2 Standard Curve 
Stock [ ] Final [1x] in experiment 
30 µM  100 nM 
10 µM  33 nM 
3 µM  10 nM 
1 µM  3.3 nM 
300 nM 1 nM 
100 nM 0.33 nM 
30 nM  0.1 nM 
3 nM  0.01 nM 
 
Estrogen Receptor Solution: 
The range finding assay showed that a receptor concentration of 312 cell equivalents/ml 
would result in 8.8% binding. To make this dilution, the original 1,000,000 cell 
equivalents/ml stock solution was thawed on ice. This was gently mixed by slow 
inversion or pipette before 50 µl was removed and added to 3,950 µl of TEDG binding 
solution in a borosilicate glass tube. This was gently mixed and kept on ice until use.  
 
Plate Preparation Procedure: 
While on ice, the following solutions are added to a 96-well, round bottom plate. 
For the total binding wells, add 50 µl of ethanol and TEDG binding buffer (made by 
added 1.3 µl of 100% ethanol to 200 µl TEDG binding buffer and mixing) to each of 
three wells. 
For the non-specific binding wells, add 50 µl of unlabeled E2 solution to each of the three 
wells. 
For all chemical dilution wells, add 50 µl of the working stock solution to each of three 
wells per dose.  
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Using a repeat pipettor, add 25 µl of the 4x [3H]-E2 stock solution to each well. Add 25 
µl to each of three scintillation vials as well, for the total added to each well calculation. 
Keep this at 4°C until their use on day 2. 
Shake the plate lightly on speed 2.5 for 10 minutes at 4 °C. 
Using a repeat pipettor, gently add 25 µl of the diluted 4x receptor stock solution to each 
well.  
Cover the plate with plate sealing film and lightly shake the plate on setting 2.5 
overnight, at 4°C. 
Solutions are added in the following scheme to the 96-well plate. 
 
Table B.1. Diagram of the competitive binding 96-well plate.  
 1 2 3 4 5 6 7 8 9 10 11 12 




MA 10 nM 
B E2 33 nM NSB E2 DCAN 0.1 nM MA 3.3 nM 
C E2 10 nM DCAN 330 nM DCAN 0.033 
nM 
MA 1 nM 
D E2 3.3 nM DCAN 100 nM DCAN 0.01 
nM 
MA 0.33 nM 
E E2 1 nM DCAN 33 nM BLANK MA 0.1 nM 
F E2 0.33 nM DCAN 10 nM MA 330 nM MA 0.033 nM 
G E2 0.1 nM DCAN 3.3 nM MA 100 nM MA 0.01 nM 
H E2 0.01 nM DCAN 1 nM MA 33 nM BLANK 
E2 = estradiol; DCAN = dichloroacetonitrile; MC = mucochloric acid 
 
5% Dextran Coated Charcoal Solution Preparation: 
The dextran coated charcoal solution is prepared by suspending 0.325 g of dextran-coated 
charcoal in 6.5 mls of TEDG binding buffer in a 50 ml falcon tube. This is caped and 





To harvest the receptors, the plate and charcoal slurry are removed from the cold 
room. To each well, 50 µl of the charcoal solution is added using a repeat pipettor. The 
plate is then returned to the shaker for 30 minutes at 4 °C. During this time, 4.5 mls of 
opti-fluor scintillation cocktail is added to each scintillation vial labeled to correspond 
with each well on the plate, as well as to the three total added vials prepared on day 1. 
The plate is then removed and centrifuged at 2200 rpm, 4 °C, for 5 minutes. With the 
plate at a 45-degree angle, 25 µl of each sample is removed and added by pipette to the 
corresponding scintillation vial. These are briefly swirled to mix and the outside of the 
vials is wiped with methanol to prevent misreading on the scintillation counter. 
The vials are then read on the scintillation counter to determine the estrogenic 
activity of each of the two test chemicals, as compared to the standard E2 curve. 
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APPENDIX C: OPTIMIZATION STUDIES OF A VERTICAL FLOW STALITE 
FILTER STUDY 1 DATA 
	
APPENDIX C.1. Study Design 
	
An initial study was completed with columns run in the order of hypoxic-aerobic-
hypoxic, based on the design of an operating wetlands system in Chatham County, NC. 
This study was undertaken to prepare for future work in our laboratory that was to utilize 
a field site with a similar operational design. The alternation between hypoxic and 
anaerobic zones is to enhance the nitrification/denitrification process for the removal of 
ammonia, nitrate, and nitrite, which can be harmful to receiving water bodies and are 
important aspects in wetland design (1-3). The use of hybrid systems such as this area 
also becoming increasingly popular, as they have been shown to have better removal for 
some target emerging organic contaminants (4). The study was run for 14 days for each 
dose interval, as described in section 4.3.  The interval period was meant to allow for 
stabilization of the column effluent samples, with consistent results observed between 
sampling points. The consistent removal at each time point for the target compounds and 
TOC, however, indicated that a shorter experimental period could be used for each dose 
interval in study 2. The period required to reach consistent readings for the TN, DN, and 
DOC, indicated that a 9-day study would be suitable to accurately indicate the removal of 
the columns for each dose interval. The poor target chemical removal from the 48 h 
interval, however, along with the inconsistency in the water quality indicators measured 
for those samples over the course of that study, resulted in it being excluded from study 2 
and replaced by the 8 h saturated interval. These results are described briefly in Appendix 
C, section C.2. 
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Figure C.1. Diagram of the columns for Trial 1 packed with layers of (A) 3/8”, (B) 5/16”, 
and (C) sand-sized Stalite® material for the column experiments showing sampling ports 
1a-c, 2a-c, and 3a-c.  
 
APPENDIX C.2. Preliminary Study 1 Results 
	
 The study analysis was carried out as previously described in section 4.3. Results 
are shown below for the chemical analysis, TOC, DOC, TN, DN, ammonia, nitrate, and 
nitrite measurements of these preliminary experiments. YES assays were not run on these 
samples. The behavior of these chemicals and water quality indicators are presented for 
each time point over the course of the study to demonstrate the equilibration period of the 







































study 2. The results from these 14-day dose intervals indicate that the removal of the 
target chemicals after column 3, which is the result of the cumulative exposure to all 
three columns and is presented for each time point as a 24 h composite sample of all 
effluent collected in that period, are consistently high for all compounds except CBZ and 
ATZ, which is expected to be due to the reasons described for study 2. The results for 
each of the samples representing the overall removal from the system at each time point 
in the interval are shown in Figures A. are shown in The percent of each compound 
removed, relative to the concentration spiked (100 µg/L) for the final time points from 
columns 1, 2 and 3 are presented in Table C.1. The average overall removal after column 
3, which is again after treatment with all of the columns, is shown as well. 
Table C.1. Target chemical percent removal for trail 1 experiments of 8, 24, 36, and 48 h 
dose intervals at the final time points for columns 1, 2, and 3 and the average daily 


















1 37 ≥90 49 ≥90 ≥90 ≥90 LOQ 
2 -10 ≥90 13 ≥90 n/d ≥90 LOQ 
3 -18 ≥90 9 ≥90 n/d ≥90 LOQ 
3 (Avg) 0.8 ≥90 15 ≥90 ≥90 ≥90 LOQ 
24 
1 14 ≥90 37 49 ≥90 ≥90 ≥90 
2 28 ≥90 37 82 ≥90 ≥90 LOQ 
3 10 ≥90 31 76 ≥90 ≥90 LOQ 
3 (Avg) 12 ≥90 33 83 ≥90 ≥90 LOQ 
36 
1 7.3 64 16 67 88 ≥90 ≥90 
2 10 ≥90 27 77 78 ≥90 LOQ 
3 5.9 ≥90 28 88 ≥90 ≥90 LOQ 
3 (Avg) 8.7 ≥90 18 87 ≥90 ≥90 LOQ 
48 
1 28 ≥90 37 65 89 ≥90 LOQ 
2 23 ≥90 38 57 ≥90 ≥90 LOQ 
3 12 ≥90 43 -145 ≥90 ≥90 LOQ 
3 (Avg) 16 ≥90 37 57 ≥90 ≥90 LOQ 
 
These data show that the overall removal of E2, 4-NP, TCS, and CAF were high, 
while DEET showed consistently high removal from the final column but after columns 1 
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and 2 there was limited removal, which did not show trends between dose intervals. The 
removal of ATZ and CBZ, which are both known to be persistent water pollutants and 
recalcitrant, were minimal and varied. The daily percent removal results for each 
compound are presented in Figures C.1 – C.7 and the daily removal of TOC (Figures C.8 
– C.10), DOC (Figures C.11 – C.13), TN (Figures C.14 – C.16), and DN (Figures C.17 – 
C.19) are presented below. These results indicate that, consistent with the chemical 
results, the shorter dose interval of 8h is the most effective at removal of both organic 
carbon and organic nitrogen.   
 



























Figure C.3. Caffeine daily percent removal from column 3 for all dose intervals.  
 
 
























































































































































































































































































































































































































































































































































Figure C.21. The ammonia concentration in effluent samples from column 1 for each 
time point from each dose interval. 
 
 
Figure C.22. The ammonia concentration in effluent samples from column 2 for each 
























































Figure C.23. The ammonia concentration in effluent samples from column 3 for each 
time point from each dose interval.  
 
 
Figure C.24. The nitrate concentration in effluent samples from column 1 for each time 






















































Figure C.25. The nitrate concentration in effluent samples from column 2 for each time 
point for each dose interval.  
 
 
Figure C.26. The nitrate concentration in effluent samples from column 3 for each time 





















































Figure C.27. The nitrite concentration in effluent samples from column 1 for each time 
point for each dose interval.  
 
 
Figure C.28. The nitrite concentration in effluent samples from column 2 for each time 























































Figure C.29. The nitrite concentration in effluent samples from column 3 for each time 
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APPENDIX D: FULL DATA SETS FOR CHAPTER 4 STUDY 2 AND 
SUPPORTING YES DATA 
	
APPENDIX D.1. Dose interval clarification. 
	
A key to clarify the meaning of the sample codes and which specific hour in the 
study each point corresponds to is given below. Note, the last sample for each dose 
interval is listed as C3, but samples from all three columns were collected on that day. 
Table D.1. Dose interval time points compared to hours and days for clarification. 
Hours Days 8h & 8h Saturated 12h 24h 36h 
0 0.0         
4 0.2         
8 0.3         
12 0.5         
16 0.7         
20 0.8         
24 1.0         
28 1.2         
32 1.3         
36 1.5         
40 1.7 T1C3       
44 1.8         
48 2.0         
52 2.2         
56 2.3         
60 2.5         
64 2.7 T2C3       
68 2.8         
72 3.0   T1C3 T1C3   
76 3.2         
80 3.3         
84 3.5         
88 3.7 T3C3       
92 3.8         
96 4.0   T2C3 T2C3   
100 4.2         
104 4.3         
108 4.5       T1C3 
112 4.7 T4C3       
116 4.8         
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120 5.0   T3C3 T3C3   
124 5.2         
128 5.3         
132 5.5         
136 5.7 T5C3       
140 5.8         
144 6.0   T4C3 T4C3 T2C3 
148 6.2         
152 6.3         
156 6.5         
160 6.7 T6C3       
164 6.8         
168 7.0   T5C3 T5C3   
172 7.2         
176 7.3         
180 7.5       T3C3 
184 7.7 T7C3       
188 7.8         
192 8.0   T6C3 T6C3   
196 8.2         
200 8.3         
204 8.5         
208 8.7 Y8C3       
212 8.8         
216 9.0   T7C3 T7C3 T4C3 
 
APPENDIX D.2. Additional data for the YES assay work. 
	
The pertinent data from Kathleen McDermott for addition YES testing for the 























12.16 10.64 8.59 10.5 ± 1.79 12.51 17.8% 
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Table D.3. Comparison of EEQs for SPE Extracts for the Batch Study from LCMS and 
YES Data. 



























4.58 µg/L 8.43 µg/L 54.3 4.58 µg/L 8.43 µg/L 54.3 
T0 + 100 
µg/L 
1.27 mg/L 11.2 
mg/L 
11.3 1.27 mg/L 11.2 mg/L 11.3 




6.92 mg/L 13.0 
8 hours 14.2 mg/L 7.01 
mg/L 
202 5.15 µg/L 5.80 mg/L 0.089 




0.203 6.98 µg/L 2.73 mg/L 0.256 
 
Table D.4. Comparison of EEQs Calculated from LCMS and YES Assay Derived Data.  
Dose Interval EEQ of T0 + 100 µg/L  Predicted EEQ 
8 hour 6.20 ± 1.92 mg/L 
1.21 mg/L 
8 hour flooding 128± 14.9 µg/L 
12 hour 693 ± 86.6 µg/L 
24 hour 8.11 ± 4.37 mg/L 
36 hour  8.11 ± 0.884 mg/L 
 
The average concentrations of the total organic carbon (TOC), dissolved organic 
carbon (DOC), total nitrogen (TN), and dissolved nitrogen (DN) data and the ammonia, 
nitrate and nitrite concentrations data for specific time points are presented below. The 
percent removals of the TOC, DOC, TN, and DN are graphed to make viewing trends 
over the course of the each dose interval easier. This data shows the behavior of these 
indicators over the course of Study 2. The average percent removals are presented in 
Chapter 4, section 4.3.1.2. 
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Table D.5. The results for the TOC, DOC, TN and DN measurements of effluent from 
each column presented for the final time points and as the average and standard deviation 













Final Avg Final Avg  Final Avg. Final Avg. 
8 
Saturated 







2 5.7 5.9 ± 0.5 5.8 
5.9 
± 0.5 0.9 
1.5 
± 1.5 0.6 
1.4 
± 1.5 



















± 1.1 8.8 
9.4 
± 1.2 




































































Figure D.1. Dissolved organic carbon (DOC) removal percentages measured at each time 
point (T) and for each column (C) for the wastewater through the 8h saturated dose 
interval, for example T3C3 is time point 2, column 3. 
 
		
Figure D.2. Dissolved organic carbon (DOC) removal percentages measured at each time 











































































































































































Figure D.3. Dissolved organic carbon (DOC) removal percentages measured at each time 
point (T) and for each column (C) for the wastewater through the 12h dose interval. 
 
 
Figure D.4. Dissolved organic carbon (DOC) removal percentages measured at each time 






























































































































































Figure D.5. Dissolved organic carbon (DOC) removal percentages measured at each time 
point (T) and for each column (C) for the wastewater through the 36h dose interval.  
 
		
Figure D.6. Total organic carbon (TOC) removal percentages measured at each time 















































































































Figure D.7. Total organic carbon (TOC) removal percentages measured at each time 
point (T) and for each column (C) for the wastewater through the 8h dose interval. 
	
		
Figure D.8. Total organic carbon (TOC) removal percentages measured at each time 







































































































































































Figure D.9. Total organic carbon (TOC) removal percentages measured at each time 




Figure D.10. Total organic carbon (TOC) removal percentages measured at each time 





































































































































Figure D.11. Dissolved nitrogen (DN) removal percentages measured at each time point 
(T) for each column (C) for the wastewater effluent of the 8h saturated dose interval.  
 
		
Figure D.12. Dissolved nitrogen (DN) removal percentages measured at each time point 










































































































































































Figure D.13. Dissolved nitrogen (DN) removal percentages measured at each time point 
(T) for each column (C) for the wastewater effluent of the 12h dose interval. 
 
 
Figure D.14. Dissolved nitrogen (DN) removal percentages measured at each time point 



























































































































































Figure D.15. Dissolved nitrogen (DN) removal percentages measured at each time point 
(T) for each column (C) for the wastewater effluent of the 36h dose interval.  
 
 
Figure D.16. Dissolved nitrogen (TN) removal percentages measured at each time point 













































































































Figure D.17. Dissolved nitrogen (TN) removal percentages measured at each time point 
(T) for each column (C) for the wastewater effluent of the 8h dose interval. 
 
 
Figure D.18. Dissolved nitrogen (TN) removal percentages measured at each time point 












































































































































































Figure D.19. Dissolved nitrogen (TN) removal percentages measured at each time point 
(T) for each column (C) for the wastewater effluent of the 24h dose interval. 
 
 
Figure D.20. Dissolved nitrogen (TN) removal percentages measured at each time point 
















































































































































Table D.6. Batch study chemical concentrations.  
 Stalite : Wastewater (g : mL) 




















1 119 >90 NM 72 
2 102 >90 NM 75 
3 101 >90 78 68 
4 112 >90 65 66 
CAF 
1 98 84 NM 75 
2 78 86 NM 76 
3 85 87 79 71 
4 94 82 75 78 
CBZ 
1 109 109 NM 103 
2 101 96 NM 104 
3 104 105 101 94 
4 107 99 92 107 
DEET 
1 118 133 NM 39 
2 136 136 NM 45 
3 153 113 61 61 
4 104 134 55 43 
E2 
1 87 59 NM 83 
2 72 74 NM 65 
3 84 53 106 LOQa 
4 72 60 23 LOQa 
4-NP 
1 67 36 NM 72 
2 48 35 NM 63 
3 52 16 62 70 
4 46 41 62 72 
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APPENDIX E: CHAPTER 4 DETAILED METHODS 
 
APPENDIX E.1. Yeast Estrogen Screen (YES) Protocol 
	
Note: The method and solution preparation were originally prepared by Paul Ebohon. 
The procedure is modified from the work of Routledge and Sumpter (1996) and Chen et 
al., (2007). The yeast strain (Saccharomyces cerevisiae) used for this assay was provided 
under agreement with Professor J.P Sumpter at Brunel University, UK. This protocol was 
written by Paul Ebohon at the University of North Carolina at Chapel Hill on January 4, 
2011 and modified on July 9, 2011. 
 
Part 1: Materials needed 
 
96 well plate reader* (Molecular Devices, EMAX; Sunnyvale, California) 
Centrifuge* (International Equipment Company; Needham Heights, Massachusetts) 
Shaker table** (Barnstead International; Dubuque, Iowa) 
Incubator** (Fisher Scientific; Dubuque Iowa) 
Weighing scale (Sartorius; Goettingen, Germany) 
Stirrer (Barnstead/Thermolyne; Dubuque, Iowa) 
Disposable filter sterilization flasks (Corning Incorporated; Corning, New York) 
Disposable (100 x 15 mm) sterile petri dishes (Fisher Scientific; Suwanee, Georgia) 
Disposable 96 well flat bottom microplates (Greiner-Bio-One; Frickenhausen, Germany) 
Disposable 96 deep well 1 mL plates (Fisher Scientific; Suwanee, Georgia) 
Falcon tube (Becton Dickinson Labware, Franklin Lakes, New Jersey) 
Plate Sealing Film (Denville Scientific; Metuchen, New Jersey) 
Disposable V-shaped wells for multichannel pipetting (USA Scientific; Ocala, Florida) 
Vortex mixer (Barnstead/Thermolyne; Dubuque, Iowa) 
Original potable pipette aid (Drummond Scientific; Broomall, Pennsylvania) 
50 – 300 µL 8 multichannel  pipettor: 50 – 300 µL (Thermo Labsystems; Vantaa, 
Finland) 
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100 – 1000 µL pipettor (Fisher Scientific; Dubuque, Iowa) 
Disposable (1 – 250 µL)  pipette tips  (Fisher Scientific; Suwanee, Georgia) 
20 -100 µL pipettor (Pipetman; Middleton, Wisconsin) 
Weighing paper: 152 x 152 mm (Fisherbrand; Suwanee, Georgia) 
1L reusable media/solution glass bottles (Corning Incorporated; Corning, New York) 
250 mL screw cap Erlenmeyer glass flask (Kimble Chase Kontes; Vineland, New Jersey) 
1, 5, 10 and 25 mL plastic disposable pipettes (Fisher Scientific; Raleigh, North Carolina) 
*Located in room *2104 and **1213 
Part 2: Chemicals Needed 
Table E.1. Chemicals needed for YES assays.  
Chemical    CAS #   Brand/Source used by Weinberg lab 
Difco yeast nitrogen base 2014-11-30  BD; Sparks, MD 
Ammonium sulfate 7783-20-2  Mallinckrodt; Paris, KY 
Adenine sulfate  321-30-2  Acros Organics; New Jersey, NJ 
Casamino acids  65072-00-6  Fisher Scientific; Fair Lawn, NJ 
Dextrose anhydrous 50-99-7  Fisher Scientific; Fair Lawn, NJ 
Bacto agar   2014-03-31  BD; Sparks, MD 
Bacto peptone  2012-04-22  BD; Sparks, MD 
Sucrose   57-50-1  Fisher Scientific; Fair Lawn, NJ 
aNa2HPO4 * 7H2O 7782-85-6  Mallinckrodt; Paris, KY 
bNaH2PO4 * H2O  10049-21-5  Mallinckrodt; Paris, KY 
Potassium chloride 7447-40-7  Fisher Scientific; Fair Lawn, NJ 
cMgSO4 * 7H2O  10034-99-8  Acros Organics; New Jersey, NJ 
2-mercaptoethanol (βME) 60-24-2  Acros Organics; New Jersey, NJ 
20% Sodium dodecyl sulfate151-21-3  Fisher Scientific; Fair Lawn, NJ 
dCuSO4 * 5H2O  7758-99-8  EM Science; Gibbstown, NJ 
eo-NPG   369-07-3  Research Organics; Cleveland, OH 
Sodium carbonate  497-19-8  Mallinckrodt; Paris, KY  
aNa2HPO4 * 7H2O: Sodium hydrogen phosphate heptahydrate 
bNaH2PO4 * H2O: Sodium dihydrogen phosphate monohydrate  
cMgSO4 * 7H2O: Magnesium sulfate septahydrate 
dCuSO4 * 5H2O: Cupric sulfate pentahydrate 
eo-NPG: o-Nitrophenyl-β-D-galactopyranoside 
Part 3: Preparation of solutions and buffers 
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Note: Solutions should be made in sterilized bottles or vials with laboratory grade water 
(LGW) and stored at room temperature unless otherwise stated in this SOP. Any solution 
should be discarded in the event of a visible color change or visible turbidity 
 
Liquid URA-TRP media for yeast cells growth (500 mL): 
- 3.35 g Yeast Nitrogen Base without amino acids and ammonium sulfate 
- 2.5 g ammonium sulfate 
- 2.5 mL adenine sulfate (4 mg/mL) 
- 10 g anhydrous dextrose 
- 2.5 g casamino acids 
- Dissolve in 500 mL LGW  
- Filter sterilize using a disposable filter sterilization flask and transfer into an 
autoclaved 1Lscrew top glass bottle before storing at room temperature. 
 
URA-TRP Solid media for yeast cell propagation (500 mL): 
- Add 10 g of bactoagar to 500 mL liquid Ura-Trp media 
 
- Autoclave using the liquid cycle and limit sterilization time to 15 minutes because a 
longer one will degrade dextrose in the media. 
- Place autoclaved container under hood and allow cooling until it can be handled 
without difficulty. Do not shake the content of the autoclaved bottle at this point 
because this would cause bubbles to be present in the media.  
- Pour 15-20 mL of media into disposable sterile petri dishes. 
- Let stand at room temperature to harden 
- Place petri plates in dated ziploc bags and store at 4°C. 
 
YPS Media used to make the diluted yeast solution (500 mL): 
- 5 g Yeast Nitrogen Base without amino acids and ammonium sulfate 
	 190	
- 2.5 g peptone 
- 50 g sucrose 
- Filter sterilize using a disposable filter sterilization flask and transfer into an 
autoclaved 1 L screw top glass bottle before storing at room temperature. 
 
Z-Buffer solution (1L): 
- 16.1 g disodium hydrogen phosphate heptahydrate (60 mM final) 
- 5.5 g sodium dihydrogen phosphate monohydrate (40 mM final) 
- 0.75 g  potassium chloride (10 mM final) 
- 0.246 g magnesium sulfate heptahydrate (1 mM final) 
- Adjust pH to 7.0 by using a 2 M potassium hydroxide solution 
- Filter sterilize using a disposable filter sterilization flask and store at room 
temperature. Immediately before using, add 135 µL of β-mercaptoethanol (βME) per 
50 mL of Z-buffer solution .βME cannot be added in advance because it becomes 
oxidized and loses its potency over time. 
 
10% Sodium dodecyl sulfate (SDS) used to denature proteins prior to colorimetric 
measurement: 
 
Note: Make in small batches because it will lose its potency after a month 
- Transfer 5 mL LGW into a 250 mL screw top bottle 
- Transfer 5mL 20% SDS into the bottle containing LGW and swirl contents 
- Label bottle as 10% SDS  and include intials , date and time of preparation 
1M sodium carbontate solution (500 mL) that stops the reaction of β-galactosidase with       
o-NPG by shifting the reaction mixture to pH 11: 
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- Dissolve 59.5 g sodium carbonate in enough water to make 500 mL. 
 
- Filter sterilize using a disposable filter sterilization flask and store at room 
temperature 
Copper (II) sulfate solution (250 mL): 
- Dissolve 0.122g CuSO4 * 5H20 in enough water to make 250 mL. 
 
Filter sterilize using a disposable filter sterilization flask and store at room 
temperature. 
 
10% Ethanol (EtOH) used for serial dilution of the samples and the 4-nonylphenol 
standard:. 
NOTE:  In order to avoid possible volatilization of the EtOH from LGW, make this 
solution right before performing the assay. 
 
Dissolve 1 mL ethanol in 9 mL of LGW. 
17-β-estradiol (E2) stock solutions (in 100% ethanol): 
- 1E-2M E2 stock: dissolve 27.38 mg E2 in a 10 mL volumetric flask with ethanol 
- 1E-4M E2: add 100 µL of 1E-2M E2 stock solution to a 10 mL volumetric flask with 
ethanol 
 
- 1E-6M E2: add 100 µL of 1E-4M E2 stock solution to a 10 mL volumetric flask with 
ethanol 
 
- All stock solutions should be stored at -20°C 
5E-8M E2 working solution (in 10% ethanol): 
- Add 9 mL LGW to an amber vial 
- Add 1 mL ethanol and 1 mL 1E-6M E2 stock solution to the vial 
- Add an additional 9 mL LGW to the vial. Mix the contents well. 
- Store at 4°C 
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NOTE: This E2 working standard solution can be used for at least two weeks; however, it 
is recommended to make it fresh before each assay.  
 
Part 4: Yeast Cell Propagation and Assay Procedure: 
1. Yeast cell propagation 
I. Cell growth on solid Ura-Trp media: A petri dish containing viable yeast colonies 
was provided by North Carolina State University and this dish was subsequently 
used for streaking the next yeast generations. 
 
1) Using a sterile wand, streak a single colony of yeast from a previous plate 
onto an Ura-Trp solid media plate. Seal the plate with parafilm and incubate at 
30°C. After 60 - 72 hours (when individual colonies have reached 1-2 mm in 
diameter), the plates should be removed from the incubator and stored at 4°C. 
 
NOTE: Plates containing yeast colonies can be stored at 4°C for 2 months; 
however, it is a good practice to streak fresh plates at least every month in order 
to keep the yeast colonies going. 
 
2.   Assay Procedure 
 
NOTE:  Slightly different procedures must be followed depending on whether 
samples are prepared in 10 or 100% ethanol and other solvents.  See details below 
based on what solvents your samples are prepared in. 
 
DAY 1 
II. NOTE: If your samples are prepared in 100% EtOH, you will need to prepare you
r 96 well plates today in order to allow the solvent to evaporate overnight. This    
assay procedure assumes duplicate analysis for each sample with nonylphenol      
being used as positive control, and 10% ethanol or suitable matirx as a negative  
control on every plate. A separate plate containing the samples, nonylphenol and 
negative control should also be assayed simultaneously with the assay media       
containing no yeast cells in order to determine if the samples reacts with o-NPG; 
thereby, generating false positive results. When analyzing Disinfection                 
By-Products (DBPs), do not use this step because they do not evaporate               
completely after 24 hours.  
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1) Add 200 µL of 5E-8M E2 standard (in 100% EtOH) to the first column of       
rows A and B (See Figure A.1). 
 
2) Add 200 µL of sample (in 100% EtOH) in duplicate to row C-H.  A total of 3 
samples can be run on each plate (See Figure A.1). 
 
3) Place the plates in the fume hood for 24 hours to completely evaporate solvent
 in the wells.  
 
NOTE: Cover plates loosely with Kim wipes to prevent dust from falling in. 
 
III. Grow yeast cells in liquid Ura-Trp media: 
1) Aliquot 7 mL of liquid Ura-Trp media into a 50 mL sterile falcon tube.  
 
2) Using a sterile wand, pick up one independent colony from a solid Ura-Trp    
plate and transfer it to the liquid media in the falcon tube. 
 
3) Incubate the yeast cells at 30°C on a shaker table at ∼200 rpm for 24 hours. 
 
DAY 2 
IV. Determination of yeast cell density and its dilution using YPS media 
1) Vortex the falcon tube containing the 24 hour yeast suspension culture by       
using a vortex mixer. Ensure that the 96 well plate reader is turned on at least 
10 minutes prior to use. 
 
2) Plate 100 µL (in triplicate) of the yeast suspension on 96-well flat bottom        
microplate. Also plate 100 µL (in triplicate) of the YPS media on the same      
plate.  Read the plate at an absorbance of 600 nm in a plate reader. 
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3) Calculate the total volume of yeast cell solution that is used for each set of      
experiments: 
a) Subtract Abs600YPS from Abs600Yeast 
 
b) Solve for x:  (Abs600Yeast – Abs600YPS)(x µL) = (0.07)(100 µL) 
 
c) Solve for y:  (x µL)/(100µL) = (y mL)/(33 mL) 
 
d) y mL of yeast + (33-y) mL of YPS = dilution of the yeast suspension need
ed    for the assay. 
 
e) Make the yeast dilution calculated above. In order to ensure that there is    
enough yeast solution; make 33 mL of diluted yeast suspension per YES  
plate.  
 
f) Check your yeast dilution to make sure that the Abs600 falls in the range of
0.06 and 0.08 (Once again, subtract Abs600YPS to account for background). 
 
g) Add 100 µL of CuSO4 solution per 10 mL to the diluted yeast solution and
vortex to mix. 
 
V. Prepare 96 deep well 1 mL plates: If your samples were prepared in 10% ethanol, 
ignore step 2 below. 
 
   NOTE:If your samples and nonylphenol working standard solution were prepared  
   in 100% EtOH, you should have completed this step on Day 1 in order to allow    
   evaporation overnight.  
 
1) For samples prepared in 10 and 100% EtOH: Using a multichannel pipettor,   
add 100 µL of freshly prepared 10% ethanol to each well in columns 12-2 of a
 96 deep well 1 mL plate. 
 
2) For samples prepared only in 100% EtOH: Using a multichannel pipettor, add 
200 µL of 10% EtOH to each of the wells in column 1. Aspirate each well       
thoroughly with the multichannel pipettor in order to resuspend the samples in
the 10% EtOH. 
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3) For samples prepared in 10% EtOH: Add 200 µL of 2.50E-04M nonylphenol  
 working standard solution to the first column of rows A and B (Wells A1 and 
B1).  Add 200 µL of samples (prepared in 10% EtOH) in duplicate to row     
C-H. A total of 3 samples can be run on each plate (See Figure A.1). 
 
4) Using a multichannel pipettor, dilute each column serially in 1:2 dilutions.      
(Transfer 100 µL of sample from column 1 to column 2; mix thoroughly by as
pirating, then transfer 100 µL from column 2 to column 3. Continue the serial 
dilution across entire plate until you get to column 11. After mixing the          
contents of column 11, withdraw 100 u L that would be discarded as waste so 
that the column 12 wells containing the negative control as shown in the YES 
assay template (Figure A.1) has only 10% ethanol at this point. 
 
  
   1 2 3 4 5 6 7 8 9 10 11 12 





C Sample 1 in rows C and D 
D 
E Sample 2 in rows E and F 
F 
G Sample 3 in rows G and H 
H 
                 Figure E.1 YES Assay Template. 
 
VI. Exposure of yeast cell to samples: 
1) Add 300 µL of the diluted yeast solution to each well of the 96 deep well 1 mL 
plate containing the samples, nonylphenol and negative control. Ensure that you 
perform this addition by starting from column 12, which contains the negative 
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control. Ensure that each pipette has the same level of diluted yeast solution and 
no bubbles prior to placing in wells. 
 
2) Cover plate with a plate sealing film and incubate for 3 days at 30°C while 
shaking at ∼200 rpm. Ensure that you avoid opening and closing the closing the 




VII. Measurement of optical densities (Endpoint): 
 
1) Aliquot the amount of Z-buffer you will need into a 250 mL screw top bottle.   
You will need about 50 mL of Z-buffer per assay plate. Add 135 µL of βME per
 50 mL of Z-buffer and mix thoroughly.   
 
2) Prepare o-NPG assay buffer: Do not allow o-NPG to cool down to room             
temperature before use. Use as soon as you remove from freezer and return        
immediately. For each assay plate, dissolve 42 mg of o-NPG in 41 mL of the     
freshly-prepared Z-buffer + βME. o-NPG takes approximately 30 to 35 minutes 
to dissolve. Once dissolved, add 1 mL 10% SDS and an additional 525 µL of    
βME. Mix the contents of this solution thoroughly. 
 
3) Using a multichannel pipettor, add 50 µL of Z-buffer (NOTE: Plain Z-buffer +  
βME and not the assay buffer) to each well of the 96 deep well 1 mL plate.         
Replace the plate sealing film on the plate if you observe any vapors or liquid   
on it. Mix the plate’s contents at room temperature by shaking at ∼300 rpm for   
3-5 minutes on a shaker table. 
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4) Remove the plate sealing film and use a multichannel pipettor to add 400 µL of 
the o-NPG assay buffer to each well. NOTE: Ensure that no bubbles are present 
in the pipette tips and each has the same level of o-NPG assay buffer. Reseal the
well with the same plate  sealing film.  
 
5) Incubate the plate at 30°C for 20 minutes while shaking at ∼200 rpm. 
 
6) Using a multichannel pipettor, add 200 µL of 1 M sodium carbonate to each     
well to stop the reaction. 
 
7) Centrifuge the plate at room temperature for 10 minutes at 3000 rpm in order to 
allow the yeast cells settle to the bottom of the 96 deep well 1 mL plate. 
 
8) Using an 8 channel multipipettor, withdraw 100 µL of clear supernatant from    
each well and place on a sterile 96 well flat bottom microplate. Ensure that you 
do not withdraw any yeast cell debris during this step. Avoid allowing bubbles   
in the 96 well flat bottom microplate because they will interfere with the plate   
reader’s result. 
 
9) Measure the absorbance of the contents of the plate above at 450 nm by using a 
plate reader. Export the 450 nm measurements into an excel spreadsheet and      
transfer the spreadsheet into a USB drive. Proceed to calculations below (See    
part V of this protocol). Once the data analysis is complete and you are sure       
that you do not need to re-measure the absorbance of the samples at 450 nm,     
proceed to step 11. 
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10) Using a multichannel pipette, thoroughly mix the contents of the 96 deep well1 
mL plate so that the yeast cells are resuspended in the wells. 
 
a) Using a multichannel pipettor, mix the contents of column 12 by aspirating   
each well about 10 to 15 times. 
 
b) Transfer 100 µL of the contents of column 12 into a sterile 96-well flat         
bottom microplate. 
 
c) Push the top of multichannel pipettor’s button so that the contents of the       
pipette tips are discarded on a Kim wipe. Continue this process until no         
bubbles are visible on the pipette tips. Repeat the process again for column   
11 and work your way to column 1.  
  
11) Measure the absorbance of the plate (in step 10) containing the resuspended      
yeast solution at 600 nm and place raw readings under template 4 that is set up  
exactly as template 2 under part V of this protocol. Compare the samples absorb
ance at 600 nm to that of the negative control’s average. Values that are 10%     
less than that of the negative control’s average are taken as indication of            
cytotoxicity to the yeast cells due to the presence of the sample. Such cytotoxic 
concentrations are excluded from the data set used to plot the dose response      




1) All plates and disposable containers that have been inoculated with yeast cells sho
uld be autoclaved prior to disposal. 
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2) All glassware should be cleaned according to the glassware cleaning procedure,   
wrapped with aluminum foil and stored in their appropriate cabinet. 
      
Pour unused assay media, and chemicals into properly labeled disposal container and 
store appropriately according to laboratory procedure. 
 
VIII.    Yeast Estrogen Screen Calculation Procedure to Determine EC50 for 4- 
nonylphenol  
             
Calibration Curve 
 
For the calibration curves, you should have two rows (A & B) containing 11  
concentrations of nonylphenol, ranging from a pre-dilution concentration of 2.50E-03 M  
to 2.44E-07 M. Remember that you added 100 µL of the nonylphenol standard to the  
wells before diluting it with 300 µL of yeast suspension; therefore, the actual final  
concentrations/concentration factors are the pre-dilution concentrations divided by 4.  In  
your calculations nonylphenol concentrations will range from 6.24E-05 to 6.09E-08 M. 
 





Column A: Labeled as compound with the corresponding samples listed as ran on the  
YES assay plate. 
 
Column C: Labeled as absorbance at 450 nm  
 
Column N: Labeled as negative control 
 
Column P: Labeled as average of negative control 
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1) Transfer the raw absorbance readings into template 1 of the excel spreadsheet. 
The highest absorbance for nonylphenol should be at cells C2 and C3. 
 
2) Average the absorbance 450 nm (Abs450) of the negative controls in order to get a 
single negative control value.  
 
3) Leave some spaces after template 1 and set up template 2 (in the same format as 
template 1 but exclude column P) on the same page of the excel spreadsheet. 
Template 2 will contain your corrected absorbances for E2, and samples. 
 
4) Template 2: For each well on the plate, subtract the single Abs450 of the negative 
control from Abs450 of sample. This value (Abs450 of sample – Average Abs450 of 
negative control) will   simply be referred to as “Abs 1” and “Abs 2”. 
 
5) Leave some spaces after template 2 and set up template 3 (as shown below) on the 
same page of the excel spreadsheet in order to plot the dose response curve for 
nonylphenol and samples. 
 
Template 3: Columns may vary based on how you want your sheet set up. 
 
Column A: Concentration. 
 
Column B: Abs 1. 
 
Column C: Abs 2. 
 
You have 2 absorbances since each sample was run on 2 rows during the assay. 
Column D: % Induction 1. 
 
Column E: % Induction 2. 
 
Column F: Top. 
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Column G: Bottom. 
 
Column H: EC50. 
 
Column I: Lower 95th % confidence interval for EC50. 
 
Column J: Upper 95th % confidence interval for EC50. 
 
Column K: Hillslope. 
 
Column L: EC10. 
 
6) Transfer the E2 concentrations into column A of template 3 with the highest 
concentration being on top. 
 
7) Transfer the corrected absorbances at 450 nm into column B and C of template 3 
and proceed to Appendix B.  
 
APPENDIX E.2. MO Bio FastDNA Spin Kit Protocol 
	
The DNA samples were extracted using the proprietary method by MO Bio 
(Germantown, MD) according to the instructions. All solutions and reagents were 
provided as part of the kit and prepared by MO Bio and acronyms refer to those provided 
by MO Bio. 
 
1) Stalite samples were first mixed with 122 μl MT Buffer and 978 μl Sodium 
Phosphate Buffer and shaken for 1 h.  
2) Samples were centrifuged for 5 min at 14000 g, 4 °C. The supernatant was 
removed. 
3) PPS Buffer (1 ml) was added. 
4) The sample was centrifuged for 5 min at 14000 g, 4 °C. The supernatant was 
recovered and Stalite was discarded. 
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5) DNA binding matrix (1 ml) was added to the supernatant and vortexed for 12 min 
at room temperature. 
6) The sample was centrifuged for 2 min at 14000 g, 4 °C. 
7) Guanidine thiocyanate 5.5 M (500 µl) was added and the sample was transferred 
in stages to a Spin Filter tube, sequentially spinning down the sample on a 
centrifuge for 2 min at 14000 g, 4 °C until all of the sample has been added. 
8) SEWS-M (500 µl) is then added and the sample was centrifuged for 1 min at 
14000 g, 4 °C then discarding supernatant, followed by 2 min at 14000 g, 4 °C, 
then again discarding supernatant.  
9) The Spin Filter was then allowed to air dry for 5 min before adding 150 µl of DES 
solution then centrifuged for 1 min at 14000 g, 4 °C. The spin filter was discarded 
and the DNA stored at -20 °C. 
